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ABSTRACT
Background and aims: End stage renal disease (ESRD), an increasing global 
major public health problem, has greatly increased cardiovascular disease risk 
(CVD) than the general population for unknown reasons. Preliminary data suggest 
that adipose tissue, shown to contribute to CVD risk in non-ESRD populations, 
may also play a part in ESRD. Adipose tissue is a complex organ which not only 
functions as a fat storing depot, but also plays an essential role in lipid 
metabolism. Recently, researchers have recognized that adipose tissue is also an 
endocrine organ since it secretes several cytokines and adipokines including 
leptin, adiponectin and interlukin-6 (IL-6). Alteration in circulating adipokines has 
been shown in ESRD patients. The objective of the study was to clarify the role 
that adipose tissue and lipoproteins may have in ESRD. The work presented in 
this thesis has focused on the role of adipose tissue in ESRD patients undergoing 
haemodialysis and peritoneal dialysis. Both the nutrient and endocrine functions 
of adipose tissue were addressed in this thesis.
Materials and methods: Most studies were carried out on novel in vitro 
adipocyte assay system developed for these experiments. Novel approaches to 
investigate ESRD included isolating lipoprotein fractions (VLDL, LDL and HDL) 
by ultracentrifugation from ESRD and matched human controls followed by 
incubation with the normal adipocytes in the novel assay system developed for 
these experiments. One experiment involved collection of human adipose tissue 
samples. Given the scope of the thesis mainly gene expression data was collected 
on candidate genes analysed by quantitative real-time PCR in these novel pilot 
studies.
XVIII
Results: An atherogenic lipoprotein profile was seen in ESRD patients. 
Haemodialysis patients had increased serum triglycerides and decreased HDL- 
cholesterol compared to the control subjects. Both haemodialysis and peritoneal 
dialysis groups had increased VLDL. The lipoprotein pattern in the present study 
also indicated the peritoneal dialysis group had more atherogenic lipoproteins, 
IDL and small dense LDL.
Expression of lipoprotein lipase, hormone-sensitive lipase and regulatory proteins 
of lipid metabolism complement protein 3 and low density lipoprotein receptor 
were downregulated when treated with uraemic lipoproteins in vitro. Serum 
concentrations of total adiponectin, high molecular weight adiponectin and leptin 
were significantly higher in the ESRD. Gene expression of adiponectin, IL-6 and 
leptin was lower in ESRD patients. The results showed a tendency towards an 
increased accumulation of macrophages in adipose tissue in ESRD patients.
Discussion: These findings are strongly suggestive of a defective storage 
function as well as impaired ability to release fatty acids consistent with 
dysfunctional adipose tissue in ESRD. These data strongly suggest that normal 
adipocyte function is altered when exposed to a uraemic environment in vitiv. 
Macrophage infiltration into adipose tissue has been suggested to play role in 
insulin resistance and systemic inflammation. The results from the modulation of 
this in vitiv adipocyte assay system not only serves as a convenient and unique 
model to study mechanisms of disease such as ESRD and its treatments but has so 
far also provided an initial insight that strongly suggests several mechanisms that 
could contribute to the CVD risk associated with ESRD.
XIX
Conclusion: An in vitro system to study the effect of uraemic lipoproteins and 
serum on adipose tissue nutrient and endocrine function through adipocyte gene 
expression was conducted and compared where available with the corresponding 
circulating protein measurements. Further studies in ESRD, both by broadening 
the number of adipocyte genes (and proteins) and undertaking a mechanistic 
approach to clarifying the reasons for the changes observed would be necessary 
and informative.
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CHAPTER 1
INTRODUCTION
1
1.1 The Kidneys
The kidneys are two bean-shaped organs located outside the peritoneal cavity and 
close to the posterior part of abdomen wall. The kidney is complex organ and 
composed of nephrons which are the functional units in the kidney. There are 
approximately one million nephrons in each kidney. The kidneys are surrounded 
by a layer of fat and are loosely connected to the abdominal wall by connective 
tissue. The major function of the kidney is the excretion of metabolic waste from 
the body besides others including regulation of water and electrolyte balance, 
regulation of arterial blood pressure and regulation of vitamin D production 
(Eaton et al., 2009, Greenberg and Cheung, 2009).
Glomerular filtration rate (GFR) is a measure of kidney function. GFR is defined 
as the volume of plasma ultrafiltrate presented to the nephrons per unit time in the 
process of urine formation and expressed as millilitres per minute. Mean GFR 
values in young men and women are approximately 130 ml/min/1.73 m2 and 120 
ml/min/1.73 m2 respectively (Schwartz and Furth, 2007). Traditionally, GFR 
estimation relied on timed urine collections and blood sampling and is associated 
with a number of pitfalls including incomplete collection. GFR measurements 
assume that the substance used to characterise GFR is freely filtered at the 
glomerulus and following filtration is neither reabsorbed nor secreted, thereby 
only reflecting the filtration function of the nephron. This is true in the case of 
solutes such as inulin but not others such as creatinine. Creatinine is not only 
filtered but also secreted by tubules thereby overestimating the GFR. In addition 
to inulin and creatinine, other approaches have employed substances such as 
99mTcDTPA and 51 CrEDTA. Although there are a large number of functions
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performed by the kidney, traditionally GFR has been chosen as the measure that 
reflects function. Creatinine clearance has been the main approach to characterise 
GFR and is relatively easy to carry out compared to other measurements described 
earlier (Stevens et al., 2006b). The level of creatinine in the blood is a useful guide 
to kidney function since decreasing GFR leads to increasing creatinine. Therefore 
steady state serum creatinine can be used to estimate GFR (eGFR) using age, sex, 
and race, and this is often calculated by computer and reported along with the 
creatinine blood test. It is only an estimate, A number of equations have been 
developed to estimate the GFR based on creatinine measurements and is shown in 
Table 1.1 and in the UK some form of the MDRD equation is in use. eGFR is 
most likely to be inaccurate in people at extremes of body type, for example the 
malnourished and amputees. It is not valid in pregnant women or in children. The 
MDRD equation tends to underestimate normal or near-normal function, so 
slightly low values should not be over-interpreted. Some racial groups may not fit 
the MDRD equation well and this usually involves a correction for race. 
Furthermore, laboratory differences in creatinine estimations may lead to 
significant differences. The K/DOQI distinguishes 5 grades of severity of CKD 
and is shown in Table 1,2.
1.2 End-stage renal disease (ESRD)
End-stage renal disease (ESRD) is rapidly becoming one of the major public 
health problems worldwide. The third National Health and Nutrition Examination 
Survey (NHANESm) reported that 11% of US adult population had diagnosed 
chronic kidney disease (CKD) (Kwan and Beddhu, 2007). In addition, it is 
estimated that the incidence of kidney disease has also increased (Mitka, 2008).
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ESRD has many adverse outcomes which need to be monitored and managed. A 
wide variety of diseases including cardiovascular disease (CVD) and obesity are 
associated with ESRD.
CKD is defined as persistence for 3 or more months of either kidney damage or 
GFR less than 60 ml/min/1.73 m2. Kidney damage can be detected by urinary 
testing for the presence of microalbuminuria, macroalbuminuria, abnormal urinary 
sediment or scanning the kidney by imaging tools (Fuster, 2008).
As already described in detail, GFR is considered the most useful measurement 
for assessing kidney function in clinical practice (Schwartz and Furth, 2007). The 
National Kidney Foundation in the USA support the use of a number of different 
predictive equations based on serum creatinine measurement to estimate GFR 
(Table 1.1) (2002, Stevens et al., 2006a). One method to estimated GFR, also 
employed in the current thesis, is the Modification of Diet in Renal Disease 
(MDRD) equation:
GFR (ml/min/1.73m2) = 175x [serum creatinine (pmol/L)x0.011312'U54]x[Age]" 
0‘203x[1.212 if black] x [0.742 if female].
Renal Disease can be classified into stages according to the GFR and presence of 
structural damage (2002). Patients with stage I have normal GFR but can be 
recognized by either albuminuria or structural kidney damage. Patients with stage 
5, (GFR rate < 15 ml/min/1.73 m2) or End-stage Renal Disease (ESRD) require 
renal replacement therapy (2002) (Table 1.2).
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Cockcroft-Gault formula
Estimated creatinine clearance (Clcr) = ((140-age (years))*weight 
(Kg10)* 1.2/serum Cr (jamol/L))* 0.85 if female
Mayo Quadratic formula
Clcr = exp [1.91 l+5.249/SCr-2.114/SCr (umol/L) 2-0.00686xage (years) 
"0.205 if female]
Schwartz formula
Clcr= (k*Height)/ serum Cr
Tablel.l Commonly used formulae for estimating kidney function
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ESRD is the final common pathway for all renal disease and causes include 
factors such as ischaemia, hypoxia, proteinuria and hypertension besides many 
others (Yu, 2003). In addition, there are various chemical mediators and several 
predisposing factors such as smoking, diabetes and hyperlipidaemia (Ejerblad et 
al., 2006, Stenvinkel et al., 2008, Yu, 2003).
Obesity is also one of the major risk factors for ESRD (Beddhu and Kwan, 2007, 
Wang et al., 2008b). Obesity mainly contributes to the progress of ESRD because 
of its role in pathogenesis of hypertension and Type 2 diabetes (Hall et al., 2004), 
but may also independently increase CKD risk. The focus of this thesis was on 
patients with ESRD.
1.3 Renal Replacement therapy
Replacement therapy, which includes dialysis and kidney transplantation, is 
required in end-stage disease. Transplantation is considered the best replacement 
therapy but due to the limited availability of organ donors dialysis is by necessity 
the alternative choice (Levey et al., 2003, Levey et al., 2005).
Dialysis may involve haemodialysis (HD) or peritoneal dialysis (PD). There are 
various methods of HD including haemofiltration (HF), haemodiafiltration (HDF) 
and acetate-free biofiltration (AFB) (Kannaiyan et al., 2006). Haemodialysis 
works on the basis of diffusion of substances from blood into another suitable 
fluid when it is separated by a semi-permeable membrane. Molecules are cleared 
from blood depending on their molecular weight and electrical charge. Molecules 
that have molecular weight greater than 60,000 Da cannot be cleared while those 
less than 60 Da can be easily cleared (Murugan and Ken, 2007). High flux dialysis
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membranes have been recently used to improve the clearance of middle-range 
molecules (between 500 to 30,000 Da) (Himmelfarb and Ikizler, 2010, Murugan 
and Ken, 2007).
Patients can carry out peritoneal dialysis, in contrast to haemodialysis, at home 
rather than in hospital. Peritoneal dialysis is a technique where dialysis fluid is 
introduced into the peritoneal cavity. Molecules from the blood can be cleared 
depending on their concentration gradients (Tim and Martin, 2007). Although PD 
is more convenient than haemodialysis, it has drawbacks which include chronic 
inflammation (Lai and Leung, 2010). Peritoneal dialysis is often used in someone 
just starting dialysis (Oreopoulos et al., 2009).
Patients crucially require frequent dialysis to prevent or treat short-term fatal 
metabolic abnormalities like hyperkalaemia and acidosis in addition to treating 
other complications of chronic kidney disease (Ifudu, 1998). However, the longer- 
term efficacy of dialysis is limited since morbidity and mortality remains high. 
High morbidity due to cardiovascular, nutritional, haematological, sexual, 
gastrointestinal and neurological problems persist (Hill, 2007, Ifudu, 1998).
A number of studies reported that mortality in patients who are undergoing 
dialysis is around 40-60 percent (Miller et al., 2010) (Figure 1.1). This increased 
mortality clearly depends on the age of patients, duration if disease as well as 
many other factors including the underlying cause of the renal failure. The kidney 
is central to excretion of potentially toxic waste products in urine. In ESRD the 
inability to excrete these products effectively causes their accumulation; these 
have been termed uraemic toxins, which have profound biological effects having 
an adverse impact on organs of the body (Vanholder et al., 2008a).
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It has been suggested that many factors make dialysis less efficient as treatment 
compared with renal transplantation or normally functioning kidneys. These 
factors include the variability in the clearance of small molecules, inability to 
clear protein-bound molecules and the technical factors from the dialysis process 
itself like dialysate flow (Raff et ah, 2008).
1.4 Cardiovascular risk factors in ESRD
It is well established that patients with ESRD have a high incidence of CVD 
compared to the general population. Moreover, CVD is considered the major 
cause of morbidity in ESRD patients (Sarnak et ah, 2003). This association has 
not been fully understood and cannot be adequately explained by changes in the 
traditional risk factors (Stenvinkel, 2010),
Since CVD is a predominant feature in ESRD, early diagnosis of kidney 
impairment as a prelude to better preventative management could reduce CVD 
complications. In addition to early diagnosis, a fuller understanding of the 
causative factors is necessary in order to apply appropriate interventions that can 
decrease CVD prevalence in ESRD (Anavekar and Pfeffer, 2004, Yamamoto and 
Kon, 2009).
Non-traditional risk factors may contribute to the development of CVD in ESRD 
patients as many studies have suggested (Rucker and Tonelli, 2009, Sarnak, 2003, 
Sarnak and Levey, 2000, Zoccali et ah, 2004).
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Stage GFR Description
1 >90 Normal or increased GFR, 
with other evidence of 
kidney damage
2 60-89 Slight decrease in GFR, 
with other evidence of 
kidney damage
3A 45-59 Moderate decrease in
3B 30-44 ejrrv, wun or wiinoui other evidence of kidney 
damage
4 15-29 Marked decrease in GFR, 
with or without other 
evidence of kidney 
damage
5 < 15 Kidney failure
Table 1.2 Stages of chronic kidney disease 
GFR, Glomerular filtration rate
CKD staging system is mainly based on measured or estimated GFR.
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GP male —»• 
Dialysis male 
Dialysis white
GP female —A— GP black 
—o— Dialysis female —
*- GP White 
Dialysis black
25-34 35-44 45-54 55-64 65-74 75-84
Source: Faster V, O'Rourke R.A, Walsh RA, Poole-Wilson
Pi Hunt's Thm H*art, 12th Editiom http://www.accessmedicine.com
Figure 1.1: Cardiovascular mortality in the general population and in ESRD 
treated by dialysis
CVD mortality includes death due to arrhythmias, cardiomyopathy, cardiac arrest 
myocardial infarction, atherosclerotic heart disease and pulmonary edema. ESRD 
is compared with the general population.
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Risk factors such as hypercholesterolaemia, very important in the general 
population, appear to have less impact in terms of CVD mortality in ESRD 
(Yamamoto and Kon, 2009). One of the leading causes of ESRD is diabetes 
mellitus, and the attendant dyslipidaemia is commonly seen.
Even in non-diabetic ESRD, however, a higher prevalence of hypertension, 
dyslipidaemia and uraemia-related risk factors have been shown (Collins et al., 
2003, Tzanatos et al., 2009). Paradoxically, although statins decrease CVD in 
diabetes, they show less convincing benefit in improving the outcome of CVD in 
ESRD (Fellstrom et al., 2009). The focus of the studies in the present thesis is 
mainly non-diabetic ESRD.
1.5 Adipose tissue
Traditionally adipose tissue was considered to be a mainly a storage depot for 
dietary triglycerides. However, it is now also recognized to be an endocrine organ. 
This finding has attracted more research focusing on how adipokines may 
influence pathophysiological conditions.
Adipose tissue is highly specialized and not homogenous consisting of a variety of 
different cell types. These cells include adipocytes, preadipocytes, macrophage, 
endothelial cells, fibroblasts and leukocytes (Beddhu and Kwan, 2007).
The adipocytes (and other cells in adipose tissue) produce cytokines, chemokines, 
growth and complement factors which may have a role in ESRD (Chudek and 
Wiecek, 2006, Trayhurn, 2007). A major function of adipocytes is to store energy 
in the form of triglycerides during the fed-state and release the stored energy in 
the form of fatty acids in the post-absorptive state (Fruhbeck et al., 2001).
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Adipose tissue may be classed histological and functionally as white (WAT) or 
brown (BAT). WAT can be found distributed in different compartments (depots), 
subcutaneous or visceral, each type displaying unique metabolic characteristics. 
Subcutaneous adipose tissue can expand outward and is mainly used for long-term 
energy storage. In contrast, visceral adipose tissue depot is smaller but is an 
important source of short-term energy (Lefebvre et ah, 1998). The expansion of 
these depots may result due to enlargement of existing adipocytes (hypertrophy) 
and formation of new adipocytes (hyperplasia) (Karastergiou and Mohamed-Ali, 
2010).
WAT is characterized by having more lipid content and free fatty acid release via 
lipolysis. In contrast, BAT is more cellular with highly packed mitochondria and 
highly vascularised. Many factors have been described to increase fat 
accumulation and include environmental and genetic factors (Bays et ah, 2008). 
Subcutaneous adipose tissue is considered less metabolically active compared 
with visceral. Visceral adipose tissue has been known to be associated with 
metabolic risk factors, comprising the metabolic syndrome as well being as an 
important predictor of coronary artery disease (Shen et ah, 2006). The present 
thesis is focused on WAT.
1.5.1 Brown adipose tissue (BAT)
BAT is present in significant amounts in humans during fetal life and the number 
decreases progressively with ageing. BAT cells are spherical and contain 
multilocular fat droplets with diameters ranging from 10 to 50 urn. BAT, under 
the electron-microscope, is clearly distinguished by prominent peroxisome, Golgi 
complex, rough and smooth endoplasmic reticulum (Cinti, 2007). In addition,
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numerous mitochondria are found since BAT has the main responsibility for 
thermogenesis. This activity is achieved by uncoupling protein 1 (UCP1), which 
are located in the inner mitochondria, and this protein is considered as a marker of 
brown adipocytes (Cinti, 2005).
1.5.2 White adipose tissue (WAT)
WAT represents about 15 to 25% of body weight in health reaching more than 
50% in obesity (Mullerova and Kopecky, 2007). WAT is considered the 
predominant type in adult humans. Its functions include energy storage, insulation 
and protection of vital organs. The present studies focus on white adipose tissue 
function in culture in vitro as well as in vivo.
The nutrient function of the adipose tissue is important to allow optimal 
lipoprotein metabolism. The interaction of triglyceride-rich lipoproteins with 
adipose tissue is crucial in this regard and is an important focus of present studies. 
Various proteins and enzymes are involved in the lipoprotein-adipocyte 
interaction including lipoprotein lipase and hormone-sensitive lipase. Fat storage 
results from the uptake of fatty acids following the action of lipoprotein lipase on 
triglyceride-rich lipoproteins. There is limited de novo lipogenesis in adipose 
tissue (Kolditz and Langin, 2010).
1.6 Development of adipocytes
In view of the foregoing account highlighting the importance of adipose tissue 
function, it is necessary to analyse and understand adipose tissue development to 
better understand its role in health and disease. Adipogenesis takes place in both
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the prenatal and postnatal states. However, the primary adipogenesis starts early in 
the prenatal period at the 14th to 16th week followed by secondary adipogenesis 
after the 23rd week of gestation. Like all connective tissue cells, adipocytes 
originate from mesenchymally-derived stem cells (Ross, 2003). The process of 
adipogenesis includes preadipocyte proliferation and adipocyte differentiation 
(Gregoire et al., 1998).
After differentiation as shown in figure 1.2, the lipoblast develops from the small 
vessels in the fetus. When lipoblasts differentiate, smooth-surface vesicles begin 
to increase with decline in number of rough endoplasmic reticulum. Consequently, 
small lipid inclusions and pinocyotic vesicles appear. Then, mature adipocytes 
increase in size and become spherical and lipid mass compresses the nucleus to an 
acentric position (Ross, 2003).
It is necessary for a cascade of specific cell signaling pathways, both stimulatory 
and inhibitory to be activated for adipogenesis to proceed. Peroxisome 
proliferator-activated receptor y (PPARy) activation is considered a key step, as it 
is required to induce adipocyte differentiation in fibroblasts and to maintain the 
differentiated state (Rosen and MacDougald, 2006). PPARy activates many 
important adipose tissue specific genes including fatty acid binding proteins, 
lipoprotein lipase, acyl coenzyme A synthase and phosphoenolpyruvate 
carboxykinase (Otto and Lane, 2005). Along with PPARy, many CCAAT- 
enhancing binding proteins (C/EBPs) are also required for adipogenesis (Farmer, 
2010).
It has been shown that different depots of WAT have different appearances and 
functions during development suggesting a possible difference of their origin
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(Billon and Dani, 2011). The gene expression profiles of cultured primary 
preadipocytes extracted from different depots of human WAT were analysed in 
one study and around 503 out of more than 900 genes identified differ among 
depots suggesting a heterogeneous developmental origin between different WAT 
depots (Tchkonia et ah, 2007). This has provided more understanding of the 
adipose tissue development.
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mesenchymal cell
early ^
lipoblasts
(preadipocyte)
■ early 
lipoblast
fibroblast
midstage
lipoblast
brown
adipocytes
late
lipoblast
mature lipoblast 
(white adipocyte)
Figurel.2: Development of adipose tissue.
Adipocytes are derived from mesenchymal cells. One of the key adipogenesis 
steps is the characteristic alteration in cell shape as the cells convert from 
fibroblast (preadipocyte) to spherical morphology (adipocyte). Several key 
regulators involved in the adipogenesis include C/EBPa and PPAR y.
Adapted from :(Ross, 2003)
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1.7 Study of adipose tissue function using in-vitro and in-vivo models
White adipose tissue has been studied by several methodologies in order to 
investigate its function and structure. The use of experimental models is a crucial 
and basic step of experimental biology. In vitro and in vivo systems have been 
used for study of adipose tissue and have their individual advantages and 
disadvantages (Trayhurn and Beattie, 2001).
White adipose tissue is a heterogeneous organ that is composed of many cells 
types including adipocytes, macrophages, preadipocytes, endothelial and epithelial 
cells (Karastergiou and Mohamed-Ali, 2010). Many methods have been used to 
isolate the different adipose tissue fractions (Poulos et al., 2010).
\n vivo studies can better approximate physiological conditions prevailing in the 
human body whereas the in vitro studies employing cultured single cell types have 
the advantage of better control of the physiochemical environment in adipocytes 
(Freshney, 1994, Poulos et al., 2010). In terms of gene expression, determining 
whether the expression is a result of adipocytes or other cells is important 
(Trayhurn and Beattie, 2001). Changes in expression can be confirmed by 
analysing blood collected from the venous drainage. Alternatively, in situ 
hybridisation for the direct localization of mRNA can be used (Trayhurn and 
Beattie, 2001).
In vitro studies can be carried out by using cell lines or primary cell cultures. 
Human adipocytes, from different cell lines, show differences in metabolism and 
endocrine function. One such cell line, is the mouse 3T3-L1, which following 
clonal expansion is used for in vitro studies (Jones, 1996).
17
Primary adipocytes can be cultured by employing different methodologies 
including culturing of adipose tissue explants, culturing freshly isolated mature 
adipocytes or by culturing stromal cell fraction of adipose tissue (Jones, 1996). 
Moreover, knockout models can also be useful in studying specific factors in 
adipose biology (Poulos et ah, 2010).
Human Simpson-Golabi-Behmel Syndrome (SGBS) preadipocyte cell strain has 
been used as a human primary adipocyte model, SGBS cells are characterized by 
stable adipogenic differentiation for many generations during their proliferation 
(Fischer-Posovszky et ah, 2008). SGBS was developed from stromal-vascular 
fraction within adipose tissue (Wabitsch et ah, 2001), Primary human 
preadipocytes are also available commercially from different sources like 
PromoCell and Zen-Bio. In this thesis, the SGBS and Promo Cell human 
adipocytes were employed as in vitro adipose tissue models.
1.8 Adipose tissue as endocrine gland
Adipose tissue was considered solely an energy storage organ for a long time. 
However, modern techniques and advances have lead to a better understanding of 
adipose tissue biology. The discovery of leptin secretion from adipocytes changed 
our perception of adipose tissue from a purely storage organ to one which also has 
a substantial endocrine activity. The endocrine function of the adipose tissue 
involves the production and secretion of a large number of hormones of which are 
the focus of the present study. The best known among these factors is leptin; an 
adipocyte-derived hormone that acts in the hypothalamus and decreases food 
intake, increases energy expenditure, and in peripheral tissue modulates
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metabolism and other cellular functions. In addition to leptin, many other factors 
have been identified including tumour necrosis factor (TNF-a), adiponectin (also 
known as Acrp30 and AdipoQ), plasminogen activator-inhibitor, interleukin 6, 
resistin, transforming growth factor-p, adipsin and retinol-binding protein (Ahima 
and Osei, 2008, Trayhurn and Wood, 2004). The adipokines that are the focus of 
present studies are briefly reviewed.
1.8.1 Leptin
Leptin is an important adipocyte product being the first adipokine to be identified 
in 1994. It is a 16 KDa protein and encoded by ob gene (Zhang et ah, 1994). 
Initially, leptin was thought as an obesity inhibitor in rodents. In humans it 
appears to be a hormone signal indicating energy deficiency (Maury and Brichard, 
2010). Obesity is associated with high levels of plasma leptin which may reflect 
leptin resistance (Ahima and Osei, 2008). Leptin is produced mainly by 
adipocytes and also by other sites including skeletal muscle and placenta (Wolf et 
al, 2002).
Leptin has many functions elicited through specific interaction with its receptor 
(obR) found in most tissues. Leptin has many actions including those in the brain, 
pancreas, liver and immune system. Mainly, leptin inhibits food intake by its 
primary action on the brain (Ahima, 2006, Trayhurn and Beattie, 2001, Galic et 
al., 2010). Its action on the brain and in particular the hypothalamus was linked 
subsequently to the energy homeostasis and reproductive function (Badman and 
Flier, 2007). Leptin receptor (ob-R) is found in the brain in high concentrations; in 
adipose tissue and skeletal muscle ob-R is found in low concentrations (Tartaglia, 
1997).
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Adipose tissue mass has been reported to correlate positively with plasma leptin 
levels (Wolf et al., 2002). Leptin levels are high in chronic renal failure (CRF) 
patients especially those undergoing PD (Heimburger and Stenvinkel, 2005) and 
its role in the nutritional status in ESRD has been studied (Kwan and Beddhu, 
2007). Increased plasma levels of leptin have been proposed to contribute to 
malnutrition of uraemia as an indicator of low protein intake (Young et al., 1997).
Leptin has been shown to be excreted by the kidney (Cumin et al., 1996). 
Moreover, leptin has been proposed to play a role in inflammation (Kataoka and 
Sharma, 2006). Nordfors and colleagues showed that leptin gene expression in 
biopsy studies of adipose tissue is decreased in chronic renal failure (Nordfors et 
al., 1998) even though circulating concentrations are increased suggesting a major 
role for the kidneys in the degradation and elimination of leptin.
1.8.2 Adiponectin
Adiponectin is a 30 kDa protein that is produced only by mature adipocytes and is 
a member of soluble defence collagen family (Ahima, 2006, Bauche et al., 2006). 
Adiponectin structure comprises 244 amino acids and it belongs to the 
complement Iq family that contains a carboxyl terminal globular domain and 
amino terminal collagenous domain (Hu et al., 1996). Adiponectin expression 
increases during the preadipocyte differentiation to mature adipocytes (Korner et 
al., 2005). Human adiponectin has been observed in three different forms; low, 
middle and high molecular weights. The low molecular weight adiponectin is a 
tri-mer, middle molecular weight is a hexa-mer whereas the high molecular 
fraction is a dodeca-mer (Shen et al., 2008). Each adiponectin monomer has three 
domains; a variable N-terminal region, an a-helical collagenous and distinctive C-
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terminal globular domains (Shapiro and Scherer, 1998). These forms are different 
in their biological action (Sowers, 2008). The high molecular weight is considered 
the active form (Schraw et al., 2008). High molecular weight form was also found 
to correlate with insulin resistance better than total adiponectin (Hara et al., 2006). 
The importance of high molecular weight adiponectin form has led to an assay 
being developed for the specific measurement of the high molecular weight 
fraction (Tanita et al., 2008).
Two receptors have been identified; AdipoRl and 2. AdipoRl and AdipoR2 are 
expressed in many tissues and organs but predominantly in muscle cells and liver 
cells, respectively (Beige et ah, 2009, Shen et ah, 2008). AdipoRl has been 
showed to be involved in the inhibition of gluconeogenesis and increased fatty 
acid oxidation through the activation of AMPK pathways. AdipoR2 has also been 
showed to activate fatty acid oxidation in skeletal muscle and suppress oxidative 
stress and inflammation through the activation of PPAR-a pathway (Ouchi et ah, 
2000, Yamauchi et ah, 2002, Yoon et ah, 2006). Any dysregulation of these 
pathway might result in accumulation of triglycerides, inflammation and oxidative 
stress (Shen et ah, 2008).
Unlike other adipokines, adiponectin has a negative correlation with the BMI 
(Brichard et al., 2003). Adiponectin has antiatherogenic, anti-inflammatory and 
insulin sensitizing functions (Bauche et al„ 2006). Adiponectin inhibits oxidised 
LDL-mediated cell proliferation, lipid accumulation in monocyte-derived 
macrophages and transformation of macrophages into foam cells (Chudek and 
Wiecek, 2006).
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In contrast to leptin, adiponectin is negatively associated with WAT mass 
(Ahima, 2006). Adiponectin shows a negative correlation between its plasma 
levels and BMI (Hu et al., 1996). Surprisingly, although low plasma adiponectin 
concentrations are associated with coronary artery disease and type 2 diabetes, 
plasma adiponectin is high in uraemia suggesting that the kidney may again be an 
important site for degradation and elimination (Chudek and Wiecek, 2006, Huang 
et al., 2004). This is rendered more likely in view of data suggesting that 
adiponectin gene is downregulated in ESRD (Marchlewska et al., 2004). Despite 
the paucity of data, what evidence there is suggests that circulating adipokine 
concentrations are altered in ESRD. Circulating levels of adiponectin are 
markedly elevated in ESRD (Wiecek et al., 2002). Adiponectin is also inversely 
associated with other metabolic risk factors, such as body mass index, blood 
glucose, insulinaemia as well as serum triglyceride and HDL cholesterol levels 
(Zoccali et al., 2003).
1.8.3 Interleukin-6
Interleukin-6 (IL-6) is a 22 to 27 kDa polypeptide produced by many cells 
including adipocytes, macrophage, fibroblast and endothelium (Pecoits-Filho et 
al., 2003). About 15-35% of detected plasma levels of interleukin-6 is produced 
by adipocytes (Mohamed-Ali et al., 1997).
It has been reported that plasma levels of interleukin-6 are positively correlated 
with adipose tissue mass (Bastard et al., 2007). Interleukin-6 is a proinflammatory 
mediator induced by stress and activates an acute phase protein response in the 
liver (Fruhbeck et al., 2001). With regard to adipose tissue production, 
Interleukin-6 is produced mainly in visceral adipose tissue, a fat depot known to
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be associated with insulin resistance and inflammation (Maury and Brichard, 
2010).
Interleukin-6 has been found to have a significant relationship with plasma high 
sensitivity C-reactive protein (hsCRP) in dialysis patients (Kwan and Beddhu, 
2007). Interleukin-6 activates fatty acid oxidation and glucose uptake in skeletal 
muscle which might contribute to insulin resistance (Galic et ah, 2010).
Interleukin-6 is involved in insulin resistance by inhibiting insulin signaling 
pathway through impairment of insulin-induced insulin receptor and IRS-1 
phosphorylation in adipocytes and hepatocytes (Galic et ah, 2010). Interleukin-6 
plasma levels have been found to be increased in ESRD (Taskapan et ah, 2007, 
Wang et ah, 2008b).
1.8.4 Monocyte chemoattractant protein-1 (MCP-1)
Monocyte chemoattractant protein-1 (MCP-1) is a 13 KDa protein produced by 
the expression of the CCL2 gene on chromosome 17 (Yadav et ah, 2010). 
Monocyte chemoattractant protein-1 is produced by variety of cell types including 
macrophage, endothelium and adipocyte (Kanda et ah, 2006).
Monocyte chemoattractant protein-1 has been suggested to contribute to 
inflammation in adipose tissue (Kanda et ah, 2006). Monocyte chemoattractant 
protein-1 binds to its receptor CCR2 in monocyte recruitment which is involved in 
many biological inflammation related processes (Yadav et ah, 2010).
It has been reported that Monocyte chemoattractant protein-1 expression 
correlates with adipocyte size (Sartipy and Loskutoff, 2003), with one exception 
being the epicardial adipocytes (Eiras et ah, 2010). It has been found that
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proinflammatory markers like interleukin-6 can induce Monocyte chemoattractant 
protein-1 expression (Karastergiou and Mohamed-Ali, 2010). Monocyte 
chemoattractant protein-1 plasma levels have been found to be increased in ESRD 
suggesting a possible role for MCP-1 in inflammation in ESRD (Stinghen et ah, 
2009) . Monocyte chemoattractant protein-1 and its receptor have been proposed 
to contribute to ESRD progression by initiation and progression of tubule- 
interstitial damage and/or glomerular lesions (Viedt and Orth, 2002).
1.9 Macrophage infiltration into adipose tissue
Macrophage infiltration into adipose tissue has been shown to contribute to 
increased expression of pro-inflammatory adipokines in obesity (Weisberg et al., 
2003, Xu et al., 2003). BMI in human has also been found to correlate positively 
with macrophage infiltration (Weisberg et al., 2003).
Macrophage infiltration can be detected by using a specific macrophage protein 
expression like cluster of differentiation 68 (CD68) and disintegrin and 
metallopeptidase domain 8 (ADAM 8) among others (Khazen et al., 2005). The 
mechanism(s) underlying macrophage infiltration in adipose tissue are still not 
fully known. It has been suggested that adipose tissue expansion leads to some 
process that in turn contributes to the initiation of macrophage recruitment. These 
including fatty acid flux, vascularisation, increased leptin secretion, hypoxia and 
adipocyte cell death (Surmi and Hasty, 2008). Increased accumulation of 
macrophages in adipose tissue may contribute to systemic inflammation in 
obesity. Pro-inflammatory markers such as TNF-a, IL-6 and resistin have been 
shown to be produced by macrophages (Bouloumie et al., 2005). Lean adipose
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tissue, on the other hand, when infiltrated by macrophages, exhibit an increase in 
expression of anti-inflammatory cytokine genes such as interleukin 10 (IL-10) 
(Lumeng et al., 2007).
Macrophages are heterogeneous in function and several types have been 
described. One type of macrophage, Ml, has features that are typically considered 
to reflect these cells such as pro-inflammatory capacity as well as the ability to 
cause insulin resistance. It has been found that the expansion of adipose tissue is 
associated with classically activated macrophages Ml (Lumeng et al., 2007). 
Alternatively activated macrophages (known as M2), on the other hand, are 
associated with normal adipocyte function and insulin sensitivity.
1.10 Adipose tissue in End-stage renal disease
White adipose tissue has been known to be involved in the regulation of many 
biological processes including body weight homeostasis, carbohydrate and lipid 
metabolism, immunity and others. Studying adiposity-related metabolism will 
improve the understanding of how adipose tissue contribute to cardiovascular 
disease and therefore potentially contribute to the development of appropriate 
treatment(s) (Chudek et al., 2006).
Obesity increases the risk of ESRD (Wang et al., 2008b) and plays a role in 
development and progression of kidney disease itself (Beddhu and Kwan, 2007). 
Body mass index was identified as a predictor for elevated serum creatinine, 
ESRD and chronic renal disease (Ritz, 2008). In addition, in dialysis patients, 
BMI is associated with several adverse cardiovascular features such as insulin 
resistance, diabetes, anaemia, inflammation, coronary calcification and carotid
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atherosclerosis (Rutkowski et al., 2006, Zoccali and Mallamaci, 2008). Body mass 
index also has been considered a risk factor for mortality in patients on 
haemodialysis and at the same time was used as an indicator of the nutritional 
status of ESRD patients (Iglesias and Diez, 2010).
Patients on peritoneal dialysis are likely to have more fat mass due to glucose- 
containing peritoneal dialysis solution being instilled into the peritoneal cavity; 
the result is an intra-abdominal fat accumulation (Fernstrom et al., 1998). As 
discussed already, excess visceral adipose tissue is considered a risk factor for 
cardiovascular disease.
A number of adipokines have been proposed to play an important patho­
physiological role in patients with ESRD. These adipokines are of special interest 
in ESRD since they may have a role in inflammation especially interleukin-6 and 
tumour necrosis factor-a (Axelsson et al., 2006a, Zoccali et al., 2003).
Obesity, especially when associated with metabolic syndrome, is considered a risk 
factor for CVD. In addition, it has been shown that ESRD is associated with 
obesity. Obesity in ESRD patients is associated with many complications such as 
hypertension, dyslipidaemia, insulin resistance and kidney damage. Obesity is 
associated with an expansion of adipose tissue mass and consequently a potential 
increase of adipokine secretion. A number of adipokines including leptin, TNF-a, 
MCP-1, IL-6 and adiponectin are linked to chronic inflammation. The 
contribution of adipokines to ESRD is still not fully understood. There is limited 
evidence about the effect of leptin on the kidney pathophysiology. Leptin is 
associated positively with increased fat mass. Leptin has been shown to stimulate
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proliferation of endothelial cells leading to hypertrophy of mesangial cells and in 
turn results in stimulation of vascular inflammation and oxidative stress. Previous 
studies showed that ESRD patients have a significant increase in circulating 
adipokines. A number of studies have tried to explain the effect of obesity on 
kidney disease, although the current data remains poorly understood. However, 
some researchers have hypothesized mechanisms to explain the effect of obesity 
including endocrine changes, low-grade inflammation, oxidative stress and 
endothelial dysfunction (Iglesias and Diez, 2010). An improved understanding of 
obesity related mechanisms influencing the CVD in ESRD may contribute to 
development of new prevention and treatment approaches. The role of some 
adipokines in the pathogenesis of cardiovascular and renal diseases is studied in 
this thesis (chapter 5).
It has been shown that obesity correlates with macrophage infiltration into adipose 
tissue (Weisberg et al., 2003). Furthermore, macrophage accumulation has been 
known to contribute mainly to the production of inflammation markers (Weisberg 
et al., 2003). It has been found that adipose tissue in ESRD patients also has 
increased macrophage numbers (Roubicek et al., 2009). Understanding the 
contribution of the adipose tissue to ESRD more fully is therefore important.
1.11 Uraemic toxins
In health, kidneys potentially remove toxic compounds from the blood and 
eliminate these in the urine. In ESRD, the loss of the renal capacity to eliminate 
these toxic substances causes their accumulation in the body. These potentially 
toxic compounds have been termed uraemic toxins and can be classed into three
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groups namely (1) small water-soluble compounds with a molecular weight less 
than 500kd, (2) middle molecules with a MW of more than 500kd and (3) protein- 
bound substances (Dhondt et al., 2000) , These are shown in Tables 1.3 and 1.4. 
Even as far back as 2003, more than ninety toxins were identified with molecular 
weights between 60 Da (urea) to 32,000 Da (Interleukin Ip [IL-ip]) (Vanholder et 
al., 2003). Uraemic toxins affect every organ system in the body including the 
cardiovascular system. One publication listed some of these substances affecting 
the cardiovascular system, the focus of this thesis, and is shown in Table 1.5.
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Classification Characteristics Prototypes Toxicity
Small water-soluble 
molecules
MW < 500 Da, easily 
removed by any 
dialysis strategy
Urea,
creatinine
Not necessarily toxic
Middle molecules MW > 500 Da, 
removed only through 
large-pored membranes
P2-M,
leptin
Large array of biological 
impacts
Protein-bound
molecules
Any MW, difficult to 
remove with any 
dialysis strategy
Phenols, i 
ndoles
Large array of biological 
impacts
Table 1.3 Current classifications of uraemic retention solutes
Adapted from (Vanholder et al., 2008b)
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Small Hater-soluhlccompounds ’rotcin-hound compounds Middle molecules
1 -Methyiadenosine 2-Methoxyresorcinol Adrenomedullin
1-Methylguanosine 3-Deoxyglucosone Atrial natriuretic
1-Methylinosine CMPF 0;-MicroglobuIin
ADMA Fructoselysine P-Endorphin
a-keto-5-Guanidinovaleriate Glyoxal P-Lipotropin
a-N-Acetylarginine Hippuric acid Cholecystokinin
Arabinitol Homocysteine Clara cell protein
Argininic acid Hydroquinone Complement factor D
Benzylalcohol Indole-3-acetate Cystatin C
P-Guanidinopropionate Indoxyl sulfate DIP 1
Creatine Kinurenine 5-Sleep-inducing
Creatinine Kinurenic acid Endothelin
Cytidine Melatonin Hyalur
Dimethyl Methylglyoxal onic
glycine N'-Carboxymethyllysine acid
Erythritol p-Cresol Interle
Guanidine Pentosidine X-lg Light chain
Guanidinoacetate Phenol Leptin
Guanidinosuccinate p-OHhippurate Methionine-
Hypoxanthine Putrescine Neuropeptide Y
Malondial Quin Parathyroid
dehyde olinic hormone
Mannitol acid Retinol binding
Myoinositol
N2,N2-Dimethylguanosine
N4-Acetylcytidine
N6-Methyladenosine
N6-Threonylcarbanioyladenosine
Orotic acid
Orotidine
Oxalate
Phenylacetylglutamine
Pseudouridine
SDMA
Sorbitol
Taurocyamine
Threitol
Tliymine
Uracil
Urea
Uric acid
Uridine
Xanthine
Xanthosine
Table 1.4 List of uraemic retention solutes
Adapted from (Vanholder et al., 2008b)
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Uremic toxins Leukocytes Endothelial Smooth Thrombocytes
cells musclecells
AGE X X X
AOPP X X
AQE-B-
microglobulin X
Angiogenin-DIP X
(mcroglobulin X X X
Complement 
factor D
X
Cytokines X X X X
Homocysteine X X X
Leptin X X X
Ig-light chain
X
Guanidines
X
Indoxyl sulfate
X
Phenylacetic
acid
X
Table 1.5 Some uraemic toxins shown to have a potential cardiovascular
impact
AGE advanced glycation end products; AOPP advanced oxidation protein 
products;
(Vanholder et al., 2008b)
1.12 Lipoproteins
Lipoproteins are a family of assembled proteins and lipid particles. Lipoproteins 
play an important role in transport and metabolism of dietary lipids. Abnormal 
lipoprotein metabolism is associated with an increase in the risk of cardiovascular 
disease (CVD). Depending upon density, compositional and functional properties, 
the lipoproteins are divided into several classes. These classes are chylomicrons 
secreted from absorptive enterocytes, very low density lipoprotein (VLDL) 
secreted by hepatocytes, low density lipoprotein (LDL) produced by metabolism 
of VLDL, and high density lipoprotein (HDL) produced by the intestine and the 
hepatocytes (Havel, 2001, Jain et al., 2007). The main function of lipoproteins is 
transport of lipids (cholesterol and triglycerides) between different tissues 
(Habenicht et al., 1994). Lipoproteins contain varying proportions of triglyceride 
(TG), free cholesterol, esterified cholesterol, and phospholipids, besides a large 
number of proteins (Figure 1.3).
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Mol Wt Size 
(Daltons) (nm) Lipoprotein name/Apo Content Percent Lipid Content
400x10*
10-80 x 10*
5.10x10*
2.3x10*
1.7-3.6x10*
Trig Choi
Chylomicrons
75-1200 • • • Apos B-48, A-l, A-H. A-IV. W, C-H. C-lll, E • • • 80-95 2-7
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Figure 1.3: Characteristics of the Major Classes of Lipoproteins in Human 
Plasma
The most common classification of lipoproteins is based on flotation 
density/ultracentrifugation. The physical properties of the major lipoprotein 
classes are shown. Other common classification systems include differentiation by 
apolipoprotein content or electrophoresis.
Taken from (Saland and Ginsberg, 2007)
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1.12.1 Chylomicrons (CM)
Chylomicrons are the largest lipoprotein particles with a molecular weight of 50- 
lOOOxlO6 Da. Chylomicrons are very rich in dietary TG and proportionally 
contain much less cholesterol, phospholipids and protein. Chylomicrons are 
produced in the intestines and have apo B-48 as the major protein as well as apo 
A-I, apo A-II and apo A-IV. Dietary TGs, diacylglycerol (DG), 2-monoglycerol 
(2-MG) and fatty acids are taken up by enterocytes in the small intestine to form 
nascent chylomicrons. Released nascent chylomicrons reach the venous 
circulation after traversing the thoracic duct. Interestingly, glucagon-like peptide 2 
(GLP-2) increases chylomicron production in the intestine through the CDS 6 
pathway (Kindel et al., 2010).
In the systemic circulation, nascent chylomicrons undergo several exchanges of 
apoproteins where apo C and apo E are transferred to nascent chylomicrons from 
HDL in exchange for apo A-I and apo A-IV (Vaziri, 2006). In the circulation, 
nascent chylomicrons bind to lipoprotein lipase (LPL) in endothelium of the 
capillaries in the skeletal muscle and adipose tissue. LPL mediated hydrolysis of 
TG leads to the liberation of fatty acids that can be taken up by those tissues for 
storage and metabolism (Figure 1.5). The residual particles, called remnant 
chylomicrons, is then released into the circulation and cleared by hepatocytes 
(Havel, 2001, Kindel et al., 2010, Vaziri, 2006). Apo C-II is required for LPL 
activation, apo E is required for binding of chylomicrons to the endothelium 
surface, whereas apo C III is an inhibitor of LPL (Redgrave, 2004). Following the 
hydrolysis of nascent chylomicron content, apo C and apo E are returned to HDL, 
and remnant chylomicrons are taken up by hepatocytes through LDL receptor-
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related protein (LRP) (Redgrave, 2004, Vaziri, 2006). In addition to LRP, LDL 
receptor has been proposed to be involved in the clearance of remnant 
chylomicrons (Redgrave, 2004).
1.12.2 Very Low Density Lipoproteins (VLDL)
Next to chylomicrons, VLDL is also considered a large lipoprotein that contains 
TG as its main lipid content. VLDL molecular weight is 10-80x106 Da. The major 
structural proteins in VLDL are apo B-100 as well as apo E, apo A-I and apo A-II 
(Havel, 2001, Shelness and Sellers, 2001, Vaziri, 2006). Similar to chylomicrons, 
nascent VLDL also acquires apo C and apo E from HDL in the circulation. 
Together with chylomicrons, VLDL is considered as TG-rich lipoproteins. TG in 
VLDL is derived from de novo synthesis in hepatocytes or from plasma uptake of 
remnants and free fatty acids. These triglycerides are transferred into apo B-100 
containing VLDL via the microsomal triacylglycerol transfer protein (MTP) 
(Shelness and Sellers, 2001). Following the secretion into the circulation, VLDL 
undergoes LPL-mediated hydrolysis similar to chylomicrons and this will lead to 
the formation of remnant VLDL which is also known as intermediate density 
lipoprotein (IDL) (Figure 1.6). One possible fate of IDL is uptake by the liver by 
LRP.
Unlike chylomicrons which are almost fully hydrolysed by LPL, LPL-mediated 
VLDL hydrolysis is partial and this can be explained by difference in the size. 
VLDL remnant particles are removed by VLDL receptor in myocytes and 
hepatocytes (Takahashi et al., 2004). Alternatively, VLDL undergoes further 
lipolysis by hepatic triacylglycerol lipase action leading to the formation of 
cholesterol-rich LDL.
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1.12.3 Low Density Lipoproteins (LDL)
LDL is the major cholesterol-containing lipoprotein. LDL molecular weight is 
2,300,000 Da with the major structural protein being the apo B-100. LDL is 
formed during the progressive lipolysis of VLDL and IDL. LDL particles are 
taken up mainly by liver or by extrahepatic tissue via LDL-receptor. LDL is the 
most important lipoprotein in terms of potential for atheromatous CVD and the 
availability of effective treatments.
1.12.4 High Density Lipoprotein (HDL)
HDL is synthesized in the liver and also by the intestine and carries apo A-I, A-II, 
and A-IV. HDL molecular weight is between 67,000 to 360,000 Da. HDL can be 
divided into subtypes including HDL-2 and HDL-3 depending on the size (Ansell 
et ah, 2005, Havel, 2001). Circulating HDL is able to remove cholesterol from cell 
surfaces (caveolae) and return it to liver, a process known as reverse cholesterol 
transport (Figure 1.7). This process is mediated by lecithinecholesterol 
acyltransferase (LCAT) and cholesterol ester transfer protein (CETP) (Yokoyama, 
2006). CETP is required to facilitate the exchange of cholesterol and TG between 
HDL and LDL and TG-rich lipoproteins. LCAT plays an important role by 
esterfication of cholesterol taken up by nascent HDL forming cholesterol ester- 
rich lipoprotein HDL2 particles. This process is known as the HDL maturation. 
Cholesterol ester-rich HDL is large and more spherical (Cho, 2009, Havel, 2001). 
LCAT is activated mainly by apo A-I. Other factors also play important roles in 
the transfer of cholesterol such as ATP-binding cassette transporter Al(ABCAl) 
which is considered the rate-limiting step for HDL assembly (Yokoyama, 2006).
36
HDL plays an essential part in the metabolism of other lipoproteins. One example 
is when HDL provides apo C and apo E for hydrolysis of nascent chylomicrons 
and VLDL (Cho, 2009). Since HDL is considered to be protective, anti-oxidant 
and anti-atherogenic, its metabolism and potential interaction with adipose tissue 
is also of interest in ESRD (Ansell et al., 2005, Michael and Peter, 2007).
1.13 White adipose tissue metabolism
It has been known that WAT plays a significant role in the regulation of lipids and 
glucose metabolism. Any imbalance between storage and mobilization of TGs in 
WAT will result in disease including obesity and therefore lead to abnormal 
plasma lipids. Abnormal circulating lipids are a leading causal risk of 
cardiovascular disease. WAT is the largest organ of energy storage. The synthesis 
and break down processes of TGs are controlled by hormonal and dietary factors 
as well as the key enzyme, hormone-sensitive lipase (HSL).
1.13.1 Triglyceride synthesis and storage
1.13.1.1 Synthesis from Fatty Acids
Fatty acids can be obtained either by de novo lipogenesis or by uptake from 
plasma. De novo lipogenesis is synthesis of fatty acids from non-lipid molecule 
mainly glucose. De novo lipogenesis is regulated by hormones and nutritional 
states. These include insulin and poly-unsaturated fatty acids (PUFA). Citrate is 
converted in the cytoplasm into acetylCoA and oxaloacetate by ATP-Citrate lyase 
and then into malonyl-CoA. Acetyl-CoA combines with malonyl-CoA to 
synthesize acyl-CoA by fatty acid synthase (FAS) (Dinel et ah, 2010). Figure 1.4 
shows lipogenesis pathway in adipocytes. The regulation by insulin and PUFA is
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under action of transcription factor sterol response element binding protein 1c 
(SREBP-1C) and carbohydrate response element binding protein (CHREBP). The 
regulation of de novo lipogenesis in human adipocytes is still not well defined.
Another source of fatty acids is up take from plasma. These fatty acids are 
circulating in plasma as non-esterified fatty acids bound to plasma albumin or 
derived by hydrolysis of TG-rich lipoprotein. Human adipocytes express several 
fatty acid transporters on the plasma membrane; these include the protein CD 36, 
the fatty acid transport protein, and the fatty acid binding protein plasma 
membrane (Large et al., 2004, Trayhurn, 2007)
1.13.1.2 Source of glycerol-3-phosphate (G-3-P)
G-3-P is required for synthesis of TG. Since the adipose tissue lacks glycerol 
kinases, the G-3-P can be produced only from glucose through glycolysis or from 
gluconeogenesis. Glucose transporters 1 and 4 (GLUT 1 and 4) play important 
roles for glucose entry into adipocytes (Large et al., 2004).
1.13.1.3 TG synthesis
TGs are produced by a pathway in which G-3-P reacts with fatty acyl CoA to 
form TG involving many steps. The intermediate products are involved in adipose 
tissue signaling which regulate many biological processes. Therefore any 
dysregulation in this pathway may result in a defect of the cellular function (Large 
et al., 2004).
1.13.2 Lipolysis
Adipose tissue is considered as largest organ in the body for energy storage and a
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major source of metabolic fuel. During lipolysis, triglycerides are sequentially 
hydrolysed into diacylglycerol (DAG), monoacylglycerol, and glycerol, releasing 
one molecule of fatty acids at each step. Several lipases and lipid droplet- 
associated proteins such as perilipins are required in the hydrolysis of stored TG 
(Lafontan and Langin, 2009). Three enzymes are known at the present time 
involved in the hydrolysis of triglycerides: adipose triglyceride lipase (ATGL), 
hormone-sensitive lipase (HSL) and monoglyceride lipase (MGL) (Girousse and 
Langin, 2011).
During fasting, lipolysis is activated due to the decreased insulin and increased 
glucagon concentrations in the post-absorptive states. HSL and other lipases 
hydrolyze TG to yield free fatty acids, via diacylglycerol and monoglycerol, and 
glycerol which are released into the blood stream. Fatty acids bound to albumin 
enter muscles and other tissues to be oxidized for energy while glycerol is 
converted by the liver to glucose during fasting during gluconeogenesis. HSL and 
ATGL appear to be the main responsible enzymes in the adipose tissue lipolysis 
that is controlled by insulin and catecholamines. The coordination of lipid storage 
and utilization is regulated by the perilipin family of lipid droplet coat proteins 
(Ducharme and Bickel, 2008). Perilipin A is the most highly phosphorylated 
protein stimulated by lipolytic hormones in adipocytes and is required for the TG 
hydrolysis stored in adipocyte lipid droplets by adipocyte lipases (Lafontan and 
Langin, 2009).
HSL and perilipin phosphorylation is an essential step to activate the lipolysis. In 
addition, perilipin phosphorylation leads to interact with ATGL which in turn 
initiate TAG breakdown (Girousse and Langin, 2011, Lafontan and Langin,
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2009).
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Figure 1.4: An overview of lipid metabolism in white adipose tissue
Adipocyte in basal and stimulated state. In the basal (unstimulated) state, HSL 
remains in the cytosol while ATGL, perilipin and the ATGL co-activator ABHD5 
are located at the LD surface. Perilipin and ABHD5 form a complex, maintaining 
the latter in an inactive state and thereby limiting basal ATGL-mediated lipolysis. 
When stimulated, activating pathways trigger protein kinase phosphorylation 
leading to HSL and perilipin phosphorylation. Phosphorylated HSL migrates from 
cytosol to the LD where it is enzymaticaly active while LD surface undergoes 
major rearrangements and fragmentation because of protein kinase-mediated 
phosphorylation of perilipin. Perilipin phosphorylation is also responsible for 
ABHD5 release, which can in turn interact with ATGL, to initiate TAG 
breakdown. ABHD5, abhydrolase domain containing 5; ADRP, adipose 
differentiation-related protein; ATGL, adipose triglyceride lipase; DAG, 
diacylglycerol; FA, fatty acid; FABP4, fatty acid-binding protein 4; Fsp27, fat- 
specific protein 27, also called Cidec; G0S2, G0/G1 switch gene 2; HSL, 
hormone-sensitive lipase; MAG, monoacylglycerol; MGL, monoglyceride lipase; 
PLlNla, perilipin A; TAG, triacylglycerol.Adapted from:(Girousse and Langin, 
2011).
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1.14 Key protein factors in lipid metabolism
1.14.1 Lecithin: cholesterol acyltransferase (LCAT)
LCAT is a plasma enzyme for the esterification of cholesterol to be taken up by 
HDL. It is expressed mainly in adipose tissue and in small amounts in the brain. 
Cholesterol esterification is an essential step in the reverse cholesterol transport. 
LCAT also enhances the HDL maturation from cholesterol-poor to cholesterol- 
rich particles (Rousset et al., 2009). LCAT requires apo A-I as an activator which 
is found on the HDL surface. LCAT activity has been noted to be low in ESRD 
patients (Vaziri, 2006).
1.14.2 Lipoprotein lipase (LPL)
LPL is an enzyme that belongs to the TG lipase gene family of protein that acts as 
an esterification factor for TG and phospholipase. This family includes hepatic 
lipase, pancreatic lipase, and endothelial lipase (Wang and Eckel, 2009).
LPL synthesized in adipocytes as well as in other cell types such as myocyte, 
cardiomyocyte and macrophage (Kobayashi et al., 2007). The main targets of LPL 
are chylomicrons and VLDL particles as it converts them into remnant forms to 
facilitate their clearance. Post-heparin plasma is used to measure LPL activity as 
LPL is detached from the endothelial cells in the presence of heparin (Kobayashi 
et al., 2007). In ESRD, LPL activity has been reported as low in postheparin 
lipolytic activity. In addition, Apo C-II which is an LPL activator has also been 
noted to be low in plasma (Vaziri, 2006).
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1.14.3 Cholesterol ester transfer protein
CETP is a transfer protein belongs to a family of protein that enables lipid 
exchanges in the circulation. This family includes lipopolysaccharide binding 
protein (LBP), bactericidal/permeability-increasing protein (BPI) and 
phosphoplipid transfer protein (PLTP) (Quintao and Cazita, 2010). CETP is a 
74000 Da secreted mainly by the liver and encoded by CETP gene. CETP is 
bound to HDL and transfers cholesteryl ester from HDL to other lipoproteins and 
to IDL in exchange for TG. Thus increased activity of CETP may result in 
abnormally high TG content in HDL particles (Weber et al., 2010). It has been 
suggested that the inhibition of CETP can promote the reverse cholesterol 
transport, a pathway by which excess tissue cholesterol is transported to the liver 
for excretion (Jain et al., 2007). CETP plasma levels were noted to be increased in 
ESRD patients (Vaziri, 2006).
1.14.4 LDL-receptor (LDL-R)
The LDL-R is an 839 amino acids transmembrane protein that plays an important 
role in cholesterol homeostasis. LDL-R takes up cholesterol and cholesrteryl ester 
from LDL via a process known as clathrin-mediated endocytosis (Gent and 
Braakman, 2004). LDL-R expression has been studied in many diseases, including 
ESRD, where it was found that LDL-R expression is associated with heavy 
proteinuria (Vaziri, 2006).
1.14.5 Acylation stimulating protein (ASP)
ASP is a 76 amino acid protein with molecular weight 8932 Da. ASP is composed 
of C3desArg, which is produced by adipocytes when adipsin cuts the complement
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protein B and C3 complex. C3a results from interaction of C3 with factor B in 
which adipsin cleaves this interacting complex to generate C3a and C3J3 chains. 
Arginine is removed from C3a by carboxypeptidase to form ASP. ASP is 
produced by adipocytes (Cianflone et al., 2003). Chylomicrons promote secretion 
of C3 which in turn increases the formation of C3a (Miner, 2004).
ASP stimulates TG synthesis by incorporation of fatty acids into adipose 
triglyceride. ASP also increases glucose transport (Cianflone et al., 2003). It has 
been found that ASP plasma levels increased after eating suggesting its role in 
adipose tissue metabolism and in insulin secretion (Miner, 2004).
1.14.6 Hormone-sensitive lipase (HSL)
HSL is a 775 amino acid enzyme protein produced mainly in adipose tissue 
among others (Large et al., 2004), HSL has been shown to be an important factor 
for normal structure and function of adipose tissue (Wang et al., 2008a). HSL is a 
multifunctional enzyme that hydrolyzes TG, DAG, cholesterol ester and retinyl 
ester (Lafontan, 2008). HSL"7' models showed an accumulation of DAG in 
adipocytes and muscle tissue suggesting that HSL is the rate-limiting enzyme for 
DAG lipolysis (Large et al., 2004). HSL action is regulated by many factors such 
as adipocyte protein aP2 and fatty acid-binding protein 4 (FABP4) (Lafontan, 
2008, Wang et al., 2008a).
1.14.7 Hydroxy-3-methylgIutaryl-CoA reductase (HMG CoA reductase)
HMG CoA reductase is the enzyme that is the rate-limiting step in cholesterol 
biosynthesis. It converts HMG-CoA to mevalonate that is involved in further steps 
for synthesis of cholesterol and other lipids (Istvan and Deisenhofer, 2001).
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Inhibition of this enzyme results in decreased cholesterol synthesis. For this 
reason, HMG CoA reductase inhibitors are used as cholesterol-lowering drugs 
(Jain et ah, 2007).
1.14.8 Adipose triglyceride lipase (ATGL)
Adipose triglyceride lipase (ATGL) is one of lipase enzymes. ATGL is 54 KDa 
also known as desnutrin, encoded by PNPLA2 (patatin-like phospholipase 
domain-containing-2) (Zimmermann et ah, 2004). ATGL hydrolyse the first and 
rate-limiting step in TG breakdown to DAG and NEFAs. At each step of TG 
breakdown one molecule of NEFA produced and final step generated NEFA and 
glycerol, which are released by adipocytes. ATGL is in found abundance in 
adipose tissue and its expression increases during adipocyte differentiation 
(Mairal et ah, 2006). Studies showed that ATGL- deficiency in mice result in 
obesity due to TG accumulation in adipose tissue (Haemmerle et ah, 2006). 
ATGL and HSL are the major TG lipases. ATGL plays crucial rules in the 
lipolysis as it provides DAG to HSL. HSL in turn completes full TG hydrolysis 
(Lafontan and Langin, 2009).
1.14.9 Perilipin
TG is predominately stored within lipid droplets in adipocytes that are surrounded 
by a phospholipid monolayer containing various lipid droplet proteins. The 
perilipin family are groups of proteins belong to the PAT family (Lafontan and 
Langin, 2009). Perilipin A (PeriA) is the most abundant adipocyte lipid 
phosphoprotein, which is activated by protein kinase A (PKA) and is involved in 
the regulating of lipid metabolism in adipocytes by controlling various proteins
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(Brasaemle, 2007). Moreover, perilipin A is the most highly phosphorylated 
protein in adipocytes stimulated by lipolytic hormones and is required for the 
hydrolysis of TG stored in the fat cell lipid droplets by adipocyte lipases. Absence 
of perilipin resulted in a reduction in hormone-stimulated lipolysis (Lafontan and 
Langin, 2009).
1.15 Dyslipidaemia in ESRD
It has been established that ESRD is associated with a characteristic 
dyslipidaemia. Dyslipidaemia in ESRD consists of both an alteration in function 
as well as in the structure of lipoproteins (Wanner and Krane, 2002). The 
management of the ESRD-induced dyslipidaemia is one of the principal therapies 
to decrease complications such as cardiovascular disease (Prichard, 2003). 
Generally, dyslipidaemia includes hyper-triglyceridaemia, increased VLDL, 
increase in plasma concentration of remnant lipoproteins, accumulation of 
oxidized lipids and lipoproteins, decreased plasma levels of HDL and impaired 
HDL maturation and function (Vaziri, 2009).
Hypertriglyceridaemia results from an increase in the concentration of apo B- 
containing lipoproteins. Decreased lipolysis of Chylomicrons and VLDL is 
attributed to increased apo C-III which in turn inhibits LPL (Kaysen, 2006a). LPL 
inhibition leads to accumulation of apo B-containing lipoproteins including their 
transformation into the more atherogenic forms (Vaziri, 2006). Accumulation of 
remnant chylomicrons and VLDL also results from the decrease in LRP and 
VLDL receptors (Vaziri, 2009).
Apo B-containing lipoproteins undergo composition alteration along with changes
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in concentrations. TG content in VLDL is decreased while the cholesterol content
is increased. In contrast to VLDL, LDL is associated with increased TG content 
and decreased cholesterol (Vaziri, 2006).
ESRD is characterized by normal or near normal levels of plasma cholesterol 
(Chan et al., 2008). LDL in ESRD is characterized by predominance of small 
dense LDL particles which have an abnormal content of TG (Vaziri, 2006). These 
small dense particles are more atherogenic because they are prone to more 
modifications such as oxidation and also have less binding affinity for their 
receptors (Vaziri, 2009) (Majumdar and Wheeler, 2000).
Plasma HDL levels have been noted to be decreased in ESRD along with an 
impairment of HDL maturation (Vaziri, 2006). Apo A-I and apo A-II levels are 
also decreased and lead to both decreased LCAT activity and decreased HDL 
(Vaziri, 2009).
The accumulation of remnants lipoproteins in the circulation leads to further 
modification such as oxidation, glycation or carbamoylation. These modifications 
increase the half-life, decrease receptor binding and increase the formation of 
foam cells, factors that promote atherosclerosis progression (Wanner and Krane, 
2002).
1.16 Dialysis impact on Dyslipidaemia
Dialysis is one of most effective therapies that are used to decrease ‘uraemic 
toxins’ and decrease the uraemic symptoms. The type of dialysis may influence 
the dyslipidaemia of ESRD (Tsimihodimos et al., 2008).
In haemodialysis, dyslipidaemia includes a significant increase in triglyceride-rich
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lipoproteins, decrease in HDL and predominance of small dense LDL particles. 
Circulating LDL-cholesterol or total cholesterol levels are normal or near normal 
(Chan et al, 2008). There are increases in Lp(a) (Prichard, 2003). In addition, 
decreased apoC-II/apoC-III ratio leads to low activity of LPL and therefore 
impaired catabolism of TG-rich lipoproteins (Chan et al., 2008).
In contrast to haemodialysis, peritoneal dialysis seems to be characterised by a 
more atherogenic lipid profile (Chan et al., 2008, Prichard, 2003, Tsimihodimos et 
al., 2008). Dyslipidaemia in peritoneal dialysis is characterized by an increase in 
levels of plasma cholesterol, TG, IDL,VLDL, LDL and Lp(a) (Chan et al., 2008). 
Patients with peritoneal dialysis also have more susceptibility to insulin resistance 
as well as more VLDL production due to glucose loading from peritoneal 
dialysate (Chan et al., 2008, Tsimihodimos et al., 2008).
1.17 Consequence of dyslipidaemia
The risk of CVD is well established in ESRD patients. One of the major 
consequences of dyslipidaemia in ESRD is cardiovascular disease. Several studies 
have documented that LDL and HDL cholesterol are risk factors for 
cardiovascular disease in ESRD (Chan et al., 2008). Dyslipidaemia also promotes 
the progression of kidney disease. The reabsorption of lipids by tubular epithelial 
cells may result in the structural and functional changes in the kidney tissue (Chan 
et al., 2008, Vaziri, 2006). Dyslipidaemia has also been suggested to alter energy 
metabolism by limiting the availability of fatty acids in the skeletal muscles and 
myocardium (Vaziri, 2006).
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1.1$ Management of dyslipidaemia
It has been recommended that dyslipidaemia should be managed in ESRD as it is 
associated strongly with cardiovascular disease (Marrs and Saseen, 2010). 
Reduction of total and LDL cholesterol has been shown to significantly decrease 
the' risk of cardiovascular disease in early stage of CKD (Molitch, 2006). 
Dyslipidaemia can be managed by changing the life styles of patients as well as by 
pharmacological intervention. The common pharmacological treatments include 
HMG CoA reductase inhibitors (statins), fibrates and cholesterol absorption 
inhibitor (Chan et al., 2008). Statins and fibrates have to be used cautiously in 
ESRD, at reduced doses, as suggested in a recent publication (Kasiske et al., 
2006).
The benefit of statins on the prevention of coronary artery disease is well- 
established (Nair et al., 2010). Statin have also been suggested to have additional 
effects such as anti-inflammatory effect as seen by a drop in the C-reactive protein 
(Montague and Murphy, 2009). ESRD patients on statin have been shown to have 
low mortality when compared with non-statin patients. However, some studies fail 
to show any benefit from using statin in ESRD (Wanner and Ritz, 2008).
Fibrates are used to reduce plasma triglyceride and increase HDL-cholesterol. 
Fibrates are agonists of the enzyme peroxisomes proliferator activated receptor 
alpha (PPARa) which results in the lipolysis of TG-rich lipoproteins due to 
stimulation of lipoprotein lipase, inhibition of apo C-III secretion, and by 
increasing the apo A-I production (Jain et al., 2007). Some studies recommend 
against using flbrate in ESRD whereas others suggest that they be used by 
specialists cautiously (Kasiske et al., 2006, Montague and Murphy, 2009).
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1.19 Rationale for the study of adipose tissue
The adipose tissue is crucially involved in the production and clearance of 
lipoproteins. This involves a close interaction between the lipoproteins and 
adipocytes. Understanding how this process is altered in ESRD is critical. It is 
also tempting to postulate that the lipoprotein/adipocyte interaction may also 
influence the other functions of adipose tissue including its endocrine function. 
The present studies are designed to clarify this hypothesis.
Inflammation and obesity in ESRD are independently associated with pro- 
atherogenic dyslipidaemia (Axelsson, 2008). Therefore studying the adipokine 
secretion, both pro- and anti-inflammatory, in the context of ESRD and renal 
replacement therapy is important.
It is also possible that the nutritional and the endocrine functions of adipose tissue 
may overlap. An association between low plasma adiponectin and decreased 
lipoprotein lipase activity has been described (Kwan and Beddhu, 2007).
The influence of renal replacement therapy such as dialysis on long term 
prognosis is not fully understood. Dialysis does not improve the nutritional 
function of adipose tissue since it has been shown not to correct dyslipidaemia 
(Majumdar and Wheeler, 2000). The type of dialysis may also be critical since PD 
patients have a more atherogenic lipid profile than HD patients (Prichard, 2003). 
Circulating adipokine concentrations are altered in ESRD (Wiecek et al., 2002).
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Figurel.5: Chylomicron metabolism
Chylomicrons are synthesized in the intestinal epithelial cells. After secretion 
CMs interact with HDL where apo C and apo E are transferred from HDL. On the 
luminal surface of capillary endothelium of adipose tissue, LPL hydrolyzes the 
TO and remnant CM is produced. The remnant CM is taken up by the liver 
receptor-mediated endocytosis.
Adapted from (Havel, 2001)
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Figurel.6: VLDL and LDL metabolism
Following secretion of VLDL, LPL hydrolyzes the TG forming IDL. IDL can 
either be endocytosed by the hepatocytes through a receptor-mediated process or 
undergo further hydrolysis by hepatic lipase leading to formation of LDL. LDL 
may be taken up by scavenger receptors on non-hepatic cells including 
macrophages.
Adapted from (Havel, 2001)
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Figure 1.7: HDL metabolism
HDL picks up cholesterol from cells. Cholesterol is converted to cholesterol ester 
by LCAT. HDL transports CE to LDL or TG-rich lipoprotein by CETP. HDL 
particles bind to scavenger receptor SR-B1, transferring the cholesterol and 
cholesterol esters into hepatic cells.
Adapted from (Havel, 2001)
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1.20 Novelty of studies in this thesis
Previous studies in this area have largely dealt with circulating adipokine and 
lipoprotein measurements in ESRD and following dialysis. As far as I am aware 
this is the first attempt to investigate circulating lipoprotein fractions in ESRD and 
renal replacement therapies such as HD and PD. A recent previous study has 
examined 3T3-L1 (mouse) adipocyte response to uraemic serum in a very limited 
way in terms of a single adipokine, leptin (Kalbacher et ah, 2011). This is the first 
study to attempt to characterise a full range of lipoprotein gene and protein 
changes brought about by incubation of uraemic serum with normal human 
adipocytes in vitro. For the very first time this study has attempted to characterise 
a fuller range of changes in adipokines by incubation of uraemic serum with 
normal human adipocytes. This is also a novel approach to attempt to clarify the 
effect of renal replacement therapies in their ability to alter lipoprotein 
metabolism and adipokine secretion in terms of changes in gene and protein 
expression.
1.21 Hypothesis
Adipose tissue has been shown to contribute to CVD in various ways that include 
alteration in lipoprotein metabolism as well as secretion of pro- and anti­
inflammatory adipokines. We hypothesized that the retention of ‘uraemic toxins’ 
in ESRD results in adipose tissue dysfunction affecting both adipokine production 
and lipoprotein metabolism. This could be a potential link to CVD in ESRD. This 
could also explain why ESRD patients are relatively resistant to the beneficial 
effects of statins.
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1.22 Aims and objective of study
The objective of the study was to clarify the role that adipose tissue and 
lipoproteins may have in ESRD. This in turn may increase our understanding of 
the cardiovascular risk associated with ESRD.
More specifically, we aim to:
i) Determine whether the effects of serum from normal and ESRD 
subjects on adipocyte cultures is different;
ii) Understand how the responses to serum obtained prior to and following 
dialysis influence adipocyte cultures;
iii) Clarify the effect of chylomicrons, VLDL, LDL and HDL isolated 
from plasma of normal subjects on adipocyte cultures;
iv) Examine the effect of chylomicrons, VLDL, LDL and HDL isolated 
from plasma of ESRD subjects on adipocyte cultures;
v) Study nutrient and adipokine aspects of adipocyte function both in 
adipocyte cultures and adipose tissue samples obtained from patients with 
ESRD;
vi) Show whether the adipose tissue taken from ESRD patients is different 
morphologically from a normal group.
Providing answers to these questions may contribute to a better understanding of 
the role adipose tissue in the pathogenesis of CVD in ESRD.
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CHAPTER 2
MATERIALS AND METHODS
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2.1 Reagents and Methods
2.1.1 Chemical reagents
Acetic acid Sigma
Agarose Sigma
Amphotericin B Lonza
Biotin Sigma
Bovine serum albumin Sigma
Chloroform Fisher
Copper (II) sulphate solution Sigma
Cortisol Sigma
Dexamethasone Sigma
Disodium hydrogen phosphate Sigma
Modified Eagle's medium/Ham's F12 (1:1) Invitrogen
100% Ethanol Sigma
Endothelial cell growth supplement PromoCell
Epidermal Growth Factor PromoCell
Ethidium bromide Sigma
Foetal calf serum Bio sera
Gill’s haematoxylin Sigma
GeneRuler TM 100 bp DNA Dulbecco's ladder Helena BioSciences
Goat anti-mouse conjugated to horseradish peroxidase Bio-Rad
Guanidine hydrochloride Sigma
HEPES Sigma
Human transferrin Sigma
I-methyl-3-isobutylxanthine (IBMX) Sigma
Insulin Sigma
Isoprenaline Isopropanol Sigma
Magnesium sulphate Sigma
Methanol VWR
Monoclonal Mouse Anti-Human CD68 DakoCytomation
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Noradrenaline Sigma
Normal Goat serum Vector
Optiprep Axis-Shield,UK
Pantothenate Sigma
Penicillin/Streptomycin Invitrogen
Photographic developer Sigma
Photographic fixer Sigma
Potassium chloride Sigma
Preadipocytes , Human subcutaneous white PromoCell
RNase AWAY Molecular BioProd
Rosiglitazone GlaxoSmithKline
Sodium chloride Sigma
Sodium citrate Sigma
Sodium dodecyl sulphate Sigma
Sodium dihydrogen orthophosphate Sigma
Sodium EDTA Sigma
Sodium hydroxide Sigma
lOxTBE buffer Fisher
Trichloroacetic acid Sigma
Triiodothyronine (T3) Sigma
Tris-Base Sigma
Tris-hydrochloride Sigma
Trizol Invitrogen
Trypsin/EDTA Invitrogen
Tween 20 (polyoxyethylene sorbitan monolaurate) Dakocytomation
Ultra-pure water Sigma
2.1.2 Assay Kits
DNA-free Kit Ambion
ECL detection reagents Amersham
Human Adiponectin ELISA R&D System
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Human Leptin ELISA 
Human Interleukin-6 
iScript cDNA Synthesis Kit 
QPCR Core Kit 
Eurogentec
2.1.3 Equipment
2011 Macrovue UV transilluminator
Beckman Preparative Ultracentrifuge
Benchmar Plus microplate spectrophotometer
Biophotometer
Centrifuge 5415 D
Centrifuge 5415 R
Coming filter system (0.22 pm membrane)
FC205 fraction collector 
Histocenter
Horizontal Gel Electrophoresis units
Kodak Digital Science DC 120 digital camera
Labconco Auto Densi-flow density gradient fractionator
AS 325 Microtome
Microscope ((Polyvar)
Mx3005PTM QPCR System 
PCR Express thermal cycler 
PhotoEnhancer 
3310 pH meter 
Processor 2LE
Quick-seal tube (for rotor VTi 65.1)
LB-80 Ultracentrifuge 
Roche Modular™ SWA
UVette plastic disposable cuvettes 
Water bath
12-well plate
RayBio 
PeproTech 
Bio-Rad 
Eurogentec 
Abgene
Ultra-Violet Products
Beckman
Bio-Rad
Eppendorf
Eppendorf
Eppendorf
Fisher
Gilson
Shandon
SCIE-PLAS
Kodak
Labconco
Shandon
Leica
Stratagene
Hybraid
Kodak
Barloworld
Shandon
Beckman
Beckman
Roche Diagnostics GmbH
Eppendorf
Grant
Fisher
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48-well plate 
96-well microplate
Fisher
Fisher
2.1,4 Software
GraphPad InStat version 5
Kodak Digital Science ID 1 image analysis software 
Microplate Manager v5.2
GraphPad
Kodak
Bio-Rad
StratageneMXPro™ QPCR Software
2.2 Blood and Tissue samples 
2.2.1 Subjects
18 male patients with ESRD on maintenance haemodialysis and peritoneal 
dialysis were recruited on this study. Patients diagnosed with diabetes mellitus 
were excluded where possible. The medical records of each participant were 
reviewed carefully as regards demographic data and underlying diseases such as 
coronary artery disease, hypertension, diabetes mellitus as well as medication 
history. The study protocol was approved by Liverpool Research Ethics 
Committee (REC number: 08/H1002/41). All patients gave informed consent. 
Inclusion criteria consisted of ESRD patients on dialysis, and exclusion criteria 
were age >70 years, female patients, diabetic whenever possible and 
unwillingness to participate in the study. Most patients were on antihypertensive 
medications as well as other commonly used drugs in ESRD, such as phosphate 
and potassium binders (sodium polystyrene sulphonate), diuretics, and vitamin B, 
C, and D supplementation (full list on appendix 2).
The enrolled subjects were categorized into 3 groups: (i) 9 subjects (age: 45.4 ±
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8.1 years) without CKD as controls and without any evidence of kidney injury, (ii) 
11 patients (age: 47.5 ± 5.5 years) prior to starting their dialysis as Pre­
haemodialysis group (Pre-HD), (iii) the same 11 Pre-HD patients (age: 47.5 ±5.5 
years) following their dialysis as Post-haemodialysis group (Post-HD) and (4) 7 
patients (age: 48 ± 14.2 years) on peritoneal dialysis as peritoneal dialysis group 
(PD).
2.2.2 Haemodialysis procedure
Haemodialysis (HD) is a method for removing waste products such as creatinine 
and urea, as well as free water and other toxins from the blood when the kidneys 
are in renal failure. HD is one of three renal replacement therapies (the other two 
being renal transplant and peritoneal dialysis). HD in the studies described in this 
thesis was carried out as an outpatient therapy on the renal wards of the 
RLUH. HD treatments were initiated and managed by specialized staff made up of 
doctors, nurses and technicians on the renal wards at the RLUH.
The principle of HD is the same as other methods of dialysis involving diffusion 
of solutes across a semipermeable membrane. HD utilizes counter current flow, 
where the dialysate is flowing in the opposite direction to blood flow in the 
extracorporeal circuit. Counter-current flow maintains the concentration gradient 
across the membrane at a maximum and increases the efficiency of the dialysis. 
Fluid removal (ultrafiltration) was achieved by altering the hydrostatic pressure of 
the dialysate compartment, causing free water and some dissolved solutes to move 
across the membrane along a created pressure gradient. The dialysis solution that
61
was used was a standard sterilized solution containing mineral ions (HCO3, Ca2+ 
and K+ and Na-1*).
Eleven patients with ESRD were identified as being suitable for the study 
following an initial screening of 51 patients. These patients were stable and 
receiving HD three times a week. Each HD session lasted 4 hours. All patients had 
good vascular access due to presence of a fully functioning arteriovenous fistula. 
All HD patients received a loading dose of 1000 IU of unfractionated heparin at 
the start followed by 1000 IU per hour during haemodialysis. All patients had 
their vital signs including blood pressure and pulse monitored during and after 
dialysis. Euvolaemia was achieved in all patients post-HD.
2.2.3 Peritoneal Dialysis (PD)
Peritoneal dialysis uses the peritoneum as a natural permeable membrane through 
which water and solutes can equilibrate. PD is less physiologically stressful than 
HD, does not require vascular access, can be done at home, and therefore allows 
patients much greater flexibility. However, it requires much more patient 
involvement. Of the total estimated resting splanchnic blood flow of 1200 
mL/min, only about 70 mL/min comes into contact with the peritoneum, so solute 
equilibration occurs much more slowly than in HD. But because solute and water 
clearance is a function of contact time and PD is done nearly continuously, 
efficacy in terms of solute removal is comparable to that obtained with HD.
Dialysate in the PD carried out in the 7 patients in this thesis was instilled through 
a catheter into the peritoneal space, was left to dwell, and then drained. In the 
double-bag technique, the patient drains the fluid instilled in the abdomen in one
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bag and then infuses fluid from the other bag into the peritoneal cavity. Both bags 
are removed between dwells in what is known as the 'disconnect' system. 
Continuous ambulatory peritoneal dialysis (CAPD), used in all 7 of the patients in 
this thesis, is most commonly used because of ease of performance and lack of 
need for a machine to do the exchanges. Typically 2 to 3 L of dialysate was 
infused 4 to 5 times/day; dialysate is allowed to remain for 4-5 h during the day 
and 8 to 12 h at night. The solution was manually drained. Heparin is not required 
and was not administered for this group of patients.
2.2.4 Blood
Blood was collected from all participants, before and after dialysis for HD group, 
and once for the other groups. 30 ml of blood samples from each were transported 
to the Clinical Biochemistry Department at RLUHT and centrifuged at 3000 g for 
15 min followed by separation of serum or plasma. Samples were aliquoted and 
stored at - 80°C until analysis.
2.2.5 Preparation of pooled samples
Individual patient samples were analysed and reported in result chapters. However 
in chapters 4 to 6, pooled serum was used. Pooled serum was prepared by adding 
equal volumes taken from each patient blood sample immediately after collection. 
The objective of pooling was to study the group as a whole in terms of disease or 
health and type of therapy in general rather than to isolate individual patient 
differences. This strategy was necessary for practical purposes. Otherwise the 
workload would have been too great making it impossible to complete the studies 
and beyond the scope of this thesis.
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2.3 Biochemical analysis
Urea, Creatinine, cholesterol, TGs, LDH and total protein concentrations were 
measured on a Roche Modular™ SWA analyzer using colorimetric or enzymatic 
assays following the fully validated assay procedures in routine use in the 
department of Clinical Biochemistry (Roche Diagnostics GmbH, Mannheim, 
Germany). LDL-cholesterol was calculated from total cholesterol, and HDL- 
cholesterol and TG by means of the Friedewald formula;
LDL cholesterol = Total cholesterol - HDL cholesterol - Total triglyceride + 2.19
2.3.1 Principle of cholesterol measurement
Total cholesterol concentrations were determined enzymatically. In the reaction 
the cholesterol esterase hydrolyzes cholesterol esters to free cholesterol and fatty 
acids. The free cholesterol is oxidized to cholesten-3-one and hydrogen peroxide 
by cholesterol oxidase. Peroxidase catalyzes the reaction of hydrogen peroxide 
with 4-aminoantipyrine and phenol to produce a colored quinoneimine product. 
The system monitors the change in absorbance at 520 nm at a fixed-time interval. 
The change in absorbance is directly proportional to the concentration of 
cholesterol in the sample.
2.3.2 Principle of Triglyceride measurement
Total TG concentrations were determined enzymatically in two steps: Briefly, free 
glyceride, was first converted to glycerol 3-phosphate by glycerol kinase and 
degraded into dihydroxyacetone 3-phosphate plus hydrogen peroxide by glycerol- 
3-phosphate oxidase. The hydrogen peroxide was further degraded into H20 and 
O2 by peroxidase. In the second step, TG was degraded into glycerol by
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lipoprotein lipase in surfactant, followed by the same reactions as in the first step. 
The generated hydrogen peroxide was measured quantitatively by colorimetric 
assay. The reaction is measured at 505 nm. The change in absorbance is directly 
proportional to the concentration of TG in the sample.
2.3.3 Principle of HDL-choIesterol measurement
In this method water-soluble complex with non-HDL cholesterol fractions is 
formed by adding magnesium/dextran sulfate solution to the specimen. In next 
step, HDL-cholesterol esters are converted to HDL-cholesterol by PEG- 
cholesterol esterase. The HDL-cholesterol is acted upon by PEG-cholesterol 
oxidase, and the hydrogen peroxide produced from this reaction combines with 4- 
amino-antipyrine and HSDA under the action of peroxidase to form a purple/blue 
pigment that is measured at 600 nm.
2.4 Lipoproteins separation techniques and measurement
Plasma lipoproteins can be separated by many techniques depending on their 
physical properties. These techniques including ultracentrifugation, sequential 
precipitation, size exclusion chromatography, affinity chromatography and gel 
electrophoresis (Wasan et ah, 2000), Some of these techniques are not used as 
routine methods in the diagnostic laboratories because they are time-consuming. 
However, ultracentrifugation technique is considered the most acceptable 
technique for its ability to separate the major lipoproteins and their subclasses 
reproducibly despite limitations in equipment availability (Graham et ah, 1996, 
Wasan et ah, 2000). In this thesis, a method was developed by Graham et al 
(Graham et ah, 1996) using iodixanol density gradient centrifugation to separate
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lipoprotein fractions. This method was performed by using iodixanol which was 
originally used as an X-ray contrast medium due to its relative nontoxicity 
(Graham et ah, 1994).
Electrophoresis is another widely used technique in the clinical laboratories where 
lipoprotein classes can be separated on cellulose acetate, agarose and 
polyacrylamide gel. Separated lipoproteins can be quantified or semi-quantified 
by further steps such as estimation of their mass or lipid content. However, 
measurement of cholesterol in the lipoprotein particles, such as HDL and LDL, is 
the most widely used measurement in the diagnostic laboratories.
2.4.1 Lipoproteins fractionation
The main classes of plasma lipoprotein, very low density lipoproteins (VLDL), 
low-density lipoproteins (LDL), and high-density lipoproteins (HDL), can be 
separated depending on their differences in density and charge. Separation of 
lipoproteins into different fractions in this study was performed by the use of 
self-generating continuous gradients of iodixanol (Graham et al., 1996). Iodixanol 
is a nontoxic and inert compound capable of providing reliable and reproducible 
experimental results (Ford et al., 1994).
2.4.2 Plasma Preparation
Blood was centrifuged at 2000 g for 10 min to pellet the leukocytes and 
erythrocytes. The supernatant plasma was transferred to a conical centrifuge tube; 
0.3 mL of phosphate buffered saline (PBS) was layered on the surface, followed 
by centrifugation at 13000 g for 20 minutes when chylomicrons floated to the 
surface. The resultant chylomicron-containing layer on the surface was removed
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using an automatic pipette.
2.4.3 Generation of lodixanol gradients
4 mL chylomicron-free plasma was added to ImL of 60 % (W/V) iodixanol. 5 mL 
of 6% (W/V) iodixanol in PBS was placed in a 13x35 mm polyallomer centrifuge 
tube (Optirprep). The iodixanol-plasma was carefully layered underneath the 6 % 
(w\v) iodixanol solution. Approximately 1 mL of PBS was then added to fill the 
tube and subjected to centrifugation at 65,000 RPM, at 16°C for 190 min (VTi 
65.1 rotor, Beckham L8-80 ultracentrifuge)( Figure 2.1).
2.4.4 Collection of plasma fractions
All tubes were placed in the gradient unloader and the fractions were collected 
using an automated fractionator (autodensi-flow 451-7200, Labconco). 1 mL 
aliquots were initially removed from the top of each tube and transferred to a 
microfuge tubes. The aliquots were stored at -70 C until further analysis in order 
to identify the fraction, each fraction then assayed for the concentrations of 
triglyceride, cholesterol and total proteins.
67
Figure 2.1 Separation of plasma lipoproteins in self-generated gradients of 
iodixanol
Plasma was separated in a self-generated gradient of iodixanol. The gradients 
were collected and a sample from the fraction containing the peak VLDL, LDL, 
and HDL was analysed for cholesterol and protein. A representative centrifuge 
tube illustrating the separation is shown: 1, Plasma protein; 2, HDL; 3, LDL; 4, 
VLDL.
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2.5 Adipose tissue biopsy and histological procedures
In order to examine white adipose tissue by light microscopy samples underwent 
fixation to maintain the ultrastructure features of the cells to allow accurate 
morphometric assessment. Tissue sections from different depots of fat 
(subcutaneous and visceral ) were carefully dissected, divided into 1 cm2 
portions, fixed for 18 h and prepared using the following methods.
2.5.1 Biopsy
Patient tissue samples of omental adipose (n=6) and subcutaneous (n=6) tissue 
had been collected with informed consent during kidney transplantation or other 
open surgery. Adipose samples from the non-renal failure patients (healthy 
donors), namely omental adipose (N=6) and subcutaneous (N=6) tissue samples 
were also collected and used as controls. The study protocol was approved by 
Liverpool Research Ethics Committee (REC number: 08/HI002/41). Samples 
were placed in fixation reagent immediately upon collection.
2.5.2 Fixation
Immediately after dissection, tissue samples were placed in freshly prepared 4% 
paraformaldehyde (PBS buffer, pH 7.6) for 4-8 hours depending on the biopsy 
sizes, as a guide, 1 cm2 portions were fixed for 18 h. Samples were processed to 
form paraffin blocks using a Shandon Citadel 2000 automatic processor,
2.5.3 Dehydration
As the embedding materials are water insoluble, it is necessary to completely 
remove tissue associated water to allow maximum infiltration by the resin. The
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samples were serially dehydrated in increasing concentrations of ethanol as 
follows:
i) 15%, 30%, 50% ethanol, 2 changes, 30 minutes each
ii) 70% ethanol overnight
iii) 80%, 90%, 95% ethanol, 2 changes, 30 minutes each
iv) 100% ethanol, 6 changes, 30 minutes each
2.5.4 Embedding to paraffin wax blocks
This process allows the tissue to be infiltrated uniformly. The tissue samples were 
placed in metal moulds, and coded wax added being careful to avoid bubble 
formation.
2.5.5 Sectioning
The hardened wax-embedded tissue blocks were trimmed with a sharp razor blade 
to remove excess wax. Knives mounted on a microtome were used to cut the 
blocks down to the level of tissue. Once the block surface was smooth a new 
knife was used to cut and collect 0.5 pm sections. The sections were collected 
using metal forceps, placed on a drop of water on a glass slide, and stretched using 
a cotton stick immersed in trichloroethylene. Sections were left to dry on a hot 
plate for 5 min approximately then mounted on glass microscope slides.
2.5.6 Haematoxylin and Eosin staining
Sections were dewaxed in xylene for 15 min and rehydrated through a series of 
decreasing ethanol concentrations from 100% to 90% 2 changes 5 min each.
70
Slides were then placed in Gill’s haematoxylin for 1-2 minute and washed in 
water. Increasing concentrations of ethanol from 90 to 100 % were used to 
dehydrate the tissue sections and xylene was used to clear the sections for 15 min. 
Sections were then mounted with DPX.
2.5.7 Light Microscopy
From each biopsy one suitable section was selected and photographed using a 
digital Kodak camera attached to a photo light microscope. Sections were 
photographed at 2 magnifications (x20 and x40)
2.6 Immunohistochemistry
2.6.1 Sample fixation
Tissue samples were immediately fixed in freshly prepared 4% paraformaldehyde 
in PBS buffer pH 7.6 for 4-8 hours depending on the biopsy sizes. Samples were 
processed to paraffin blocks as described in sections 2.5.1 to 2.5.5.
2.6.2 Cutting
Sections of adipose tissue were cut using a microtome. 5 pm ribbons of paraffin- 
embedded tissue were cut with a microtome in accordance with the 
manufacturer’s instructions. The ribbon was divided into three section pieces by 
using the scalpel then transferred to the 50°C transfer bath.
2.6.3 Mounting
Sections were mounted on positively charged glass slides using a water bath 
maintained at 45° C and allowed to dry in an oven for several hours at 60° C.
71
Day 1
2.6.4 Dewaxing
Tissue sections were dewaxed in xylene by immersing the slides for 3x10 min 
each in a xylene bath and then two times for two min each in a reducing 
concentration of alcohol baths (100%, 95%, 90%, 70%) followed by rehydration 
in distilled water. The slides were rinsed with Tris-buffered saline in 0.01% 
Tween 20 (TBS/Tween20) for five min on an orbital shaker to enhance antibody 
penetration.
2.6.5 Antigen retrieval by microwaving method
30 ml of 0.1 M sodium citrate pH 6 was added in a slide bath and covered with a 
loosely fitting lid. The slide bath was placed inside a larger container with 600 ml 
of distilled water and both containers were placed inside a microwave oven 
(900W) and heated at full power, then incubated for 20 min. The slide bath was 
allowed to cool for 20 min and the slide washed 4 times in PBS.
2.6.6 Endogenous peroxidase blocking
A solution of 3% hydrogen peroxide was used to block endogenous peroxidase 
activity. The slides were incubated in blocking solution on an orbital shaker at 
room temperature for 30 minutes, rinsed 3 times in distilled water and transferred 
to TBS/Tween20 for 10 min.
2.6.7 Blocking non-specific staining
After encircling the area around the sections using a Pap-Pen, a 1:10 solution of 
normal non-immune serum, in which the secondary antibody was raised, was
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added and the sections were incubated in a humidified chamber for 30-45 min.
This step prevents background staining by blocking non-specific binding of 
antibodies to the tissue. Before the application of the primary antibody, excess 
serum was removed from the slides by gentle tapping.
2.6.8 Primary antibody
Tissue sections were incubated with the primary antibody in a humidified 
chamber at 4°C overnight. The dilution of primary antibody was established 
through experimental trials, starting with the initial dilution suggested by the 
manufacturers. Primary antibodies were diluted in Tris HC1 containing 1% BSA
Day 2
Between each step, tissue sections were washed in TBS/Tween three times for 5 
min each.
2.6.9 Secondary antibody
Biotin conjugated secondary antibody was applied at the recommended dilution in 
the appropriate non-immune serum in Tris HC1/1% BSA. Samples were incubated 
in a humidified chamber for 45 min on an orbital shaker at room temperature and 
developed using 3, 3'-Diaminobenzidine (DAB) chromogen.
2.6.10 Counter Stain
Slides were counterstained by Gill's haematoxylin for 4 minutes.
2.6.11 Dehydration
The sections were dehydrated in alcohol two times for 1 min each, followed by
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xylene three times for 2 min each.
2.6.12 Mounting
The sections were mounted with DPX and cover slips placed over them. 
2.7 Adipocyte cell Culture (Promo Cell)
2.7.1 Reagents
2.7.1.1 Pre-adipocyte medium
DMEM/Nutrient Mix FI2 
5 % FCS
9.9 pg/ml Endothelial cell growth supplement
200 pg/ml EGF
1 fig/ml Hydrocortisone
100 units/ml Penicillin
100 pg/ml Streptomycin
0.25 pg/ml Amphotericin B
2.7.1.2 Induction Medium
DMEM/Nutrient Mix F12
32 pM Biotin 
100 nM Human insulin 
1 pM Dexamethasone 
200 pM IBMX 
10 mg/ml Rosiglitazone
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llnM L-Thyroxine 
100 units/ml Penicillin 
100 |ag/mi Streptomycin 
0.25 pg/ml Amphotericin B
2.7.1.3 Feeding Medium
DMEM/Nutrient Mix F12
5 % FCS 
32 pM Biotin 
100 nM Human insulin 
1 pM Dexamethasone 
100 units/ml Penicillin 
100 pg/ml Streptomycin 
0.25 pg/ml Amphotericin B
2.7.1.4 lx PBS
0.286 M sodium chloride
5.55 mM potassium chloride
16.4 mM disodium hydrogen phosphate 
2.94 mM potassium dihydrogen orthophosphate 
Autoclaved distilled water
2.7.1.5 Trypsin/EDTA 
Autoclaved distilled water 
0.005%/0.002% trypsin/EDTA
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lx PBS
All media were prepared using a sterilizing filter system in a cell culture 
laminated air flow hood. Media was stored at 4°C and warmed to 37°C prior to 
use. The culture and feeding media was used within 2 weeks. The induction 
medium, however, must was made immediately before use.
2.7.2 Cell recovery
Human white preadipocytes (Promo Cell, UK), stored in cryovial were removed 
from the liquid nitrogen and quickly thawed in a 37°C water bath. The thawed 
cell suspension was transferred to a 75 cm2 flask containing 20 ml of 
preadipocyte culture medium. Cells were maintained for approximately 6 days 
with one change of medium or when they had reached 80%-90% confluency. The 
cells were maintained in an incubator at 37°C in a humidified atmosphere with 
5% C02/95% air. At this point, the cells were ready to be passaged and 
subcultured. Prior to trypsinisation, the cells were briefly washed once with 
sterilized lx PBS. Then, 9 ml of trypsin/EDTA was added to the flask and 
placed at 37°C for 1 min to detach the cells. Cell detachment was maintained 
by light microscopy. After the cells were entirely detached, 9 ml of culture 
medium was added in a final volume of 10 ml. The cell suspension was mixed by 
sterile pipettes several times. An equal density of preadipocytes was seeded into 
new flasks, and 12-well or 48-well plates according to the experimental 
requirement.
2.7.3 Cell induction
Differentiation of the cells was initiated 24 h after plating. Following
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aspiration of the old medium, the cells were gently washed with pre-warmed 
lx PBS, three times and then incubated for 4 days in the FCS-free induction 
medium. Differentiation into adipocytes was examined under a light 
microscope by phase contrast at lOOx magnification. The phase contrast 
image of the accumulation of lipid droplets during the development of 
adipocytes was captured and photographed by a CCD video camera (UVP Inc., 
California, USA) (Figure 2.2). More than 90% of Promo cells underwent full 
differentiation into mature adipocytes after day 10 post-induction.
2.7.4 Cell Treatment
To examine the adipokine gene expression and secretion, fully differentiated 
adipocytes were incubated with serum or lipoprotein fractions; at day 12-14 
post-induction for 4 and 24 h. Cells incubated in adipocyte medium without 
added serum or lipoprotein fractions for the same period were used as controls. 
Incubations at each time-point were performed in replicates of 4 or 6.
2.7.5 Harvesting the Cells
According to the particular experimental design, the cells were collected at 
several time-points in 700 pi of Trizol per well. Samples were stored at -80°C 
until analysis.
2.7.6 Cytotoxicity study
At the end of the exposure period, the cytotoxicity was evaluated by lactate 
dehydrogenase (LDH) release and by examining microscopically the cell shape 
and integrity (Roche, Germany). The culture medium was harvested for the 
measurement of LDH activity. The LDH activity of the medium and cell lysate
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was determined by spectrophotometric monitoring of the decreasing level of 
NADH described in the following reaction:
Pyruvate + NADH+H+ -—-> Lactate+NAD+
The following formula was used to calculate cytotoxicity:
Cytotoxicity (%) = (experimental value - low control)/high control - low 
control) *100
Low control was defined as the sample containing assay medium and cultured 
cells only while the high control containing cells and triton X-100 solution. All 
evaluated samples were performed in triplicate.
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Figure 2.2: Human adipocytes culture system
The photographs above show the differentiation of human preadipocytes in vitro, 
(A) untreated preadipocytes appeared as fibroblast-like cells. (B) preadipocyte at 
the plating stage. (C) day 12 after the induction period, cells enlarged, attained a 
polygonal contour and accumulated tiny lipid droplets (D) lipid-filled multilocular 
cells showing typical morphological features of mature adipocytes in vitro.
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2.8 Adipocyte cell Culture (SGBS Cell)
2.8.1 Reagents
2.8.1.1 Serum-containing medium
DMEM/Nutrient Mix FI2 
33 pM Biotin 
17 pM Pantothenate 
100 units/ml Penicillin 
100 fig/ml Streptomycin 
10% FCS
2.8.1.2 Feeding Medium
DMEM/Nutrient Mix FI2
33 pM Biotin
17 pM Pantothenate
100 units/ml Penicillin
100 pg/ml Streptomycin
10 pg/ml Human Transferrin
10 nM Insulin
100 nM Cortisol
200 pM Triiodothyronine (T3)
2.8.1.3 Induction Medium
DMEM/Nutrient Mix FI2 
33 pM Biotin
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17 (iM Pantothenate 
100 units/ml Penicillin 
100 fj.g/ml Streptomycin 
10 pg/ml Human Transferrin 
10 nM Insulin 
100 nM Cortisol 
200 pM T3
250 nM Dexamethasone 
500 mM IBMX 
10 mg/ml Rosiglitazone
All media were prepared using a sterilizing filter system in a cell culture fume 
cupboard. The media prepared was stored in a fridge with a temperature of 4°C. 
Before use, the media was warmed up to 37°C in a water bath. The culture and 
feeding media prepared was used within 2 weeks. The induction medium, 
however, was made fresh immediately before use.
2.8.2 Culture Method
SGBS preadipocytes were kindly supplied by Professor Martin Wabitsch 
(University of Ulm, Germany). They are a human preadipocyte cell “strain” 
derived from the stromal-vascular fraction of the subcutaneous white adipose 
tissue of an infant with Simpson-Golabi-Behmel syndrome. The cell strain found 
shows a high capacity for adipose differentiation, resulting in mature fat cells 
which are biochemically and functionally similar to human adipocytes (Wabitsch 
etal., 2001).
A frozen SGBS cell stock in a cryovial was taken out from the liquid nitrogen and
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quickly defrosted in a 37°C water bath. To entirely thaw the cells, 1 ml of pre­
warmed culture medium was added to the cryovial and gently pipetted up and 
down several times. The thawed cell suspension was then transferred to a 25 cm2 
flask containing 2 ml of culture medium. The cells were maintained in an 
incubator at 37°C in a humidified atmosphere with 5% C02/95% air. The culture 
medium was changed two to three times a week until 80%-90% of the cells were 
confluent. At this point, the cells were ready to be passaged and subcultured. Prior 
to trypsinisation, the cells were briefly washed once with sterilized 1 xPBS. Then, 
1 ml of trypsin/EDTA was added to the flask and the flask immediately put in a 
37°C incubator for 1 min to help quickly detach the cells. To examine whether the 
cells were trypsinised completely, the flask was checked under a light microscope. 
After the cells were entirely detached, 9 ml of culture medium was added in a 
final volume of 10 ml. The cell suspension was gently pipetted in and out for 
several times to mix cells evenly. Equal density of preadipocytes was seeded in 
new flasks, and 6-well or 12-well plates according to the experimental 
requirement. The culture medium was changed two or three times a week until 
cells were ready to be induced.
2.8.3 Differentiation of SGBS cells
Differentiation of the cells was initiated 24 h after 100% confluence in the plates. 
After aspiration of the old medium, the cells were gently washed with pre-warmed 
lx PBS three times, and then incubated for 4 days in the FCS-free medium 
containing 0.25 pM dexamethasone, 500 pM 3-isobutyl-1-methyl-xanthine, 10 
nM insulin, 200 pM triiodothyronine (T3), 1 pM cortisol and 2 pM rosiglitazone. 
Differentiation into adipocytes was examined under a light microscope by phase
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contrast at lOOx magnification. More than 90% of SGBS cells underwent full 
differentiation into mature adipocytes after day 10 post-induction.
2.8.4 Harvesting the Cells
The cells were maintained in the feeding medium containing insulin, cortisol and 
T3, which was renewed two or three times a week. According to the particular 
experimental design, the cells were collected at several time-points.
2.9 Enzyme-linked immunabsorbant assay (ELISA)
2.9.1 Measurement of IL-6
The total amount of IL-6 in serum or media was measured by enzyme-linked 
immunosorbent assay (ELISA) (PeproTech, USA) according to the 
manufacturer’s protocol. The stated minimal detectable amount was 50 pg/ml. A 
96 well microplate (Fisher .UK) was initially treated with 100 pi capture antibody 
(100pg/ml) (1:100) diluted in PBS for overnight incubation at room temperature. 
300 pi of 1% BSA in PBS was used to block the capture antibody for 1 hour, 
followed by three washes with 0.05%Tween20 in PBS. 100 pi of serum or plasma 
was added in duplicate for each subject and incubated for 2 hours at 25°C. The 
detection antibody lOOpl was incubated for 2 hours at 25°C. Detection was 
initiated with 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)); 150 
pi was added to the well. The reaction was stopped by adding 100 pi of 2N H2SO4 
to each well and absorbance was measured at 405 nm with wavelength correction 
set at 650 nm. Horseradish peroxidase (HRP) enzymatic activity was responsible 
for the colour change in the ABTS substrate; there was a relation between the 
amount of IL-6 and the absorbance at wavelength of 405 nm. Data was collected
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and analysed with Microplate Manager V5.2 software (Bio-Rad) to determine the 
IL-6 concentration in each well.
2.9.2 Measurement of Adiponectin
ELISA measurement of total adiponectin was carried out following the same 
protocol as for IL-6 using a human adiponectin kit (R&D System). High 
Molecular weight adiponectin measurement was performed in the department of 
Clinical Chemistry, University of Liverpool, according to the manufacturer’s 
protocol (Alpco, USA). The sensitivity of the ELISA for total adiponectin and 
HMW adiponectin was 50 and 0.19 ng/ml respectively.
2.9.3 Measurement of Leptin
ELISA measurement of leptin was carried out following a similar protocol as for 
IL-6 using human leptin kit (RayBio, UK).
2.10 RNA extraction
The commercially available, Tri-reagent (Sigma) 1 ml was added to the tube and 
the sample homogenized using either a glass or an electric homogenizer 
(Polytron Ultra-Turrax T25). The tissue or cells homogenate was transferred into 
a 2 ml tube and centrifuged at 12,000 g for 10 min at 4°C. The clear 
supernatant was aspirated and transferred into a fresh 2 ml tube. Care was taken 
not to aspirate the cell debris pellet or any lipid layer overlying the supernatant.
For RNA extraction, the cells were first collected using Tri-Reagent as described 
and homogenized by triturating 10 times using a 1 ml syringe with a 23 gauge 
needle.
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After incubating the tissue or cell homogenate at room temperature for 5 min, 
200 jil of chloroform was added per ml of Tri-Reagent used. The tube was 
shaken vigorously for 15 sec by hand and then maintained for 2-3 min at room 
temperature. This was followed by centrifugation at 12,000 g for 15 min at 4°C5 
leading to separation of three layers - a colourless upper aqueous phase 
containing RNA, a white interphase containing DNA and a red phenol phase 
containing protein. The aqueous layer containing the RNA was transferred into a 
fresh 2 ml tube, taking care to avoid contamination with either of the other two 
phases. If protein isolation was required the phenol phase was saved and stored at 
-20°C.
To minimise any possible genomic DNA contamination, an optional step 
(recommended by Sigma) was performed. Fifty pi of isopropanol was added to 
the sample per ml of Tri-Reagent used. This was mixed by vortex, allowed to 
stand for 5 min at room temperature and then centrifuged at 12,000 g for 
10 min at 4°C. The supernatant was transferred to a 1.5 ml tube, taking 
care not to aspirate in the area where any DNA pellet would have been 
precipitated.
Isopropanol was then added to the sample (450 pi per ml of Tri-Reagent used in 
sample preparation), followed by vortexing, incubation of the sample for 10 
min at room temperature and centrifugation at 12,000 g for 10 min at 4°C. After 
these steps the precipitated RNA pellet could usually be identified at the base of 
the tube.
The supernatant was discarded and 700 pi of 75% ethanol added to the RNA 
pellet. This was followed by vortexing and centrifugation at 10,000 g for 10
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min at 4°C. The supernatant was again poured off, and any remaining volume 
aspirated by pipette. The RNA pellet was allowed to air dry for 2-3 min and then 
dissolved by adding 10-15 pi of ultra-pure water. Samples could be stored 
temporarily if required at -20°C prior to DNase treatment and/or 
quantification. Scissors, tweezers and glass homogenizers or electric 
homogenizer blade components were soaked in 1% Virkon solution for 1-2 h for 
decontamination, then cleaned of any tissue debris prior to rinsing.
2.10.1 Quantification of RNA
The RNA extracted samples were passed through a spectrophotometer 
(BioPhotometer) to determine their concentration. RNA was diluted in RNase- 
free water to give a 1 in 70 dilution. The RNA tubes were measured 
immediately making sure that the cuvette was rinsed with water before each 
use. The RNA concentration was determined from the absorbance at 260 nM 
(Nielsen, 2011) . To determine the concentration of RNA, the Beer-Lambert law 
was used.
[RNA] pg/pl - A260 x 44 x 70 / 1000 
44= coefficient number for single stranded RNA.
2.10.2 Integrity
2.10.2.1 Reagents
Ultra-pure water
Sample buffer (1 ml 40% glycerol, 40 pi saturated BPB 
solution) Reagents for agarose gel electrophoresis 
RT-PCR was performed using the isolated RNA samples. Once the cDNAs had
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been synthesized, their quality was checked by performing PCR using primers 
for the housekeeping gene p-actin and running the products on a gel. The band 
intensity indicated the quality of the cDNA sample from which the integrity 
of the original RNA template could be inferred. Faint or undetectable bands 
suggested degradation of the isolated RNA or a failed RT reaction. The 
former could be investigated by checking the RNA integrity directly and if 
found to be significantly degraded, the RNA was re-extracted from the tissue. 
mRNA comprises 1-5% of a total RNA sample, whereas ribosomal RNA 
(rRNA) makes up >80% of total RNA, the majority of that consisting of 28S 
and 18S rRNA species (in mammals). The method used to directly check RNA 
integrity (denaturing gel electrophoresis) relies on the assumption that rRNA 
quality and quantity reflect that of the underlying mRNA population, with the 
caveat that there may be a degree of difference between the integrity of the 
long lived and abundant rRNA molecules and that of the underlying mRNA 
population, which turns over much more rapidly (Palmer & Prediger, 2005).
2.10.2.2 Method
One pg of RNA was diluted with RNase-free water to a total volume of 5 pi in a 
0.2 ml tube and 2 pi of sample buffer added. The sample was mixed by 
vortexing briefly, loaded onto a 1 % agarose gel and run at 80-100 V for 30-40 
min. An image of the gel was recorded digitally. An intact RNA sample would 
have two clearly visible and well- defined bands representing 28S and 18S 
rRNA with little or no visible debris at the base of the gel. RNA degradation 
would be inferred from smudging or absence of the rRNA bands and a strong 
signal at the base of the gel.
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2.11 Reverse transcriptase -polymerase chain reaction (RT-PCR)
2.11.1 RT-PCR
2.11.1.1 Reagents
iScript cDNA Synthesis Kit:
5X cDNA synthesis kit buffer 
iScript enzyme mixture 
Nuclease-free water
2.11.1.2 Method
0.5 pgRNA was reverse transcribed with iScript™ cDNA Synthesis Kit (BioRad) 
in the presence of mixture of oligo (dT) and random hexamer primers in a total 
volume of 10 pi. The samples were heated at 25°C for 5 min to remove secondary 
structures in the mRNA. Each sample was reverse transcribed to cDNA at 42°C 
for 30 min. The samples were further heated at 85°C to inactivate the iScript 
Reverse Transcriptase. The cDNA samples were stored at -20°C until required.
2.11.2 PCR
The PCR generates multiple copies of a cDNA. A master mix was prepared that 
includes the DNA, which was placed in a PCR thermal cycler. Firstly, the 
temperature was increased to 94°C, which causes the DNA double helix to 
separate (denaturation). Secondly, the temperature was lowered, which causes the 
primers to anneal (attach) to the double stranded DNA. Primers are specific 
DNA oligonucleotides that match to specific DNA sequences, which initiate the 
process of making new DNA. Thirdly, an enzyme called Taq polymerase (ready
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mix) was used to make new DNA chains. The temperature was again increased 
and the enzymes made new DNA to match the DNA strands that were separated. 
The cycles were repeated many times; after only 20 cycles, there would be a 
million copies of the original DNA.
2.11.2.1 Reagents
DNase/RNase free water 
10 pM each sense and antisense primer mix 
ReddyMix PCR Master Mix Kit: 
l.lxReddyMix
2.11.2.2 Method
This procedure was carried out using sterile 0.2 ml RNA/DNase-free tubes and 
filter tips and reactions were performed using a thermal cycler (PCR Express). 
A master mix containing 11.25 |il of l.lx ReddyMix, 0.25 pi of primer mix and 
0.5 pi of (ultra- pure) water per sample was prepared, vortexed and centrifuged. 
Twelve pi of this master mix were transferred into each tube and 0.5 pi of the 
appropriate cDNA added for a 12.5 pi final reaction volume (all volumes 
proportionately scaled up for a 50 pi reaction); ultra-pure water was used for the 
'no template' control. The tubes were vortexed, centrifuged and placed into the 
cycler with the PCR program set as follows:
94°C, 2 min (denaturation)
20-38 cycles (specified cycle number for each primer 
pair) of:
i. 94°C, 20 sec (denaturation)
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ii. 54°C, 30 sec (annealing; Ta)
iii. 72°C, 30 sec (extension)
iv. 72°C , 5 min (final extension)
2.11.3 Agarose electrophoresis
2.11.3.1 Reagents
Agarose
5 mg/ml ethidium bromide 
lOx TBE buffer
100 bp DNA ladder (GeneRuIer or ReddyRun Super-ladder low 100 
bp)
Distilled water
The gel casting tray was prepared by sealing the ends with autoclave tape. The 
agarose was weighed directly into a 500 ml conical flask, the lx TBE added and 
the flask heated for ~2 min in a microwave (flask taken out and swirled every 30 
sec) until the agarose was completely dissolved. The solution was cooled to 
approximately 50° C prior to adding the ethidium bromide. The mixture was 
poured into the gel casting tray avoiding any bubble formation. The combs were 
then placed into their slots and the gel allowed to set for at least 15 min. The 
autoclave tape was removed and the tray with the gel placed in the gel tank. The 
tank was filled with 1 x TBE until the gel was submerged in the buffer before 
removing the combs.
For analyzing the PCR products on the gel, 10 pi of each sample was pipetted 
into separate wells. Two pi of DNA ladder (Helena BioSciences, UK) was loaded
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near the samples as a reference to assess whether the PCR product was located at 
the expected size. The end wells were avoided if possible, as these are most likely 
to run aberrantly. The gel was run at 85-100 V for 30-60 min or until the samples 
had run an approximately similar distance. For band detection, the gel was placed 
on a UV transilluminator (2011 Macrovue). The images were recorded using a 
DC 120 digital camera and analysed using ID 1 image analysis software.
2.12 Real time-polymerase chain reaction
Real-time PCR can be used for absolute or relative quantitation of the initial 
amount of template in a sensitive, specific and reproducible manner. It is 
preferable to alternative forms of PCR quantification because it quantifies the 
initial template cDNA rather than the final amount of amplified PCR product. 
This is possible as real- time PCR monitors the fluorescence emitted during the 
reaction as an indicator of amplicon production during each PCR cycle. The 
fluorescent signal increases in direct proportion to the amount of PCR product. 
During the exponential phase of the PCR reaction, there is a significant increase 
in the amount of PCR product. By monitoring the fluorescence, the cycle at 
which this phase commences can be determined. The more initial template 
there is, the earlier the fluorescent signal will be significantly increased.
7Real-time PCR also offers a wide dynamic range of up to 10 -fold, compared to
3
only 10 -fold in conventional PCR, which means that large variations in 
template amount can be quantified sensitively and accurately.
2.12.1 Taqman Q-PCR
The real-time PCR work performed in this study employed the Taqman system
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(Applied Biosystems), which involves the use of a primer pair and a Taqman 
probe. The probe is an oligonucleotide with a fluorescent (reporter) dye 
(usually FAM) on the 5' base, and a quenching dye (usually TAMRA) typically 
on the 3' base. When the probe is intact, energy is transferred from the reporter 
dye to the nearby quenching dye molecule (FRET - fluorescence resonance 
energy transfer) rather than emitted as fluorescence (Giulietti et al., 2001). 
During the annealing phase of the PCR cycle, the probe binds to an internal 
region of a PCR product and when the Taq polymerase replicates a template 
onto which a probe is bound, its 5' exonuclease activity cleaves the probe. This 
separates the reporter and quenching dyes and ends the FRET. The reporter dye 
now starts to emit fluorescence (at 518 nm for FAM) which increases in each 
cycle proportional to the rate of probe cleavage. Accumulation of PCR products 
is detected by monitoring the increase in fluorescence (AR) of the reporter 
dye (usually plotted as ARn after normalisation of the reporter dye signal to a 
reference dye [usually ROX] to correct for differences in reaction mix volumes 
between wells) (Giulietti etal, 2001).
2.12.2 Primers and Taqman probes
Primer and Taqman probe sequences are detailed in Table 2.1, together with the 
optimized final reaction concentrations. For a new primer/probe set, optimal 
primer concentrations were determined by performing an assay with final 
concentrations of sense and antisense primers ranging from 50 nM to 900 nM, in 
all possible combinations, with the probe concentration fixed at 200 nM. The 
resulting amplification plots were then examined and the combination with the 
lowest Ct and, the highest ARn was selected. Taqman probe optimisation was
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then performed at concentrations from 25-225 nM using the optimised primer 
concentrations and the amplification plots were used to select the optimal probe 
concentration.
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Gene Sequence (5'-3’) Size, bp
Adiponectin
Forward
Reverse
Probe
CCCAAAGAGGAGAGAGGAAGCT
GCCAGAGCAATGAGATGCAA
TTCCCAGATGCCCCAGCAAGTGTAAC
73
Leptin
Forward
Reverse
Probe
CCAAAACCCTCATCAAGACAATT
AGTCCAAACCGCTGTCTTTCTG
TGACATTTCACACACGCAGTCAGTCTCCT
93
IL-6
Forward
Reverse
Probe
GGTACATCCTCGACGGCATCT
GTGCCTCTTTGCTGCTTTCAC
TGTTACTCTTGTTACATGTCTCCTTTCTCAGGG
83
MCP-1
Forward
Reverse
Probe
CATAGCAGCCACCTTCATTCC
TCTGCACTGAGATCTTCCTATTGG
CAGCCAGATGCAATCAATGCCCC
104
POLR2A
Forward
Reverse
Probe
ATGGAGATCCCCACCAATATCC
CATGGGACTGGGTGCTGAAC
TGCTGGACCCACCGGCATGTTC
81
LPL Assay ID Details( Applied Biosystem):Hs 00173425_ml
HSL Assay ID Details( Applied Biosystem):Hs 00181192 ml
LDL-R Assay ID Details( Applied Biosystem):Hs 00181192_ml
C3 Assay ID Details( Applied Biosystem):Hs 00163811 ml
Table 2.1 Real-time PCR primer and Taqman probe sequences
The table shows the sequences of the primers and Taqman probes employed in real- time 
(q) PCR analysis for (relative) quantitation of gene expression.
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2.12.3 Preparation of 96 well plates for real-time PCR
2.12.3.1 Reagents
qPCR Core Kit: 
lOx reaction buffer 
50 mM magnesium chloride 
5 mM dNTP mix 
5 U/jil Hot Goldstar enzyme
Sense primer, antisense primer and Taqman probe stock solutions 
Ultra-pure water
2.12.3.2 Method
Working solutions of the primers and probes were prepared at lOx concentration 
(e.g.9000 nM for a final reaction concentration of 900 nM) by diluting the stock 
solution with ultra-pure water. A master mix was made up which contained all 
the necessary components for the PCR, minus the cDNA template as follows:
10 x reaction buffer 
50 mMMgCl 
5 mM dNTP
2.5 pi per well (lx final concentration) 
2.5 pi (5 mM)
1 pi (200 mM)
Forward primer 
Reverse primer 
Taqman probe 
5 U/pl Hot Goldstar enzyme 
Ultra-pure water
Once the master mix had been made
2.5 pi 
2.5 pi 
2.5 pi
0.125 pi (0.025 U/pl)
11.375 pi
up, 25 pi were aliquoted to each well. One
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jiil of the appropriate template cDNA was then added to each well for a 
total reaction volume of 26 pi and the plate sealed with an optical cover. All 
samples were run in duplicate, or triplicate if practical. No primer and no 
template controls were included on the plate for each set of primers and probe. 
The plate was spun at 1000 rpm for 20 sec to ensure the reaction mix was not 
sticking to the well sides. If the assay was not to be performed immediately, the 
plate could be stored for up to 5 days at 4°C. If a set of samples (comprising 
several groups) required analysis over several plates, at least one group (usually 
the control group) was present on all plates. Data were normalized such that the 
mean ACT for the control group had the same value for each assay, enabling the 
data on the different plates to be directly compared.
Reactions were performed using an Mx3005P cycler (Stratagene). Default 
conditions were used except that the reaction volume was specified as 26 pi. 
Once the cover temperature had reached 105°C, the plate was inserted into the 
heat block and an optical pad placed on top so that the holes aligned with the 
well positions. The cover was screwed into position and the run started.
Amplifications were performed commencing with a 2 min activation stage at 
50°C, then a 10 min denaturation stage followed by 40 cycles consisting of a 
denaturation step of 15 sec at 95°C and a combined primer annealing and 
extension step for 60 sec at 60°C. Data were collected automatically by the 
software, and analysed once the run was complete (total run time was ~2 h).
2.12.3.4 Analysis of real-time PCR
The amplification plots were displayed in log scale using the Sequence Detector
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software and the threshold manually adjusted to ensure that it was clear of any 
noise. The software automatically recalculated the Ct value for each well (Ct 
defined as the cycle number at which the fluorescence emitted from the well 
crossed the threshold). The results were exported as a Microsoft Excel file and
gene expression analysed by relative quantitation with the 2"^^ method 
(Livak & Schmittgen, 2001). All samples were normalised to values of p -actin, 
the difference of CT values between the control and treated samples were 
calculated and the relative fold changes obtained between the two groups. The 
formulae used for calculation are as follows:
ACt= Ct (Target gene) - Ct (Reference gene)
AACT = Mean ACT (patient samples) - Mean ACT (control
samples) Fold Change=2"z^^
2.13 Statistics
Data are expressed as mean ± SEM or mean ± SD as appropriate. The statistical 
significance of the difference between the means of two groups of samples was 
assessed by Student’s M:est. For comparison between groups, ANOVA was used 
followed by post hoc testing with Bonferroni correction. Paired Student test was 
used to determine the significance between the pre and post dialysis data means. 
Differences between study groups in tissue staining score in chapter 6 were tested 
using Mann U test. Differences were considered to be significant when the p 
value was less than 0.05 ip < 0.05).
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CHAPTER 3
LIPOPROTEIN SUBTRACTION PROFILE OF PATIENTS WITH END
STAGE RENAL DISEASE
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3.1 Introduction
End-stage renal disease (ESRD) is a major public health problem worldwide. 
Although dialysis is an effective therapy, ESRD is associated with other major 
health problems. Dialysis patients have been noted to have shorter life expectancy 
compared to the general population. The most common cause of death in ESRD is 
cardiovascular disease (CVD) (Wheeler, 2007). CVD mortality in younger ESRD 
patients is about 500-fold higher than healthy patients and was 5-fold higher in 
older patients (Sarnak, 2003). This strong association is not fully understood. 
However, many risk factors have been proposed to contribute to CVD in ESRD 
(section 1.3 and 1.4). These factors become worse over time in keeping with 
ESRD progression (Fellstrom et al., 2009). Several studies pointed out that risk 
factors in ESRD might have different effects from that observed in general 
population (Yamamoto and Kon, 2009).
Dyslipidaemia is a well-known risk factor of CVD in ESRD (Anavekar and 
Pfeffer, 2004, Rucker and Tonelli, 2009). The characteristic dyslipidaemia of 
ESRD is not consistent between patients. Dyslipidaemia in ESRD depends upon 
many factors including the degree of renal failure, etiology of primary renal 
disease, type of dialysis and the presence of proteinuria (Fellstrom et al., 2009, 
Yamamoto and Kon, 2009). ESRD-induced dyslipidaemia is characterized by 
hypertriglyceridaemia, low high-density lipoprotein (HDL) and normal or near 
normal levels of plasma cholesterol (Attman and Samuelsson, 2009). However, 
these characteristics are prone to modification depending on the type of dialysis, 
co-morbid disease and medications (Chan et al., 2008). Hypertriglyceridaemia is 
regarded as a common feature in kidney disease (Yamamoto and Kon, 2009). In
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addition to lipid concentration changes in ESRD, lipoproteins also undergo an 
alteration in composition (Lee et al., 2002).
The purpose of the studies in this chapter was to characterise the distribution of 
dyslipidaemia in relation to ESRD and its treatment by dialysis. The specific aim 
was to determine the lipoprotein subfraction pattern and to explore the altered 
lipoprotein composition. A further objective was to investigate whether these 
abnormalities are found both in haemodialysis and peritoneal dialysis.
3.2 Methods
3.2.1 Subjects
See section 2.2.1
3.2.2 Blood
See section 2.2.4
3.2.3 Biochemical analysis
Urea, creatinine, cholesterol, TGs, LDH and total protein concentrations were 
measured on a Roche Modular™ SWA analyser using colorimetric or ensymatic 
assays following the procedures provided by the manufacturer (Roche Diagnostics 
GmbH, Mannheim, Germany).
3.2.4 Lipoprotein fractionation
Lipoprotein fractions were done using a self-generating iodixanol gradient. 1.2 ml 
of 60% iodixanol was added to 4.8 ml of EDTA/plasma and mixed. 4.8 ml of 6% 
(w/v) iodixanol in phosphate buffer saline was placed in a 13x35 mm polyallomer
100
centrifuge tube. The iodixanol-plasma was carefully layered underneath the 6% 
(w/v) iodixanol solution. Approximately 1 ml of PBS was then added to the top of 
each tube and the tubes centrifuged at 65,000 rpm and 16 °C for 190 min (VTI
65.1 Rotor, Beckman L8-80 ultracentrifuge). 1 ml aliquots were removal from the 
top first by automated fractionators (Autodensei-flow 451-7200, Labconco) into
1.5 ml microfuge tubes. The aliquots were stored at -70 °C until further analysis.
3.2.5 Statistics
Data are expressed as mean ± SEM or mean ± SD as appropriate. For comparison 
between groups, ANOVA was used followed by post hoc testing with Bonferroni 
correction. Paired Student test was used to determine the significance between the 
pre and post dialysis data means. Differences were considered to be significant 
when the p value was less than 0.05 (p < 0.05).
3.3 Results
3.3.1 Clinical and biochemical characteristics
Clinical and biochemical data of all subjects are reported in Table 3.1. Altogether, 
18 ESRD patients and 9 control subjects (healthy) completed the study. There was 
no difference in age and body mass index (BMI) in the three groups. The mean 
creatinine concentration was 938.8 (±159.4) pmol/L in the haemodialysis patients, 
775 (± 363.3) pmol/L in the peritoneal dialysis group and 87.6 (± 31.8) pmol/L in 
the control groups. The mean urea concentration was 23.8 (± 4.9) mmoI/L in the 
haemodialysis patients, 21.5 (±5.8)mmol/L in the peritoneal dialysis group and 
5.7 (± 2.3) mmol/L in the control groups. Post-dialysis mean of creatinine was
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401.9 (±128.3) |imol/L and for urea 8.5 (± 4.1) mmol/L. Higher creatinine and 
urea levels confirmed the presence of renal failure in both the HD and PD groups.
3.3.2 Plasma lipid profile
Initially, lipid parameters (Cholesterol, Triglycerides, LDL-cholesterol and HDL- 
cholesterol) were measured for all subjects. As shown in table 3.2, haemodialysis 
patient groups (pre and post) had increased plasma triglyceride and decreased 
HDL cholesterol levels. There was no difference in LDL-cholesterol compared 
with controls. Interestingly, peritoneal dialysis patients exhibited decreased in TG 
compared with the Pre-HD and Post-HD (p < 0.05) and increased in HDL- 
cholesterol compared with the Pre-HD ip < 0.01). Peritoneal dialysis patients 
exhibited no significant changes in plasma lipids profile compared the controls.
All patient groups had normal or near normal serum cholesterol and LDL 
cholesterol levels.
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11 HD PD
Number 9 11 7
% Male 100% 100% 100%
Ethnicity 9 Caucasian 11 Caucasian 7 Caucasian
Mean age (years) 45.1± 7.9 47.5 ± 14 45.4 ±8.1
BMI (Kg/irf) 26.7 ± 2.9 29.2 ±5.5 27.6 ±3.8
Smoker 2 2 2
Diabetes 0 0 1
CVD events 0 5 1
Hypertension 0 10 7
Medication
% Statin 0% 36.4% 71.4%
Miscellaneous *
Table 3.1: Clinical and biochemical characteristics of subjects
H, Healthy group; HD, Haemodialysis group; PD, Peritoneal dialysis group; BM1, 
body mass index. *Please see appendix 2 for full list of medication
Data are means ± SD
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II Pre-HD Post-III) PD Significance by ANOVA
TC
(mmol/L)
4.7± 1.1 3.9 ± 1.2 4.4 ± 1.4 4.5 ± 1.2 NS
TG
(mmol/L)
1.4 ±0.6 2.9 ± 1.5 3.0 ± 1.6 b 1.3 ± 0.6 d P< 0.001
HDL-C
(mmol/L)
1.3 ±0.3 0.8 ±0.2 8 0.9 ± 0.2 b 1.3 ± 0.3 c P< 0.0001
LDL-C
(mmol/L)
2.8 ± 1.2 1.8 ± 1.0 2.1 ± 1.3 2.6 ± 1.1 NS
Table 3.2 Plasma lipid profile of subjects
Data are mean ± SD
Abbreviations: H, healthy group; Pre-HD, pre-haemodialysis; Post-HD, post­
haemodialysis; PD, peritoneal dialysis; TC, total cholesterol; TG, triglycerides; 
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein 
cholesterol.
Differences among the four groups were analysed by one-way ANOVA. a,b,c,d 
Significant difference between H and Pre-HD (a), between H and Post-HD (b), 
between Pre-HD and PD (c) and between PD and Post-HD (d) assessed by 
multiple comparison (Bonferroni correction,/! < 0.05).
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3.3.3 Effects of HD on biochemical parameters
To investigate the effect of dialysis on the lipid profile, pre and post dialysis 
samples were compared. Plasma concentrations of cholesterol, triglycerides, LDL- 
cholesterol and HDL-cholesterol were determined before and after haemodialysis. 
Cholesterol and HDL-cholesterol concentrations were significantly increased after 
haemodialysis as shown in Figure 3.1 (p < 0.001 and 0.0001 respectively). No 
significant change was observed in triglycerides and LDL-cholesterol 
concentrations.
3.3.4 Cholesterol distribution of lipoprotein subfractions
We determined the distribution of the conventional VLDL, LDL, and HDL 
isolated by the iodixanol density gradient in control (Fig. 3.2), HD (Fig. 3.3), and 
PD groups (Fig. 3.4) .The lipoproteins show distinct distributions in the gradient. 
VLDL was recovered in fractions 1-2 (density 1.007); LDL in fractions 4-7 
(density 1.016- 1.043); and HDL in fractions 8-9 (density 1.043-1.076). Figure 
3.5 shows the differences between these groups. Cholesterol distribution of 
lipoprotein fractions showed that a significant increased VLDL (p < 0.05) and 
presence of small dense LDL in patients groups compared to control subjects. 
Peritoneal dialysis patients had increased and presence of small dense LDL and a 
shift in cholesterol to IDL. Multiple comparison analysis (Table 3.3) showed a 
significant increase in fraction 1 in Pre-HD compared to healthy groups {p < 
0.05) as well as an increase in fraction 10 in PD compared to healthy groups {p < 
0.05).
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Figure 3.1 Plasma lipid profile before and after HD
Blood samples were collected immediately before and after haemodialysis. Total 
cholesterol (A), Triglycerides (B), LDL-cholesterol (C) and HDL-cholesterol (D) 
were investigated. Values are mean ± SD. Change in cholesterol was positive in 9 
subjesta, TG in 6 subjects, LDL-C in 8 subjects and HDL-C in 10 subjects.
*p < 0.05; ** p < 0.01; *** p <0.001 significant difference from the Pre-HD group 
(n=l 1)
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Figure 3.2: Density profile of the iodixanol gradient and cholesterol 
distribution of plasma lipoproteins (control group)
Separation of plasma lipoproteins on iodixanol gradients using Optiseal TM tubes 
in the VTi 65.1 rotor. Fractions (1 ml) were taken from the top of the gradient. 10 
fractions were analysed for total cholesterol and total protein in order to identify 
the Lipoproteins fraction. There was similarity in VLDL fractions (1-2) and HDL 
(8-9) while LDL fractions (4-7) showed a peak variation between the subjects.
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Figure 3.3: Density profile of the iodixanol gradient and cholesterol 
distribution of plasma lipoproteins (haemodialysis group)
(A) pre-dialysis and (B) post-dialysis groups.
Separation of plasma lipoproteins on iodixanol gradients using Optiseal TM tubes 
in the VTi 65.1 rotor. Fractions (1 ml) were taken from the top of the gradient. 10 
fractions were analysed for total cholesterol and total protein in order to identify 
the lipoproteins fractions. In contrast to the healthy group, dialysis patients 
showed a big variation in all fractions with a markedly different pattern in some 
patients.
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Figure 3.4: Density profile of the iodixanol gradient and cholesterol 
distribution of plasma lipoproteins (peritoneal group)
Separation of plasma lipoproteins on iodixanol gradients using Optiseal TM tubes 
in the VTi 65.1 rotor. Fractions (1 ml) were taken from the top of the gradient. 10 
fractions were analysed for total cholesterol and total protein in order to identify 
the lipoproteins fractions. PD group showed similarity in VLDL fraction and a 
distinct variation in LDL and HDL fractions
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H Pre-HD Post-HD PD
Fraction number
Figure 3.5: Density profile of the iodixanol gradient and cholesterol 
distribution of plasma lipoproteins (Pooled Data)
Means of Iodixanol lipoprotein cholesterol distribution in all groups; control 
{green line), pre-haemodialysis group {brown line), post-haemodialysis group {red 
line) and peritoneal dialysis group {blue line), p value shown in table 3.3. Values 
are means ± SEM {n = 9 for control group, n=\ \ for HD group and /7 = 7 for PD 
group).
110
Fraction Significance by ANOVA
1
VLDL
P < 0.05 a
2 P < 0.0518
3 NS
4 NS
5 LDL NS
6 NS
7 NS
8 NS
9 HDL NS
10 P < 0.05 b
Table 3.3: Multiple comparison analysis for lipoprotein fractions
HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very density 
lipoprotein.
Differences among the four groups were analysed by one-way ANOVA. a’ b 
Significant difference between healthy and pre-haemodialysis group (a), between 
healthy and peritoneal group (b) assessed by multiple comparison (Bonferroni 
correction, p < 0.05). (n = 9 for control group, « = 11 for HD group and « = 7 for 
PD group. NS, not significant.
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3.4 Discussion
ESRD patients have an extremely high rate of morbidity and mortality from CVD. 
Although many factors other than dyslipidaemia may contribute to the CVD in 
ESRD, dyslipidaemia plays a role both in the progression of ESRD and in 
generating CVD events. Dialysis patients in this study had dyslipidaemia with 
many different patterns. Haemodialysis patients had increased serum triglycerides 
and decreased HDL-cholesterol compared to the control subjects, 
Hypertriglyceridaemia and low HDL-cholesterol are considered as the main 
features of dyslipidaemia in ESRD. The exact mechanism for 
hypertriglyceridaemia in ESRD is not fully understood and seems to be 
multifactorial (Prinsen et al., 2003).
Hypertriglyceridaemia can result from the accumulation of intact and/or partially 
metabolised TG-rich apo B containing lipoproteins. This accumulation, in turn, is 
related to defects in lipolytic enzyme activity in ESRD, especially lipoprotein 
lipase (LPL) and hepatic lipase. LPL plays a major role in regulation of plasma 
lipoprotein and energy metabolism.
LPL deficiency leads to impaired VLDL and chylomicron metabolism. Several 
studies have reported a decrease of post-heparin activity in ESRD (Vaziri, 2009). 
Moreover, LPL down-regulation has been demonstrated to be associated with 
hypertriglyceridaemia in ESRD (Vaziri and Liang, 1996). Decreased activity of 
LPL in ESRD is attributed to the effect of frequent heparin (during dialysis 
treatments) that diminishes the pool of endothelial-bound lipoprotein lipase 
(Vaziri, 2009). LPL is activated by apoC-II and inhibited by apo C-III. Apo C-
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II/Apo C-III ratio has been reported to be low in ESRD patients (Alsayed and 
Rebourcet, 1991). However, it has been reported that LPL may not be the main 
cause for impaired degradation of TG-rich apo B lipoproteins in ESRD (Lee et ah, 
2002). Lipoproteins may be abnormally altered leading to decreased ability of 
enzymes to hydrolyze these particles. This was noted, for example, with isolated 
VLDL from haemodialysis patients which acted as a poor substrate for bovine 
lipoprotein lipase in vitro (Arnadottir et al., 1996). Moreover, 
hypertriglyceridaemia can be explained by an overproduction of TG-rich apo B- 
containing lipoproteins (Prinsen et al., 2003).
Consistent with the previous finding, cholesterol plasma levels were within or 
below normal values with no change seen in the gene or protein expression of 
enzymes involved in cholesterol metabolism such as HMG-CoA reductase 
(Pandak et al., 1994) or in hepatic LDL receptor (Liang and Vaziri, 1997b).
Heparin was given as a 1000 IU loading dose and 1000 IU every hour for four 
hours totaling 5000 IU over 4 hours. This is a small dose over the 4 hour period 
which appears to have had a negligible effect on circulating lipoprotein 
metabolism since pre and post HD triglycerides were similar. It is therefore 
unlikely that heparin had a major effect on circulating lipids and composition of 
lipoproteins following HD.
The results demonstrated a marked reduction in HDL-cholesterol in the 
haemodialysis group. Low HDL-cholesterol has been reported as a risk factor for 
atherosclerosis and cardiovascular disease in the general population (Expert Panel 
on Detection and Treatment of High Blood Cholesterol in, 2001, Pekkanen et al.,
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1990) . In ESRD patients, low HDL-C was also associated with coronary artery 
disease (Koch et ah, 1997). It has been reported that in some ethnic groups, 
plasma HDL-cholesterol levels are increased after haemodialysis and peritoneal 
dialysis (Burrell et al., 1991). All recruited subjects in this study were Caucasian. 
According to National Cholesterol Education Program Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP-ATP III), 
lipid management can be applicable to all population (Expert Panel on Detection 
and Treatment of High Blood Cholesterol in, 2001). However, African-Americans 
showed higher mortality from CVD compared with whites (Sumner et al., 2005). 
LDL-cholesterol levels are similar in white and black races where HDL- 
cholesterol levels are higher in blacks (Vega et al., 1998). Lp(a) levels were found 
to be significant higher in blacks compared to whites (Emerging Risk Factors et 
al., 2009).
Although many studies have reported that peritoneal dialysis is associated more 
with dyslipidaemia rather than haemodialysis (Attman et al, 2003), data obtained 
in this study was unable to detect any significant alterations in lipid profile. 
However, the failure to detect a change in lipid profile could be explained by the 
low number of recruited subjects in this group and also that all patients were 
unavoidably receiving lipid lowering medications, such as statins.
To further explore uraemia-induced dyslipidaemia, lipoproteins were separated 
using iodixanol gradient ultracentrifugation and the present studies, for the very 
first time using this technique, clarifies and quantifies discrete lipoprotein 
fractions in ESRD.
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The findings were consistent with published work in this field. Results showed 
that both hamodialysis and peritoneal dialysis groups had increased levels of 
VLDL. VLDL is primarily produced by the liver. VLDL in ESRD has a reduced 
catabolism in ESRD due to the low activity of lipolytic enzymes or the change in 
composition or from the increased content of apo C-III (Attman et al.} 1999). The 
lipoprotein separation pattern in the present study also indicated the peritoneal 
dialysis group had more atherogenic lipoproteins, namely IDL and small dense 
LDL. It has been speculated that these lipoproteins are associated with 
atherosclerosis in ESRD (Shoji et al., 2001). Moreover, IDL was considered as an 
independent risk factor for aortic atherosclerosis in ESRD patients (Shoji et al., 
1998). It has been suggested that long-term exposure to glucose presented in the 
peritoneal dialysate, may affect the glycaemia and therefore the lipid profile in the 
PD group. However, in a very recent study (Li and Fengxian, 2011) have reported 
that glucose does not contribute to the abnormal lipid profile in peritoneal dialysis. 
IDL is produced as a result of the VLDL metabolism and removed by the liver via 
LDL-receptor related protein (LPR). Moreover, it has been reported that LRP is 
downregulated in ESRD leading to high levels of the atherogenic remnant 
lipoproteins (Kim and Vaziri, 2005).
Although some reports have suggested that statin treatment may be associated 
with an increase in HDL-cholesterol (Kostapanos et al., 2009), these changes are 
generally considered less important than the LDL lowering effect of statins. In this 
study, HDL-cholesterol distribution was increased in both haemodialysis and 
peritoneal dialysis. The studies in thesis showed that HDL was smaller following 
PD compared with healthy group.
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Although presence of dyslipidaemia is well established in ESRD patients, 
treatment of dyslipidaemia indicates that using lipid lowering drugs have a limited 
effect. Many studies have been shown that not all ESRD groups achieved 
therapeutic targets (Marrs and Saseen, 2010). Studies that examined the potential 
benefits of statin in the light of CYD risk associated with haemodialysis failed to 
show an improvement in outcome. The 4D (Die Deutsch Diabetes Dialysis) study 
showed no significant reduction of CVD by using atorvastatin in diabetic ESRD 
patient when used for around 2 years (Wanner et al., 2004). A study to evaluate 
rosuvastatin in subjects on regular haemodialysis, AURORA, recruited 2775 
individuals on haemodialysis but showed no significant reduction of the CVD risk 
associated with ESRD (Fellstrom et al., 2009). However, a recent study 
employing cholesterol absorption inhibitor Ezetimibe showed a reduction in CVD 
outcomes (Baigent et al., 2011). Therefore the importance of LDL cholesterol 
reduction in ESRD is still unclear.
A number of limitations in this study were noted. Firstly, relatively low numbers 
of patients were studied, since the main goal was detailed metabolic investigation. 
Furthermore, we present data on lipoprotein subfraction cholesterol distribution in 
non-fasting samples collected before initiation of the dialysis and after. This may 
have affected the lipoprotein distribution and lipids profile observed in the present 
investigations. However, a number of studies have reported that non-fasting lipid 
measurement has no significant effect in the general population (Langsted and 
Nordestgaard, 2011), ESRD patients (Nishizawa et al., 2003) and the diabetic 
population (Lund et al., 2011). Additionally, other analytes were not measured in 
the lipoprotein subfractions such as triglycerides, and these may differ in ESRD
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and represent future directions for investigation. Finally, the data presented in this 
study are cross-sectional and clear causation cannot be determined.
In conclusion, an atherogenic lipoprotein profile is seen in ESRD patients. These 
findings suggest that differences in lipoprotein cholesterol distribution exist in 
ESRD and have the potential to contribute to CVD in ESRD. Overall, these data 
reflect the need for further investigation of the contribution of lipoprotein to CVD 
risk in patients with ESRD.
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CHAPTER 4
EFFECT OF URAEMIC LIPOPROTEINS ON THE LIPID METABOLISM 
RELATED GENES EXPRESSION IN HUMAN ADIPOCYTES IN VITRO
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4.1 Introduction
Lipoproteins are considered essential players in lipid metabolism and include 
LDL, HDL, VLDL and chylomicrons. Dysregulation of lipoprotein metabolism 
may contribute to the pathogenesis of atherosclerosis and CVD. Adipose tissue is 
one of the main organs that mediates lipid metabolism during a process where 
excess energy can be stored in adipose tissue in the form of triglycerides. Lipid 
metabolism, especially lipoproteins, is altered in ESRD (Mesquita et al., 2010). 
Lipoproteins are exposed to a uraemic environment in ESRD and thus may be 
qualitatively and quantitatively altered. Little is known about the interaction 
between lipoproteins and adipose tissue in ESRD and their characterization may 
be important to clarify CVD in ESRD.
ESRD-associated dyslipidaemia is characterised by hypertriglyceridaemia, 
impaired HDL metabolism and accumulation of apo B-containing lipoproteins 
(Attman and Samuelsson, 2009). This ESRD-associated dyslipidaemia has been 
proposed to contribute to increased cardiovascular disease risk in ESRD. In 
addition, progression of renal disease may be accelerated by dyslipidaemia 
(Sahadevan and Kasiske, 2002).
Chapter 3 described the isolation of lipoprotein fractions from patients with 
ESRD as well as healthy controls. An atherogenic lipoprotein profile was 
observed in patients treated with different dialysis modalities. The lipoprotein 
subfractions VLDL, LDL and HDL were further investigated in the present study 
in order to determine their potential role on lipid metabolism in adipose tissue. 
To achieve this, gene expression of lipoprotein lipase (LPL), the rate-limiting
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step in the catabolism of triglyceride-rich lipoprotein, hormone-sensitive lipase 
(HSL) the enzyme that hydrolyzes lipid, complement protein 3(C3) the main 
component for acylation stimulating protein and low density lipoprotein receptor 
(LDL-R) the main factor in LDL clearance were compared in VLDL-treated, 
LDL-treated and HDL-treated in human adipocyte culture. Little has been 
reported with regard to interaction of lipoproteins with adipose tissue in ESRD.
The present study was designed to test the hypothesis that uraemia alters 
lipoproteins such as VLDL, LDL and HDL. These abnormal uraemic lipoproteins 
have a different effect on adipose tissue lipid metabolism. The altered lipid 
metabolism in turn has the potential to contribute to the dyslipidaemia in ESRD.
4.2 Methods
4.2.1 Culture and differentiation of human preadipocytes (PromoCell)
Human white preadipocytes derived from subcutaneous adipose tissue of a female 
Caucasian subject (BMI 21; age 44 years) were obtained from PromoCell 
(PromoCell, UK). Preadipocytes were cultured in preadipocyte growth medium 
supplemented with lOOU/ml penicillin, 100 pg/ml streptomycin, and 0.25 pg/ml 
amphotericin B (Lonza, Tewkesbury, UK) at 37 °C in a humidified atmosphere of 
5% C02/95% air. Preadipocytes were seeded onto 12-well plates and grown until 
confluence. At confluence, cells were induced to differentiate (day 0) by 
incubation for 3 days in Dulbecco's Modified Eagle's Medium (DMEM)/Ham's 
F12 (1:1) medium containing 32 pM biotin, 1 pM dexamethasone, 200 pM 3- 
isobutyl-1-methyl-xanthine, 100 nM insulin, 11 nM L-thyroxine (all from Sigma, 
Poole, Dorset, UK), 8 pM rosiglitazone (GlaxoSmithKline, Uxbridge, UK) and
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lOOU/ml penicillin, 100 pg/ml streptomycin, and 0.25 pg/ml amphotericin B. 
After induction, cells were further maintained in feeding medium containing 3% 
fetal calf serum (PCS; Sigma), 100 nM insulin, 32 pM biotin and 1 pM 
dexamethasone until full differentiation. Differentiation into adipocytes was 
confirmed by observing the accumulation of lipid droplets under the microscope.
In a separate set of studies, adipocytes were incubated with lipoprotein fractions 
from different groups (Pre-haemodialysis, post-haemodialysis and peritoneal 
dialysis). All lipoprotein fractions in this set of studies were fractionated by self­
generating iodixanol gradients following ultra centrifugation and filtration. The 
final concentrations of each fraction in the media were 50 mg protein/L as this 
concentration shown the absence of cytotoxicity (Masella et al., 2006). The media 
used for the cells as a control had their pre-incubation medium renewed. Cells 
were then collected after 4 and 24 h in 700 pi of TRI reagent.
4.2.2 Real-time PCR
Total RNA was extracted from cells using Trizol (Invitrogen, USA) and the RNA 
concentration determined from the absorbance at 260 nm. First strand cDNA was 
reverse transcribed from 0.5 pg of total RNA using an iScript first strand synthesis 
kit (BioRad, Hercules, USA) in a final volume of 10 pi. Real-time PCR 
amplification was performed in a final volume of 12.5 pi, containing cDNA 
(equivalent to 10 ng of RNA), optimising concentrations of primers, TaqMan 
probe FAM-TAMRA and a master mix made from qPCR core kit (Eurogentec, 
Seraing, Belgium) using a Stratagene Mx3005P instrument. PCR amplification 
was performed in duplicate using 96-well plates and the PCR cycling conditions
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were as follows: 95 °C for 10 min followed by 40 cycles (95 °C for 15 s, 60 °C for 
1 min). Blank controls without cDNA were run in parallel. POL2A was used as a 
reference gene. All samples were normalised to the the POL2A values and the 
results expressed as fold changes of Ct value relative to controls using the 2-AAct 
formula.
4.2.3 Statistical analysis
The statistical differences between the groups were evaluated through ANOVA 
followed by post hoc testing with Bonferroni correction. Differences were 
considered as statistically significant when P < 0.05.
4.3 Results
4.3.1 VLDL effect on gene expression
The PromoCell adipocytes were used at day 14 post-induction to examine the 
potential effect of VLDL on adipocytes. A 50mg protein/L concentration of 
lipoproteins was employed at two time points, 4 and 24 hrs.
As shown in figure 4.1 there was no effect found on LPL mRNA level at 4 h 
while at 24 h, the differences in LPL mRNA level among the groups were 
significant (p < 0.001). However, in the case of HSL, LDL-R and C3 there was no 
difference among the groups (Figure 4.2 to 4.4).
Moreover, VLDL treatment for 24 h led to a significant downregulation in LPL 
and LDL-R gene expression, with 2-fold and 2.5-fold response to Post-HD and 
PD, respectively (p < 0.05) (Figure 4.3). There was no effect found on C3 gene 
expression at both time points (Figure 4.4).
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Comparison of VLDL treatments from the Pre-HD and Post-HD groups indicated 
that there was no difference in LPL, HSL, and LDL-R and C3 gene expression of 
the adipocytes (Figure 4.1 to 4.4).
4.3.2 LDL effect on gene expression
Gene expression of LPL, HSL, LDL-R and C3 in adipocyte cells was investigated 
by real-time PCR to examine the potential role of uraemic LDL on adipocytes.
At 4 h, the differences in LPL mRNA level among the groups were significant {p
< 0.05), Post hoc analysis (Bonferroni correction test) showed that only the 
decrease observed for post haemodialysis group (p < 0.05).
At 24 h, the differences in LPL mRNA level among the groups were significant (p
< 0.001). Post hoc analysis (Bonferroni correction test) showed that the decrease 
observed for post haemodialysis vs peritoneal group (p < 0.001) and also in Pre- 
HD vs Post-HD (p < 0.05) (Figure 4.5).
For HSL, the differences in the mRNA level among the groups were significant 
only at 4 h (p < 0.05). Post hoc analysis (Bonferroni correction test) showed that 
the decrease observed for Post-HD vs PD (p < 0.05) (Figure 4.6).
As shown in figure 4.7 there was no effect found on LDL-R mRNA level at 24 h 
while at 4 h, the differences in LDL-R mRNA level among the groups were 
significant (p < 0.05). LDL gene expression was downregulated significantly in 
the Post-HD group by 3.3-fold ip < 0.05) and and PD 2.5 fold ip < 0.05) (Figure 
4.7) according to the post hoc analysis (Bonferroni correction test).
C3 mRNA level was differet among the groups were significant at 4 h (p < 0.001)
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and 24 h (/? < 0.05). Post hoc analysis (Bonferroni correction test) at 4 h showed 
that only the decrease observed for pre-HD (p < 0.05) and Post-HD (p < 0.001) vs 
healthy groups by 3.3 fold for each (Figure 4.8), while post hoc analysis 
(Bonferroni correction test) at 24 h showed that only the decrease observed in Pre- 
HD vs PD (p < 0.001).
4.3.3 HDL effect on gene expression
Gene expression of LPL, HSL, LDL-R and C3 in adipocyte cells was also 
investigated by real-time PCR to examine the potential role of uraemic HDL 
fraction on adipocytes.
At 4 h, the differences in LPL mRNA level among the groups were significant (p
< 0.001). Post hoc analysis (Bonferroni correction test) showed that only the 
decrease observed for PD vs healthy group (p < 0.001) (Figure 4.9).
At 4 h, the differences in HSL mRNA level among the groups were significant (p
< 0.001). Post hoc analysis (Bonferroni correction test) showed that only the 
decrease observed for PD vs healthy group achieved significance (p < 0.001) 
(Figure 4.10).
No difference seen on the LDL-R mRNA level when trated by HDL fractions 
(Figure 4.11).
For C3, the differences in the mRNA level among the groups were significant 
only at 4 h (p < 0.05). Post hoc analysis (Bonferroni correction test) showed that 
the decrease observed for PD vs healthy group (p < 0.05) (Figure 4.12).
There were no significant changes at 24 h for all studied genes.
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Comparison of HDL treatments from the Pre-HD and Post-HD groups indicated 
that there was no difference in LPL, HSL, and LDL-R and C3 gene expression of 
the adipocytes (Fig. 4.9 to 4.12).
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Figure 4.1: Effect of fractionated VLDL on LPL Gene Expression in Human 
Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
VLDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 
hrs. LPL mRNA levels were normalised to human POLR2A and expressed 
relative to the healthy treated group. Treatment with peritoneal dialysis VLDL 
resulted in a marked decrease on LPL expression at 24 h. Results are mean ± SD 
(n = 6/group).NS, not significant.
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Figure 4.2: Effect of fractionated VLDL on HSL Gene Expression in Human 
Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
VLDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 
hrs. HSL mRNA levels were normalised to human POLR2A and expressed 
relative to the healthy treated group. Treatment with Post-haemodialysis VLDL 
resulted in a marker decrease on HSL expression at 24 h. Results are mean ± SD 
(n = 6/group).NS, not significant.
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Figure 4.3: Effect of fractionated VLDL on LDL-R Gene Expression in 
Human Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
VLDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 
hrs. LDL-R mRNA levels were normalised to human POLR2A and expressed 
relative to the healthy treated group. Treatment with Peritoneal and post­
haemodialysis VLDL resulted in a marker decrease on LDL-R expression at 24 h. 
Results are mean ± SD (n = 6/group).NS, not significant.
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Figure 4.4: Effect of fractionated VLDL on C3 Gene Expression in Human 
Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
VLDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 
hrs. C3 mRNA levels were normalised to human POLR2A and expressed relative 
to the healthy treated group. Treatment with VLDL fraction from all groups did 
not alter gene expression for C3 in both 4 and 24 h. Results are mean ± SD (n = 
6/group).NS, not significant.
129
OH O Pre-HD Post-HD O PD
4 h 24 I)
p < 0.05
<0.05
p < 0.05
/? <0.05
p < 0.05
Figure 4.5: Effect of fractionated LDL on LPL Gene Expression in Human 
Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
LDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 hrs. 
LPL mRNA levels were normalised to human POLR2A and expressed relative to 
the healthy treated group. Treatment with Peritoneal and post-dialysis LDL 
resulted in a marker decrease on LPL expression in both 4 and 24 h. Results are 
mean ± SD (n = 6/group).
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Figure 4.6: Effect of fractionated LDL on HSL Gene Expression in Human 
Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
LDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 hrs. 
HSL mRNA levels were normalised to human POLR2A and expressed relative to 
the healthy treated group. Treatment with Post-dialysis LDL resulted in a marker 
decrease on HSL expression at 4 h. Results are mean ± SD (n = 6/group).NS, not 
significant.
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Figure 4.7: Effect of fractionated LDL on LDL-R Gene Expression in Human 
Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
LDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 hrs. 
LDL-R mRNA levels were normalised to human POLR2A and expressed relative 
to the healthy treated group. Treatment with Peritoneal and post-dialysis LDL 
resulted in a marked decrease in LDL-R expression after 4 h. Results are mean ± 
SD (n = 6/group).NS, not significant.
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Figure 4.8: Effect of fractionated LDL on C3 Gene Expression in Human 
Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
LDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 hrs. 
C3 mRNA levels were normalised to human POLR2A and expressed relative to 
the healthy treated group. Treatment with uraemic LDL resulted in a marker 
decrease on C3 expression at 4 h. Results are mean ± SD (n = 6/group).
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Figure 4.9: Effect of fractionated HDL on LPL Gene Expression in Human 
Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
HDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 hrs. 
LPL mRNA levels were normalised to human POLR2A and expressed relative to 
the healthy treated group. Treatment with Peritoneal dialysis HDL resulted in a 
marked decrease on LPL expression at 4 h. Results are mean ± SD (n = 
6/group).NS, not significant.
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Figure 4.10: Effect of fractionated HDL on HSL Gene Expression in Human 
Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
HDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 hrs. 
HSL mRNA levels were normalised to human POLR2A and expressed relative to 
the healthy treated group. Treatment with Peritoneal dialysis HDL resulted in a 
marked decrease on HSL expression at 4 h. Results are mean ± SD (n = 
6/group).NS, not significant.
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Figure 4.11: Effect of fractionated HDL on LDL-R Gene Expression in 
Human Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
HDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 hrs. 
LDL-R mRNA levels were normalised to human POLR2A and expressed relative 
to the healthy treated group. Treatment with Peritoneal dialysis VLDL resulted in 
a marked decrease on LDL-R expression at 4 h. Results are mean ± SD (n = 
6/group).NS, not significant.
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Figure 4.12: Effect of fractionated HDL on C3 Gene Expression in Human 
Adipocytes
Differentiated human adipocytes were exposed to 50 mg protein/L of fractionated 
HDL from healthy (H) and ESRD patients’ pre and post dialysis for 4 and 24 hrs. 
C3 mRNA levels were normalised to human POLR2A and expressed relative to 
the healthy treated group. Treatment with peritoneal dialysis HDL resulted in a 
marked decrease on C3 expression at 4 h. Results are mean ± SEM (n = 
6/group).NS, not significant.
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4.4 Discussion
In this study normal adipocytes were exposed to lipoporteins from uraemic 
patients and healthy patients in vitro. This was done to assess whether there were 
any differences in the changes of gene expression of key proteins of lipid 
metabolism. Potentially these changes could play a part in the cardiovascular risk 
and dyslipidaemia of ESRD. The present study employed the lipoprotein fractions, 
VLDL, LDL and HDL, characterised in chapter 3. Adipose tissue is involved in 
lipid metabolism and linked to insulin resistance and type 2 diabetes. Moreover, 
adipose tissue is considered as an essential source for free fatty acids and therefore 
thought to be linked to many disease states (Arner, 2003).
LPL is a member of the lipase gene family and considered as the rate-limiting step 
in the hydrolysis of TG content found in the circulating chylomicron and VLDL 
which provides a supply of fatty acids to different tissues for either energy 
utilisation or storage as TG in the adipose tissue (Mead et al., 2002, Wang and 
Eckel, 2009). The results demonstrated that adipocyte LPL expression is 
downregulated to a greater extent using VLDL derived from dialysis patients 
when co-cultured. LPL is known to be regulated by post-translational control; 
therefore not seeing changes does not mean that there were no changes. mRNA 
changes, either increase or decrease, does not necessarily mean increase in protein 
or activity. It has been reported that LPL deficiency is associated with an increase 
in plasma TG, VLDL concentrations and impairment of chylomicron clearance in 
ESRD (Vaziri and Moradi, 2006). Low LPL activity has been observed in adipose 
tissue from ESRD (Goldberg et al., 1978). It has been previously reported that no
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difference was noted in plasma LPL activity between haemodialysis and 
peritoneal dialysis (Shoji et al., 1991). VLDL fractions from pre-, post-HD and 
PD groups had more cholesterol compared with the healthy group (chapter 3) and 
VLDL cholesterol is considered as an independent risk factor for CVD (Shoji et 
al., 2001). ESRD animal studies have found a downregulation in LPL gene 
expression in heart, muscle and adipose tissue (Vaziri and Liang, 1996). 
Moreover, it has been proposed that reduction in LPL expression might lead to 
diminished physical activity, wasting syndrome and skeletal and cardiac 
myopathies due to the limited availability of free fatty acids (Vaziri and Liang, 
1996). In the latter study, it has been reported that the effect of ESRD on LPL 
gene expression in adipose tissue is largely nonspecific and less of an effect when 
compared to skeletal muscle expression (Vaziri and Liang, 1996). It has been 
documented that inhibition of LPL leads to impairment of TG-rich lipoprotein, 
thereby leading to triglyceride accumulation in ESRD (Kaysen, 2006a). On the 
other hand, it has been suggested that low LPL activity is not a primary 
pathogenic factor for defective lipolysis in ESRD (Arnadottir, 1997).
Another studied gene, hormone-sensitive lipase, which hydrolyzes the stored TG 
in adipose tissue, is considered as the rate-limiting enzyme in adipose lipolysis 
(Kraemer and Shen, 2002). The results in this chapter show that HSL expression 
was lower when incubated with VLDL from pre-HD and PD groups when 
compared with the healthy group. The significance of inhibition of HSL may be 
either beneficial or harmful in terms of biology in ESRD. It would be protective if 
the main effect is to decrease overproduction of VLDL by the liver and therefore 
minimize hypertriglyceridaemia. On the other hand, it could be harmful if fatty
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acids were not available for tissue energy purposes especially during the fasting 
state (Prinsen et al., 2003). However, other investigators have suggested that HSL 
activity was similar between healthy and some pathological states such as 
metabolic syndrome (Holm et al., 2000).
The hydrolysis of lipoprotein triglycerides takes place on the surface of the 
capillary endothelium. LPL is synthesized as an inactive, monomeric proenzyme 
form in the rough endoplasmic reticulum. The major sites for the synthesis of LPL 
are the adipose tissue, cardiac and skeletal muscles (Wang and Eckel, 2009). The 
proenzyme undergoes activation by sequential glycosylation and removal of a 24 
amino acid peptide in the Golgi apparatus. Within the cell the active and inactive 
forms of the enzyme are stored in secretory vesicles which are translocated to the 
cell surface via a cAMP-mediated process (Mead et al., 2002). The precise 
mechanism for this transolcation of LPL across endothelial cells is currently 
unclear. However, recent study suggested that LPL binds to a newly discovered 
membrane-tethered protein on the luminal surface of endothelial cells, 
glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 
(GPIHBP1) (Beigneux et al., 2007). The enzyme is then released by an active 
process which can be up-regulated by heparin. After secretion, LPL becomes 
anchored to the capillary endothelial surface by binding to a specific heparan 
sulphate proteoglycan receptor. LPL synthesis and activity is regulated by various 
mechanisms like nutritional status and hormonal action. These mechanism involve 
post-transcriptional regulation including mRNA stability, translation, protein 
degradation, processing, secretion,translocation to the site of action, and 
competitive inhibition by products (Mead et al., 2002). Insulin increases LPL
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mRNA levels in adipocytes without any changes in the rate of gene transcription. 
Also, fasting result in reduction in LPL activity and has been proposed to prevent 
of transfer from the ER to the Golgi (Wang and Eckel, 2009). High concentration 
of NEFA has been shown to lead to LPL displacement (Olivecrona et ah, 1997).
HSL activity is induced by cAMP-dependent PKA pathway and protein kinase G 
(PKG). in the basal state, HSL is distributed throughout the cytosol upon its 
activated and rapidly translocated to the surface of lipid droplets (Lass et ah, 
2011).
LDL-R mediates cholesterol uptake from the circulation. In this study, LDL-R 
was downregulated with post-HD and PD VLDL. Other groups have found that 
LDL-R expression did not differ between ESRD experimental animals and healthy 
controls (Liang and Vaziri, 1997a).
The results in the present studies indicated that treatment of adipocytes with 
uraemic lipoproteins can downregulate gene expression of key lipolysis enzymes. 
One could speculate that in situations where lipoprotein was not efficiently 
cleared from plasma, as in ESRD, by lipoprotein lipase hydrolysis, the resulting 
TG-rich remnant lipoproteins could be catabolised in the liver and stimulate the 
assembly and secretion of nascent VLDL. This mechanism might be of particular 
importance during the postprandial period, with VLDL concentrations being 
stimulated and increased in the fasting state. Remnant particles are also more 
atherogenic as they can be cleared by scavenger receptors on macrophages, a 
direct link to atherosclerosis. Remnants are also cleared more rapidly than other 
lipoprotein fractions (Itabe et ah, 2011).
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There has been accumulated evidence that TG-rich lipoprotein hydrolysis is 
altered in ESRD (Amadottir, 1997). Uraemic lipoprotein fractions were more 
likely to be either structurally or functionally modified or both. VLDL and 
IDL have been shown to affect the in vitro lipolysis rates in ESRD (Lee et al., 
2002). In ESRD, altered lipoprotein metabolism can be seen more clearly in the 
apolipoprotein profile and the lipoprotein composition than in lipoprotein 
concentrations (Kastarinen et al., 2009a). ESRD-dyslipidaemia has been shown to 
be associated with CVD and renal disease. There are many factors that contribute 
to dyslipidaemia in ESRD including decreased activity of lipolytic enzymes and 
alterations in the lipoprotein substrate and diminished uptake of lipoproteins 
(Chan et al., 2008, Vaziri and Moradi, 2006).
Numerous studies have shown that atherogenic lipoproteins stimulate expression 
of inflammatory mediators in vitro. MCP-1 gene expression was upregulated in 
endothelial cell culture by diabetic IDL (Maeno et al., 2000). It has been reported 
that during acute-phase response, HDL becomes a pro-inflammatory molecule 
(Van Lenten et al., 1995). Moreover, pro-inflammatory HDL was shown to 
stimulate TNF-a and chemotaxis in monocytes (Skaggs et al., 2010). It has been 
found that lipoproteins remain for longer periods hi the circulation in ESRD and 
are likely to undergo modification in their structure (Quaschning et al., 2001). One 
of the consequences of modification is that receptor recognition is altered 
(Kramer-Guth et al., 1997). Modified lipoproteins have also been shown to be a 
poor substrate for lipolytic enzymes (Arnadottir et al., 1996). VLDL 
overproduction in combination with reduced clearance may result in the formation 
of small dense LDL, the atherogenic form. It has been suggested that the anti-
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oxidant protective capacity of HDL is decreased in ESRD and that HDL may not 
prevent LDL oxidation (Morena et al., 2000).
The results in this thesis have showed that the VLDL with LDL fractions had an 
inhibitory effect on adipocyte gene expression. There is accumulated evidence 
that VLDL is associated with atherosclerosis acceleration by upregulating pro- 
inflammatory mediators, VLDL and oxidised LDL have been reported to 
stimulate cytokine expression including TNF-a (Ares and Stollenwerk, 2006). 
Moreover, VLDL has been shown to stimulate the production of the pro- 
inflammatory cytokine, interlukin-ip in human peripheral blood monocyte- 
derived macrophage (Stollenwerk et al,, 2005) and increased expression of 
adhesion molecules in endothelial cells (Ares and Stollenwerk, 2006), ESRD 
patients in this study have been shown to have higher levels of VLDL-cholesterol, 
particularly those on peritoneal dialysis (see chapter 3).
In conclusion, expression of lipolysis enzymes and regulatory proteins of lipid 
metabolism are affected when treated with uraemic lipoproteins in vitro. These 
data may suggest that uraemic lipoproteins may play a role in dyslipidaemia in 
ESRD. It will be important to demonstrate similar findings in experimental ESRD 
and also at the protein expression level.
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CHAPTER 5
ADIPOKINE GENE EXPRESSION OF HUMAN ADIPOCYTES IN
ESRD
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5.1 Introduction
Traditionally adipose tissue was considered to be mainly a storage depot for 
dietary triglycerides. However, it is now recognised to be an endocrine organ and 
has become an active area of research. The adipocytes (and other cells in adipose 
tissue) produce cytokines, chemokines, growth and complement factors which 
may have a role in ESRD (Chudek and Wiecek, 2006, Trayhurn, 2007). The 
endocrine function of adipose tissue involves the production and secretion of a 
large number of hormones, several of which are the focus of the present study. 
The best known among these factors is leptin, an adipocyte-derived hormone that 
acts in the hypothalamus and peripheral tissues to decrease food intake, increase 
energy expenditure, and other cellular functions. In addition to leptin, many other 
factors have been identified including tumour necrosis factor (TNF-a), 
adiponectin, plasminogen activator-inhibitor, interleukin 6, resistin, transforming 
growth factor-p, adipsin and retinol-binding protein (Ahima and Osei, 2008, 
Trayhurn and Wood, 2004).
Leptin is an important adipocyte product. Leptin has many functions elicited 
through specific interaction with its receptor (LR) found in most tissues. Mainly, 
leptin inhibits food intake (Ahima, 2006, Trayhurn and Beattie, 2001). Leptin 
levels are high in chronic renal failure (CRT) patients especially those undergoing 
PD (Heimburger and Stenvinkel, 2005) and its role in the nutritional status has 
been investigated (Kwan and Beddhu, 2007). Leptin gene expression is 
decreased in chronic renal failure (Nordfors et al., 1998) even though circulating 
concentrations are increased suggesting a major role for the kidneys in the 
degradation and elimination of leptin.
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Adiponectin is produced solely by mature adipocytes and is a member of soluble 
defence collagen family (Ahima, 2006, Costacou and Orchard, 2008). 
Adiponectin has been observed in three different forms; low, middle and high 
molecular weight (Sowers, 2008). The high molecular weight is considered the 
active form (Wiecek et ah, 2002). Adiponectin has anti-atherogenic, anti­
inflammatory and insulin sensitizing functions (Costacou and Orchard, 2008). 
Adiponectin inhibits oxidised LDL-mediated cell proliferation, lipid accumulation 
in monocyte-derived macrophages and transformation of macrophages into foam 
cells (Chudek and Wiecek, 2006). In contrast to leptin, adiponectin is negatively 
associated with WAT mass (Ahima, 2006). Surprisingly although low plasma 
adiponectin level is associated with CAD and type 2 diabetes, it is increased in 
uraemia suggesting that the kidney may again be an important site for degradation 
and elimination (Chudek and Wiecek, 2006, Huang et ah, 2004).
Interleukin-6 (IL-6), a pro-inflammatory marker, is produced by adipocytes as 
well as other cells (Ahima and Osei, 2008). It is a protein 22 to 27 kDa and 
induced by many factors including oxidative stress (Stenvinkel et ah, 2005). 
Together with IL-6 and Monocyte Chemoattractant Protein -1 (MCP-1), IL-6 is 
considered important for both acute and chronic inflammation (Wozniak et al., 
2009). IL-6 has been found to have a significant relationship with plasma high 
sensitivity C-reactive protein (hsCRP) in dialysis patients (Kwan and Beddhu, 
2007). IL-6 and MCP-1 plasma levels are increased in ESRD (Stenvinkel et ah, 
2005, Taskapan et ah, 2007, Wang et ah, 2008b).
Circulating adipokine concentrations are altered in ESRD with differences 
between renal replacement therapies (Wiecek et ah, 2002). We hypothesised that
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the uraemic environment with retention of ‘uraemic toxins’ in ESRD results in
adipose tissue dysfunction affecting not only lipoprotein metabolism but also 
adipokine production. The potential abnormalities in adipokines in ESRD could 
be a further possible link to CVD. This chapter is aimed specifically at 
characterising adipokines secretion in ESRD to determine if these changes could 
help explain the association between ESRD and CVD. The gene expression of key 
adipokines, adiponectin and leptin, and the proinflammatory adipokines IL-6 and 
MCP-1 were investigated using an in vitro human adipocyte culture system in the 
presence of serum obtained from ESRD patients expected to contain uraemic 
toxins.
5.2 Methods
5.2.1 Culture and differentiation of human primary preadipocytes
5.2.1.1 PromoCells
Human white preadipocytes derived from subcutaneous adipose tissue of a female 
Caucasian subject (BMI 21; age 44 years) were obtained from PromoCell 
(PromoCell,UK). Preadipocytes were cultured in preadipocyte growth medium 
supplemented with lOOU/ml penicillin, 100 pg/ml streptomycin, and 0.25 pg/ml 
amphotericin B (Lonza, Tewkesbury, UK) at 37 °C in a humidified atmosphere of 
5% C02/95% air. Preadipocytes were seeded onto 12-well plates and grown until 
confluence. At confluence, cells were induced to differentiate (day 0) by 
incubation for 3 days in Dulbecco's Modified Eagle's Medium (DMEM)/Ham's 
F12 (1:1) medium containing 32 pM biotin, 1 pM dexamethasone, 200 pM 3- 
isobutyl-1-methyl-xanthine, 100 nM insulin, 11 nM L-thyroxine (all from Sigma,
147
Poole, Dorset, UK), 8 pM rosiglitazone (GlaxoSmithKline, Uxbridge, UK) and 
lOOU/ml penicillin, 100 pg/ml streptomycin, and 0.25 pg/ml amphotericin B. 
After induction, cells were further maintained in feeding medium containing 3% 
fetal calf serum (PCS, Sigma UK), 100 nM insulin, 32 pM biotin and 1 pM 
dexamethasone until full differentiation. Differentiation into adipocytes was 
confirmed by observing the accumulation of lipid droplets under the microscope.
5.2.1.2 SGBS Cells
Simpson-Golabi-Behmel syndrome (SGBS) human preadipocytes were 
maintained and differentiated into adipocytes. Cells were cultured in 12-well 
plates (20,000 cells/well) and maintained in DMEM/Ham’s F12 (1:1 v/v) medium 
(Invitrogen, Paisley, UK) containing 10% (v/v) foetal calf serum (PCS, Sigma, 
UK), 33 pM biotin, 17 pM pantothenate, 100 U/ml penicillin and 100 pg/ml 
streptomycin at 37°C in a humidified atmosphere of 5% C02/95% air. Once 
confluent, differentiation was induced by incubating the cells in PCS-free 
induction media containing 0.25 pM dexamethasone, 0.5 mM isobutyl IBMX, 10 
nM insulin, 200 pM triiodothyronine (T3), 0.1 pM cortisol (Sigma) and 2 pM 
rosiglitazone (GlaxoSmithKline, UK) for 4 days. The cells were then fed every 3 
days in feeding medium (induction medium without dexamethasone, IBMX and 
rosiglitazone). Differentiated SGBS cells, 10-12 days post-induction, were treated 
with serum, and control cells were incubated in feeding medium. The cells were 
harvested in 500 pi of Trizol (Invitrogen) and the medium collected; both were 
frozen at -80°C until required for analysis.
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5.2.2 Treatment with uraemic sera
To examine the effect of uraemic sera on adipokines expression and secretion, 
fully differentiated adipocytes were incubated with serum or plasma, at day 12-14 
post-induction for 4 and 24 h. Wells incubated with adipocyte medium, only for 
the same period were used as controls. Incubations at each time-point were 
performed in 6-8 replicate. Cells and the culture medium were collected, 
centrifuged at 1000 rpm for 10 min to remove cell debris, and the supernatant was 
stored at —20 °C until further analysis.
5.2.3 Real-time PCR
Total RNA was extracted from cells using Trizol (Invitrogen, USA) and the RNA 
concentration determined from the absorbance at 260 nm. First strand cDNA was 
reverse transcribed from 0.5 (ig of total RNA using an iScript first strand synthesis 
kit (BioRad, Hercules, USA) in a final volume of 10 pi. Real-time PCR 
amplification was performed in a final volume of 12.5 pi, containing cDNA 
(equivalent to 10 ng of RNA), optimised concentrations of primers, TaqMan 
probe FAM-TAMRA and a master mix made from qPCR core kit (Eurogentec, 
Seraing, Belgium) using a Stratagene Mx3005P thermocycler. PCR amplification 
was performed in duplicate using 96-well plates and the PCR cycling conditions 
were as follows: 95 °C for 10 min followed by 40 cycles (95 °C for 15 s, 60 °C for 
1 min). Blank controls without cDNA were run in parallel. POL2A was used as a 
reference gene. All samples were normalised to the POL2A values and the results 
expressed as fold changes of Ct value relative to controls using the 2~AAet formula.
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5.2.4 Measurement of adipokines
Adiponectin were measured in serum and cell culture medium using a human 
adiponectin ELISA kit (R&D System, Inc., UK) according to the manufacturer's 
instructions. The sensitivity was >50 ng/ml.
High molecular weight adiponectin was measured in serum and using a human 
adiponectin ELISA kit (Alpco, USA) according to the manufacturer's instructions. 
The sensitivity was >0.19 ng/ml.
IL-6 was measured in serum using a human IL-6 ELISA kit (PEPROTEC, UK) 
according to the manufacturer's instructions. The sensitivity was > 50 pg/ml.
Leptin was measured in serum and using a human leptin ELISA kit (RayBiotech 
inc., USA) according to the manufacturer's instructions. The sensitivity was > 6 
pg/ml.
5.2.5 Cell viability assessment
Cell viability was determined from the release of lactate dehydrogenase (LDH) 
into cell culture medium after treatment with serum using a spectrophotometric 
assay kit (Roche Diagnostics GmbH, Mannheim, Germany). LDH levels were 
measured by a spectrophotometer at 492 nm and 620 nm at room temperature.
5.2.6 Statistical analysis
Data are expressed as means ± SEM. Student's unpaired /-test was used for two 
groups’ comparison. The statistical differences between more than two groups 
were evaluated through ANOVA followed by post hoc testing with Bonferroni 
correction. Differences were considered as statistically significant when P < 0.05.
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5,3 Results
5.3.1 Cell viability assessment
In the initial set of investigations, various concentrations of serum and plasma 
were tested with regard to cytotoxicity determined by LDH release. The following 
groups were examined: healthy, pre-haemodialysis, post-haemodialysis using 
serum and plasma at the following volume: 10, 50, 100, 150 and 300 pi. 
Incubation of adipocytes with plasma resulted in clotting in the well (Table 5.1). 
To overcome the clotting problem, EDTA was added to the culture. The effects on 
cell viability were measured after 24 h incubation with different doses of 
potassium-EDTA dissolved in the normal growth medium (DMEM). The results 
of the measurements of cell viability (LDH tests) are shown in Table I. The data 
show, that potassium-EDTA concentration up to 2.5 mg/ml showed significant 
toxicity (p < 0.0001). Serum was found to have the lower cytotoxicity effect 
compared to plasma and that cytotoxicity increased with increasing volume of 
serum (Figure 5.2).
5.3.2 Dosage response to human serum levels
Varying proportions of human serum (expressed as percentage values) were added 
to SGBS adipocytes in order to assess the levels required to elicit a response in 
adipokine gene expression whilst minimising the levels of cell cytotoxicity. Gene 
expression levels of adiponectin and IL-6 were chosen as markers to optimize the 
in vitro culture assay system. As can be seen in figure 5.3, serum concentrations 
0.5% and 5% resulted in measurable changes in gene expression levels and 
produced minimal levels of cytotoxicity and were used subsequently throughout
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as low and high dose levels.
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well content 1 h 2h 3h 6h 24 h
20 jd serum + serum free media
30 ill serum + serum free media
40 til serum + serum free media
50 jil serum + serum free media
60 jd serum + serum free media
70 jil serum + serum free media
80 pi serum + serum free media
90 pi serum + serum free media
100 pi serum + serum free media
75 pi plasma + serum free media clot clot clot clot clot
100 pi plasma + serum free media clot clot clot clot
150 pi plasma + serum free media
300 pi plasma + serum free media
FCS free DM EM
Table 5.1 Comparison between effects of serum vs plasma on the cultured 
adipocytes
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p < 0.0001
EDTA (mg/ml)
Figure 5.1 Toxic effects in normal adipocyte culture incubated for 24 h with 
different doses of k-EDTA
Differentiated human adipocytes were exposed to potassium-EDTA for 24 hrs. 
Results are mean ± SEM (n = 3). NS,
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Figure 5.2: Cytotoxicity effect of various volumes of normal and uraemic 
serum and plasma on adipocyte cell cultures
At the end of the period exposure of uraemic serum and/or plasma, the 
cytotoxicity was evaluated with lactate dehydrogenase (LDH) release into the 
medium. Cytotoxicity values are represented as a percentage of the high control. 
Results are percentage ± SEM and all evaluated samples were performed in 
triplicate. Plasma was obtained from blood samples collected into EDTA.
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Figure 5.3: Gene expression of IL-6 and Adiponectin in human adipocytes in 
response to serum treatment
Differentiated SGBS adipocytes were incubated with human serum for 24 h. Cells 
and media were collected at the indicated time points. Measurement of IL-6 and 
adiponectin mRNA (A), was assessed by real-time PCR (normalised to POL2A 
compared to the untreated control group); (B) cytotoxicity effect. Data is 
presented as means ± SEM.
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5.3.3 Serum total adiponectin and high molecular weight concentrations
The differences in serum high molecular weight adiponectin levels among the 
groups were significant (p < 0.0001). Serum high molecular weight adiponectin 
concentrations in ESRD patients were higher than those in healthy subjects. PD 
group presented higher values than HD groups (Pre and Post) (8.02 ± 5.14 pg/mL 
vs 3.03 ± 1.95 pg/mL; 3.57 ± 2.44 pg/mL respectively). Post hoc analysis 
(Bonferroni correction test) showed that the increase observed for PD vs H (p < 
0.0001), PD vs Pre-HD (p < 0.05) and PD vs Post-HD (p < 0.01) (Figure 5.4A).
For total adiponectin, the difference among the groups was significant (p < 0.001). 
Both ESRD patients (HD and PD) were higher than those in healthy subjects. 
Also, PD group presented higher values than HD groups (Pre and Post) (13.7 ± 
3.04 pg/mL vs 7.95 ± 1.44 pg/mL; 6.73 ±1.2 pg/mL respectively) (Figure 5.4B), 
Post hoc analysis (Bonferroni correction test) showed that the increase observed 
for PD vs H (p < 0.001) and PD vs Post-HD (p < 0.05) achieved significance 
(Figure 5.4B).
5.3.4 Measurement of adiponectin gene expression in human adipocytes
The PromoCell adipocytes were used at day 14 post-induction to examine the 
potential effect of uraemic serum on adipocytes. 0.5 % and 5 % of serum were 
employed at two time points, 4 and 24 hrs.
The differences in adiponectin mRNA levels among the groups at 4 h with low 
dose were significant (p < 0.0001) as adiponectin gene expression was down- 
regulated 2-fold, 2.5-fold and 3-fold in the pre-HD, post-HD and PD groups, 
respectively (Figure 5.5). However, at 24 hr, adiponectin gene expression was
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changed. Post hoc analysis (Bonferroni correction test) showed that the decrease 
observed for Post-HD vs H Q? < 0.0001) and PD vs H 0? < 0.0001) (Figure 5.5).
Comparison of serum treatments between the pre-HD and post-HD indicated that 
there was no significant change in adiponectin gene expression.
5.3.5 Measurement of adiponectin release by human adipocytes
As shown in figure 5.6, total adiponectin was measured. However, only changes
noted with low dose at 4 h with no significant change was noted at 24 h.
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H Pre-HD Post-HD PD
A
p < 0.0001
p < 0.0001
15.0- p < 0.001
12.5-
p < 0.05x 10.0-
p< 0.001
p < 0.001
p < 0.0517.5-
15.0-
12.5-
10.0-
Figure 5.4 Circulating adiponectin levels in human subjects.
Serum concentrations of high molecular weight adiponectin (A) and total 
adiponectin (B) in healthy control subjects (white bars), ESRD patients pre­
haemodialysis, Pre-HD (grey bars), ESRD patients post-haemodialysis, Post-HD 
(black bars) and ESRD patients peritoneal dialysis, PD (light grey bars). Values 
are means ± SEM (n = 9 for control group, n= \ \ for HD group and w = 7 for PD 
group).
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p < 0.0001
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Figure 5.5 Adiponectin gene expression levels in adipocytes treated with 
uraemic serum
Differentiated human adipocytes were exposed to Low dose (upper panel) and to 
high dose (lower panel) of human pooled serum from healthy (H) and ESRD 
groups pre and post dialysis for 4 and 24 hrs. Adiponectin mRNA levels were 
normalised to human POLR2A and expressed relative to untreated cells. Results 
are mean ± SEM (n = 6/group). NS, not significant.
160
Low Dose High Dose
Figure 5.6 Release of adiponectin by human adipocytes treated with uraemic 
serum
Adiponectin secretion by human adipocytes in culture. A, B and C with Low dose. 
D, E and F with high dose. The adiponectin were measured by ELISA in culture 
media of cells after the incubation of serum with low dose a and high dose b for 4 
and 24 hr, and the results are given as ±SEM for groups of three at each time 
point. *P<0.05 **P<0.01. ***P<0.001. *Significant difference from the untreated 
cells.
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Figure 5.7 Circulating IL-6 levels in human subjects.
Serum concentrations of interlukin-6 (IL-6) in healthy control subjects (white 
bars), ESRD patients pre-haemodialysis Pre-HD (grey bars), ESRD patients post­
haemodialysis Post-HD (black bars) and ESRD patients peritoneal dialysis (light 
grey bars). Values are means ± SEM (n = 9 for control group, >7=11 for HD 
group and >7 = 7 for PD group. NS, not significant.
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5.3.6 Serum IL-6 concentrations
Serum IL-6 was measured using ELISA. Serum IL-6 levels in healthy, Pre-HD, 
Post-HD and PD subjects were 7.63 ± 9.2, 11.11 ± 9.17, 10.12 ± 9.41 ng/mL) and 
6.14 ± 5.58 ng/mL respectively (Fig. 5.7). There was no significant difference in 
serum IL-6 levels among all groups. Due to low sensitivity of used ELISA kit of 
IL-6 in this study ( 50 pg/ml), IL-6 levels shoewed higher levels than what been 
previously reported (Mohamed-Ali et al., 1997)
5.3.7 Measurement of IL-6 gene expression in human adipocytes treated with 
uraemic serum
The PromoCell adipocytes were used at day 14 post-induction to examine the 
potential effect of uraemic serum on adipocytes. 0.5 % and 5 % of serum were 
employed at two time points, 4 and 24 hrs.
The differences in IL-6 mRNA levels among the groups at 4 h with low dose were 
significant (p < 0.0001) and with high dose at 24 h (p < 0.05) as IL-6 gene 
expression was down-regulated 2.5-fold in the pre-HD, post-HD and PD groups 
(Figure 5.8). Post hoc analysis (Bonferroni correction test) showed that the 
decrease observed for Pre-HD vs H (p < 0.0001), Post-HD vs H (p < 0.0001) and 
PD vs H (p < 0.0001) and at 24 h was for only Pre-HD vs H (p < 0.05) (Figure 
5.8).
Comparison of serum treatments from the pre-HD and post-HD indicated that 
there was no significant change in IL-6 gene expression.
5.3.8 Measurement of MCP-1 gene expression in human adipocytes
The PromoCell adipocytes were used at day 14 post-induction to examine the
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potential effect of uraemic serum on adipocytes. 0.5 % and 5 % of serum were 
employed at two time points, 4 and 24 hrs. At low dose serum and high serum 
treatment, no significant change was seen in MCP-1 gene expression (Figure 
5.9).
Comparison of serum treatments from the pre-HD and post-HD indicated that 
there was no significant change in MCP-1 gene expression.
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Figure 5.8 IL-6 gene expression levels in adipocytes treated with uraemic 
serum
Differentiated human adipocytes were exposed to Low dose (upper panel) and to 
high dose (lower panel) of human pooled sera collected from healthy (H) and 
ESRD groups pre and post dialysis for 4 and 24 hrs. IL-6 mRNA levels were 
normalised to human POLR2A and expressed relative to untreated cells. Results
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are mean ± SEM (n = 6/group). NS, not significant.
OH O Pre-HD ■ Post-HD O PD
Low dose
High dose
l 0.5-
Figure 5.9 MCP-1 gene expression levels in adipocytes treated with uraemic 
serum
Differentiated human adipocytes were exposed to Low dose (upper panel) and to 
high dose (lowerpanel) of human pooled sera from healthy (H) and ESRD groups 
pre and post dialysis for 4 and 24 hrs. MCP-1 mRNA levels were normalised to 
human POLR2A and expressed relative to untreated cells. Results are mean ±
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SEM (n = 6/group). NS, not significant.
5.3.9 Serum leptin concentration
The differences in serum leptin levels among the groups were significant (p < 
0.05). Serum leptin concentrations in ESRD patients were significantly higher 
than those in healthy subjects. Haemodialysis group (Pre and Post) presented 
higher values than peritoneal dialysis groups (57.19 ± 19.57 pg/mL 29.03 ± 12.55 
pg/mL; vs 4.80 ± 1.46 pg/mL respectively) (Figure 5,10 A). Figures 5.9 B show 
the correlation between leptin and body weight in healthy group {r = 0.2; P < 
0.14; N=9) and ESRD group (r = 0.3; P < 0.07; 18), respectively.
5.3.10 Measurement of leptin gene expression in human adipocytes
The PromoCell adipocytes were used at day 14 post-induction to examine the 
potential effect of uraemic serum on adipocytes. 0.5 % and 5 % of serum were 
employed at two time points, 4 and 24 hrs.
The differences in adiponectin mRNA levels among the groups at 4 h with low 
dose were significant (p < 0.05). At low dose serum for 4 h, leptin gene expression 
was down-regulated 1.7-fold in PD groups (Figure 5.11 c). However, at 24 h, 
leptin gene expression was found to be unchanged (Figure 5.11).
Comparison of serum treatments from the pre-HD and post-HD indicated that 
there was significant increase in leptin gene expression with low dose serum at 24
h.
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Figure 5.10 Circulating leptin levels in human subjects and BMI correlation
(A) Serum concentrations of Leptin in healthy control subjects (white bars), ESRD 
patients pre-haemodialysis Pre-HD (grey bars), ESRD patients post-haemodialysis 
Post-HD (black bars) and ESRD patients peritoneal dialysis (light grey bars). 
Values are means ± SEM. (B) The correlation between BMI and circulating leptin 
levels in healthy group (• ) (r = 0.2; P < 0.14; N = 9) and ESRD group ( o ) (r = 
0.3; P < 0.07; N = 18), respectively and (C) shows the log of serum leptin plotted 
against the BMI in the same patients. (n = 9 for control group, n = \ \ for HD 
group and « = 7 for PD group).
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Figure 5.11 Leptin gene expression levels in adipocytes treated with uraemic
serum
Differentiated human adipocytes were exposed to Low dose (upper panel) and to 
high dose (lower panel) of human pooled sera from healthy (H) and ESRD groups 
pre and post dialysis for 4 and 24 hrs. Leptin mRNA levels were normalised to 
human POLR2A and expressed relative to untreated cells. Results are mean ± 
SEM (n = 6/group). NS, not significant.
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5.4 Discussion
CVD is considered as the major cause of death in ESRD. However, the 
mechanism(s) are still not clear but it has been suggested that the uraemic 
environment could be contributing to this association (Huang et al., 2004). In 
addition, uraemia-related factors have been shown to play a potential role in the 
progression of CVD in ESRD patients (Madore, 2003). A role for adipose tissue 
has been proposed.
The present study, aimed specifically at characterising the role of adipose tissue in 
the association between CVD and ESRD with attention focused on adipokine 
expression. The gene expression of key adipokines using an in vitro human 
adipocyte culture system in the presence of serum expected to contain substances 
and molecules retained in ESRD, collectively termed uraemic toxins, has been 
investigated.
Initially, plasma collected from healthy subjects and ESRD patients was used in 
an attempt to standardise the appropriate conditions for cell culture study. For the 
purpose of analysis, different concentrations of plasma had been separated from 
pre and post dialysis blood and then incubated for certain period (4 hr and 24 hr) 
with cultured human adipocytes. The first set of analyses examined the impact of 
ESRD plasma on biological integrity. The most striking result to emerge from the 
data was that concentrations more than 15% caused cell death while 
concentrations less than 10% result in media clotting. As an alternative, serum 
was tested which was found to be more appropriate for culture studies. Further 
analysis showed that the optimum serum concentration was between 0.5% and
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5%.
The next part of the study, adipnectin expression was investigated in cultured 
human adipocytes (PromoCell) when exposed to uraemic serum. Adiponectin has 
favourable properties including antiathergenic, anti-inflammation and insulin 
sensitizing effects (Costacou and Orchard, 2008). Patients with ESRD undergoing 
peritoneal dialysis showed a significant increase in adiponectin plasma levels both 
in total adiponectin and high molecular weight adiponectin compared to the 
healthy control group. A significant difference in circulating adiponectin levels 
was seen between Peritoneal and Haemodialysis patients. A similar finding has 
been reported in previous studies (Bakkaloglu et al, 2005, Huang et ah, 2004). 
Because the adiponectin is a 30 kd molecular weight, it is unlikely to be removed 
by the dialysis process. However, kidneys are important organs for elimination of 
many factors including protein hormones; therefore it’s likely that impaired 
kidney function could lead to adiponectin accumulation in the circulation of 
ESRD patients. Moreover, adiponectin plasma levels were found to be reduced 
markedly after kidney transplantation but still at higher levels compared to healthy 
subjects (Chudek et al., 2003). Controversy exists on how the kidneys handle this 
adipokine (Kataoka and Sharma, 2006).
Uraemia-related factors have been shown to play a potential role in the 
progression of CVD in ESRD patients (Madore, 2003). Many studies had shown 
that low levels of adiponectin can be considered as a predictor of incident 
cardiovascular events in ESRD (Adamczak et al., 2009). Moreover, plasma levels 
of adiponectin have been shown to be associated negatively with metabolic risk 
factors (Zoccali et al., 2002). Thus, the higher levels of plasma adiponectin could
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be explained by its protective role as anti-atherogenic and insulin sensitizing.
These higher levels of adiponectin in ESRD patients appear not to be from an 
increase in adipocyte gene expression. The results showed that its gene expression 
was downregulated significantly in both HD and PD groups with low serum dose. 
The studies in this thesis are the first to employ normal human adipocytes, 
exposing these cells to a uraemic environment to show changes in gene expression 
for proteins/enzymes of lipid metabolism as well as adipokines. This finding is 
consistent with results from previous studies that indicated that adiponectin gene 
expression in vivo is decreased in patients with ESRD (Marchlewska et al., 2004) 
as well as in patients with high risk of CVD (Statnick et al., 2000). In one study, 
there was no difference seen in adiponectin gene expression in peripheral blood 
mononuclear cells in patients with ESRD (Norata et al., 2009). Moreover, 
downregulation of adiponectin mRNA has been reported in experimental models 
in vitro as a result of ESRD-associated oxidative stress (Barazzoni et al., 2007). It 
has been suggested that uraemic toxins might overwhelm the positive effects of 
adiponectin in the ESRD population (Beige et al., 2009). In the optimization 
experiment in studies performed in this thesis, adiponectin mRNA was seen to be 
decreased when serum dose increases, suggesting a dose response. The reasons for 
the acute and rapid suppression of adiponectin expression and secretion are 
unknown but may include inflammation and oxidative stress as has been 
suggested by others. It has been reported that adiponectin gene expression and its 
release are suppressed by oxidative stress in cultured 3T3-L1 adipocytes 
(Furukawa et al., 2004). Moreover, low gene expression has been associated with 
oxidative stress in non-diabetic ESRD patients following adipose tissue biopsy
172
studies (Barazzoni et al., 2007). In addition, adiponectinaemia has been found to 
lower gene expression by a feedback mechanism (Bauche et al, 2006, 
Marchlewska et al., 2004). Since it has been suggested that secretion of 
adiponectin is under feedback regulation, it could be argued that since adiponectin 
was increased in the uraemic serum that was added to the adipocyte in vitro in the 
studies described in this thesis, this may have resulted in an autoregulatory 
inhibition of adiponectin transcription and secretion. Receptors for adiponectin are 
present on adipocytes. This argument would also be consistent with a dose effect 
of the uraemic serum seen in our studies. This hypothesis could be refuted by 
direct addition of adiponectin to the adipocyte cultures, not performed in these 
studies. Also, healthy serum per se downregulated adiponectin expression in 
adipocytes suggesting a response to unknown humoral components found in 
serum (Korner et al., 2005). It is possible that increased circulating adipokines, 
other than adiponectin, such as IL-6 and leptin found in this study and others not 
measured here, could influence expression and secretion of adiponectin.
Leptin is one of the most intensively studied adipokines. Leptin is mainly 
synthesised in adipocytes and its plasma levels are proportional to adiposity. 
Leptin is involved in food intake regulation as well as other functions. It has been 
documented that deficiency in leptin levels results in diabetes and obesity as a 
consequence of high food intake (Kataoka and Sharma, 2006). Similar to previous 
studies, the results presented in this thesis show that patients prior to undergoing 
haemodialysis have a significant change of circulating levels of leptin when 
among the studied group. Hyperleptinaemia has been reported to be associated 
with ESRD (Fontan et al., 1999, Sharma et al., 1997). However, these higher
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levels in haemodialysis is probably not caused by high expression as the results 
have shown a little changes in adipocyte leptin gene expression when treated with 
ureamic serum. If anything, supporting a trend of downregulation of leptin 
expression when pre- and post-HD sera were added, only reaching significance in 
the peritoneal group, there was a significant downregulation of leptin mRNA 
levels and that could be a possible explanation for non-increase in the circulating 
levels with this group. It has been also documented that leptin gene expression is 
decreased in patients with ESRD (Nordfors et al., 1998). Collectively, like for 
adiponectin, autoregulation of leptin expression and secretion by leptin itself 
cannot be excluded. As with adiponectin modulation of adipokines secretion by 
other adipokines cannot be excluded. Leptin is strongly linked with nutrition and 
may have similar implications in the studies presented in this thesis.
Data from the present thesis showed that serum leptin levels did not associated 
with BMI. Although ESRD prevents elimination of leptin and leads to high 
circulating concentrations (Merabet et al., 1997), BMI values of ESRD were 
similar to the healthy group in this thesis. However, some studies failed to show a 
positive association between serum leptin levels and nutritional status markers 
such as BMI and fat mass (Beberashvili et al., 2011) similar to those in this thesis. 
Moreover, kidney transplantation resulted in normal levels of serum leptin 
confirming an important role for the kidney in the elimination of circulating leptin 
(Kokot et al., 1998). Although there are limited studies showing the role of 
adipokines in renal pathology, leptin has been proposed to be involved in this 
process (Carrero et al., 2010). The higher levels of serum leptin have been 
suggested to be involved in the pathogenesis and progression of obesity-related
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kidney disease (Kambham et al, 2001). It has also been shown that infusion of 
leptin in normal rat resulted in development of glomerulosclerosis and proteinuria 
(Wolf et al.9 1999). The significance of increased circulating leptin in progression 
of earlier stages of renal failure may be important but its significance in ESRD is 
unclear.
It is well-known that ESRD is associated with chronic inflammation, oxidative 
stress and endothelial dysfunction (Stenvinkel, 2006). Therefore, two 
proinflammatory markers, IL-6 and MCP-1 gene expression were investigated. 
The results have shown that there is a trend towards increased in circulating levels 
of IL-6 in Haemodialysis groups which was not statistically significant. However, 
a number of studies have reported that IL-6 is not elevated in all ESRD patients 
(Stenvinkel et al., 2005). The higher levels of IL-6 are considered a strong 
predictor for cardiovascular disease in ESRD (Stenvinkel et al., 2002b). 
Moreover, the higher levels of IL-6 in ESRD patients have been attributed to the 
long half life of IL-6 along the presence of chronic inflammation (Jacobs et al., 
2004). The differences of IL-6 gene expression were observed in all patents group 
at low dose. IL-6 studied in this thesis related to the adipocyte contribution. 
Clearly inflammatory cells such as the monocyte/macrophage system may 
contribute to the inflammatory mileau, and were not studied in this thesis.
MCP-1 has been proposed to play an important role in many disease states such as 
inflammation, atherosclerosis, diabetes and nephropathies (Yadav et al., 2010). 
The results have shown that there was no significant in MCP-1 adipocyte gene 
expression. Circulating MCP protein was not measured in this thesis and an 
increase in concentration cannot be excluded. Post-transcriptional regulation can
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lead to increased production and secretion of cellular proteins. Therefore, we 
cannot exclude the possibility of altered circulating MCP-1 protein.
Several investigations have been reported that adipose tissue is involved in ESRD. 
It has also been reported that a low BMI can be an important predictor for 
mortality in the haemodialysis population (Kalantar-Zadeh et al, 2006). In 
contrast, other reports have been showed that high BMI is associated with better 
survival (Friedman, 2006, Honda et al., 2007). Moreover, the change in fat mass 
over time has been considered as a risk factor for mortality in haemodialysis 
patients (Kalantar-Zadeh et al., 2006).
In peritoneal dialysis, patents tend to gain more weight due to glucose-containing 
peritoneal dialysis solution. This increase in glucose may lead to increase 
lipogenesis in the liver and this can be considered as a potential risk factor for the 
development of CVD in ESRD in the peritoneal dialysis population (Fernstrom et 
al., 1998, Klim and Williamson, 1983).
There is controversy as to the source of adiponectin from adipose tissue, whether 
it is mainly from subcutaneous (Lihn et al., 2004) or alternatively from the 
visceral depot (Degawa-Yamauchi et al., 2005). Cultured adipocytes in this study 
originated from the subcutaneous depot. Different factors such as differentiation 
capacity, cell viability, serum-containing media and many others might play a role 
in the expression of adipokines..
Gene expression at the mRNA level is generally informative but not predictive for 
that at the protein level. Thus, further investigation for protein detection may 
allow for a deeper interpretation.
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In conclusion, an in vitro system to study the effect of uraemic serum on adipose 
tissue function through adipocyte gene expression was established. The results 
from the modulation of this in vitro adipocyte assay system not only serves as a 
convenient and unique model to study mechanisms of disease such as ESRD and 
its treatments but has so far also provided an initial insight in understanding the 
putative role of adipose tissue contributing to the associated of CVD risk in ESRD 
patients. Data also suggests that normal adipocyte function is altered when 
exposed to a uraemic environment in vitro.
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CHAPTER 6
ADIPOSE TISSUE AND INFLAMMATION IN END-STAGE RENAL
DISEASE
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6.1 Introduction
In addition to the important metabolic function, adipose tissue is considered a very 
active endocrine organ which secretes numerous hormones and adipokines that are 
linked to inflammation, insulin resistance and endothelial dysfunction (Chudek 
and Wiecek, 2006, Wellen and Hotamisligil, 2005). Adipose tissue is a 
heterogeneous tissue, which consists of many cell types in addition to adipocytes 
including preadipocytes, macrophages and vascular cells. An increase in adipose 
tissue mass is accompanied by an increased adipocyte size and number that may 
have many pathophysiological consequences. In altered adipose tissue states such 
as obesity, the production of pro-inflammatory adipokines has been linked to 
many metabolic complications (Weisberg et ah, 2003). The expression and 
production of proinflammatory adipokines, such as tumor necrosis factor a 
(TNFa). interleukin 6 (TL-6) and monocyte chemoattractant protein 1 (MCP-1), 
and tissue infiltration of adipose tissue by inflammatory cells have been shown to 
be increased in obese and insulin-resistant subjects, (de Luca and Olefsky, 2008).
It has been reported that obesity and insulin resistance are associated with 
macrophage accumulation in adipose tissue (Weisberg et ah, 2003, Xu et al., 
2003). Furthermore, increased production of pro-inflammatory adipokines from 
adipose tissue may contribute to the CVD and malnutrition in ESRD (Stenvinkel, 
2006). However, it has been recently accepted that adipocytes are not the main 
producer of inflammatory mediators secreted from adipose tissue. Adipocyte mass 
is associated with BMI and insulin resistance and also with macrophage 
infiltration (Weisberg et ah, 2003). Macrophages in adipose tissue (MAT) have 
been proposed as the main producer for inflammatory mediators rather than
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adipocytes (Surmi and Hasty, 2008). Patients with ESRD have a significantly high 
rate of morbidity and mortality from CVD . Inflammation in ESRD has been 
suggested to contribute to the CVD progression (Silverstein, 2009, Stenvinkel, 
2006). The present study was performed to investigate the extent of macrophage 
infiltration into adipose tissue in ESRD and to compare ESRD with non-ESRD 
human subjects.
6.2 Methods
6.2.1 Patients adipose tissue
Six male patients with ESRD (mean age 52±16.2 y, BMI 26.4±2.4 kg/m2) who 
underwent kidney transplantation were included in the study. Causes of ESRD 
were chronic glomerulonephritis, diabetic nephropathy and polycystic kidney 
disease. Patients on haemodialysis therapy received 3 to 4 hours of therapy 3 
times per week. The majority of patients were administered antihypertensive 
medications (angiotensin-converting enzyme inhibitors and/or angiotensin II 
receptor antagonists, [3-blockers, calcium channel blockers) and other drugs 
commonly used in patients with ESRD, such as phosphate and potassium binders, 
diuretics, erythropoiesis-stimulating agents, iron substitution, and vitamin B, C, 
and D supplements.
The study protocol was approved by Liverpool Research Ethics Committee (REC 
number: 08/HI002/41), and fully informed and written consent was obtained in all 
cases.
6.2.2 Non-ESRD adipose tissue
The non-ESRD group consisted of 6 men with no ESRD or any medication (mean
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age 61.2±18.5 y, BMI 26±2.6 kg/m2) who underwent elective cholecystectomy or 
kidney donation at Royal Liverpool University Hospital. Fat biopsies were obtained 
from two different locations; subcutaneous (n = 6), and omental (n = 6). Fully 
informed and written consent was obtained in all cases.
6. 2.2 Immunohistochemistiy for CD-68 in adipose tissue
CD-68 staining was used as a marker for macrophages. Staining was performed 
using a standard protocol on sections from formalin-fixed paraffin-embedded 
tissue blocks. Five-micron thick sections were microwave-treated in 10 mmol/1 
citrate buffer (pH 6.0) and incubated for 1 hour at room temperature with primary 
antibodies; mouse monoclonal antibody CD-68 clones KPI (Dako Cytomation). 
After rinsing in PBS buffer containing 0.25 % Triton X-100 (pH 7.2), sections 
were incubated with secondary biotinylated goat anti-mouse (Vector). Avidin- 
biotin peroxidase complexes (Vector) were added followed by visualization with 
3.3'-diaminobenzidine tetrachloride (Vector). All sections were counterstained 
with Harris haematoxylin. Tissue sections incubated without primary antibody 
were used as negative controls. Tissue sections incubated without primary 
antibody were used as negative controls.
6.2.3 IHC scoring
For each subject, the number of macrophages (identified as CD-6 8-positive cells) 
within the entire section were counted using a light microscope (Polyvar 
microscope - Leica). The percentage of positively stained cells was scored 
semiquantitatively in a “blinded” manner. The number of CD68-positive cells per 
high-power field was counted.
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6.2.4 Statistical analysis
Data are expressed as means ± SD. Differences between study groups in tissue 
staining score were tested using Mann-Whitney U test. Differences were 
considered as statistically significant when P < 0.05.
6.3 Results
Adipose tissues from 6 ESRD patients undergoing kidney transplantation (12 
samples) were procured for this study and the same number also from non ESRD 
subjects with no differences in BMI or sex distribution (Table 6.1). Positive 
staining for the macrophage marker CD-68 was investigated in 24 adipose tissue 
samples. Two different depots (subcutaneous and omental) were examined from 
participating subjects. The total number of macrophages per section area in 
subcutaneous adipose tissues did not differ between the groups, despite a tendency 
toward higher cell number in the ESRD group (Figure 6.1). The total number of 
macrophages per section area did not differ between the groups, despite a 
tendency toward higher cell number in the ESRD group in subcutaneous and 
omental depots (2.8±0.75 vs.l.8±0.5 and 3±0.0 vs.l.3±0,6, respectively, NS).
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Non-ESRD ESRD
n 6 6
Age (years) 61.2(18.5) 52(16.2)
BMI(kg/m2) 26(2.6) 26.4(2.4)
Table 6.1 Clinical characteristics of patients
Data are expressed as Mean ±SD
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Figure 6.1: Immunohistochemical detection of CD-68 macrophages in human 
subcutaneous adipose tissue.
Subcutaneous adipose tissue samples were taken from the subcutaneous 
abdominal region of human healthy non-ESRD subject whose BMI 30 kg/m2 (A 
and B) and ESRD subject whose BMI 30.2 kg/m2 (C and D). B and D represent 
negative control not stained with CD-68 antibody. Arrows are macrophages. 
Magnification x40
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Figure 6.3: Immunohistochemical detection of CD-68 macrophages in human 
omental adipose tissue.
Visceral adipose tissue samples were taken from the omental region of human 
healthy non-ESRD subject whose BM1 30 kg/m2 (A) and ESRD subject whose 
BMI 30.2 kg/m (B). Arrows are macrophages. Magnification x40
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6.4 Discussion
In the present study, macrophage infiltration into adipose tissue was investigated 
in ESRD patients in different depots. The main finding was that adipose tissue 
from ESRD tended to have higher number of macrophage cells but did not 
achieve statistical significance.
It has been reported that proinflammatory markers are considered as strong 
predictors of mortality of CVD in ESRD (Axelsson et ah, 2004). Inflammation is 
a common feature of ESRD and is associated with an adverse outcome 
(Stenvinkel et al,, 2004). Moreover, it has been suggested that ESRD has a 
common feature namely the metabolic syndrome of obesity (Beddhu et ah, 2005). 
Furthermore, it has been reported that ESRD is associated with metabolic 
syndrome-related complication such as inflammation, dyslipidaemia and 
atherosclerosis (Zanetti et ah, 2008). The high prevalence of ESRD can be 
attributed to many causes including obesity (Kalaitzidis and Siamopoulos, 2011). 
Obesity has many implications for the dialysis patients (Zoccali and Mallamaci, 
2011). Obesity is now considered as a chronic and low-grade inflammation state 
(Trayhurn, 2005). Obesity is characterised by hyperplasia and hypertrophy of 
adipocytes during the accumulation of fat mass and is associated with macrophage 
infiltration (Torres-Leal et ah, 2010).
Gene expression of adipocytes was found to be similar as in macrophage and 
these types of cells share functional capabilities (Charriere et ah, 2003). 
Moreover, there been an accumulation of evidence that adipose tissue has a link 
with immune system in terms of energy metabolism (Schaffler et ah, 2006).
Fat mass has been found to be correlated with high level of circulating
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proinflammatory markers in ESRD (Axelsson et ai., 2004). However, it has been 
explained that increase expression of inflammatory marker can be derived from 
macrophage rather than adipocytes. Xu et al (Xu et al., 2003) and Weisberg et al 
(Weisberg et al., 2003) published the first report that obesity is associated with 
macrophage infiltration. In these two studies, macrophages are suggested to be 
main contributors to the inflammatory mediator production from the adipose 
tissues studied. Macrophage marker CD-68 expression was found to be 
significantly higher in adipose tissue of obese compared to lean subjects in these 
previous pioneering observational studies.
Recently, two studies have been published to investigate CD-68 in ESRD patients. 
Roubicek et al found an increase macrophage infiltration of subcutaneous and 
visceral adipose tissue in women with ESRD (Roubicek et al., 2009). However, 
Witasp et al found no difference in CD-68 expression between ESRD and control 
(Witasp et al., 2010). The latter finding is consistent with those of the present 
study as the results showed no significant difference in the number of CD-68 
between studied groups. Moreover, it has been reported that fat mass is associated 
with increased CD-163, a circulating marker of macrophages (Axelsson et al., 
2006b), a measurement that was not carried out in the present studies.
The mechanisms for macrophage infiltration in adipose tissue remains not fully 
understood. However, two mechanisms have been proposed by which 
macrophages can infiltrate the adipose tissue. First, macrophage can be originate 
from bone marrow-derived monocytes; second, macrophages can trans- 
differentiate from preadipocytes or mesenchymal stem cells within the adipose 
tissue itself (Schaffler et al., 2006). However, it has been noted that fat mass is
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strong predictor of macrophage infiltration into adipose tissue (Tchoukalova et ah, 
2007). There are many factors have that been suggested to play a potential role in 
macrophage recruitment and infiltration including adipocyte hyperplasia, 
adipocyte hypertrophy, altered adipokine production, apoptosis and hypoxia 
(Bourlier and Bouloumie, 2009). Hypertrophic adipocytes have been showed to 
have a high pro inflammatory adipokine profile compared to smaller cells (Skurk 
et ah, 2007). Furthermore, macrophage infiltration into adipose tissue has been 
suggested to play role in insulin resistance and systemic inflammation (Bouloumie 
et ah, 2005).
Adipose tissue secretes hundreds of biologically active molecules that influence 
many physiological processes. It is therefore no surprise when thirty percent of 
these molecules are inflammatory and macrophage-specific(Schaffler et ah, 2006). 
Although there is similarity between adipose tissue functions in ESRD and 
obesity, there were also significant differences. One of the major differences is 
that adiponectin, an adipose tissue-derived hormone with anti-inflammatory, anti­
atherogenic and insulin sensitizing properties is found at high levels in the 
circulation of ESRD compared to obese subjects. Moreover, adipose tissue may 
contribute to systemic inflammation in ESRD (Barazzoni et ah, 2011). It has been 
shown that systemic inflammation may be associated with cardiovascular events 
(Berg and Scherer, 2005).
In conclusion, the present study shows a tendency towards an increased 
accumulation of macrophages in adipose tissue in ESRD patients. Increasing the 
statistical power of such studies either by collecting adipose tissue samples from 
more subjects or by studying more sections and thereby counting more cells in
188
more fields may be necessary. We are considering whether we could increase our 
statistical power by counting more sections from tissues already collected. It is 
necessary to bear in mind that adipose tissue and other samples collected in this 
and previous studies described in this thesis came from intensively treated patients 
both by pharmacological measures such as drugs as well as dialysis, thereby 
perhaps minimising the abnormal pathophysiology. One possibility is to study 
animal models of renal failure not confounded by treatment effects. Time 
constraints prevented collection of more samples. Despite these limitations, it is 
likely that inflammation of the adipose tissue in ESRD is a reality, but requires 
more proof. It remains to be determined how important this adipose tissue- 
mediated inflammation is in contributing to the systemic pro inflammatory state in 
uraemia, to cardiovascular disease and to progression of renal dysfunction in these 
patients and whether interventions suppressing such inflammation may have 
beneficial effects.
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CHAPTER 7
GENERAL DISCUSSION
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General introductory comments
The hypothesis that has driven this thesis was based on the knowledge that 
adipose tissue, which has been shown to contribute to CVD in various ways that 
include alteration in lipoprotein metabolism as well as secretion of pro and anti­
inflammatory adipokines in states without ESRD, may also be involved in ESRD. 
The proposal is that the retention of uraemic toxins in the body of ESRD patients 
may lead to adipose tissue dysfunction affecting both adipokine production and 
lipoprotein metabolism — a potential link to CVD. The specific aim was to isolate 
and characterize the role of adipose tissue in ESRD in terms of lipoprotein 
metabolism and adipokine expression and secretion.
Rationale for studies
The rationale for studies in this thesis was that the retained substances in ESRD 
could alter adipose tissue function. This was tested in two ways. One was to 
obtain adipose tissue from ESRD patients undergoing renal transplantation. This 
would provide information about the effect on long-term exposure to uraemic 
environment. Although we would have liked to have measured expression of 
adipokines and lipid metabolism genes in adipose tissue biopsies, time constraints 
prevented this. The second way we tested the possible alteration of adipose tissue 
by uraemic environment was to expose normal adipocytes to serum from ESRD 
patients to see if the lipid metabolism or adipokine function is altered in any way. 
These changes are clearly different from the effects of uraemic environment in 
ESRD patients since the adipose tissue in ESRD would have been exposed to
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uraemic substances chronically. Nevertheless changes were observed both in 
adipose tissue biopsy samples as well as the in viti’o adipocyte culture studies.
Focus on aspects of lipoprotein and adipokine metabolism in chapters
The main outcomes presented in this thesis focused on the effect of uraemic 
milieu on adipose tissue function. The results presented in chapter 3 to 6 have 
shown that both uraemic serum and uraemic lipoproteins altered adipokine 
expression, particularly those with favourable properties such as adiponectin. The 
results presented in chapter 3 corresponded to observations regarding lipoprotein 
profile in ESRD patients who were undergoing either haemodialysis or peritoneal 
dialysis. Chapter 5 was dedicated to adipokine gene expression of adiponectin, 
leptin, IL-6 and MCP-1 in human adipocytes culture in the light of uraemic 
environment. Chapter 6 relates to inflammation in adipose tissue by detecting of 
macrophage marker CD-68. Chapter 4 focused on the gene expression of lipid 
metabolism and included LPL, HSL, LDL-R and C3 in the human adipocytes 
culture exposed to the different uraemic lipoproteins.
Analytical techniques employed
The techniques utilised in all the studies of human adipocytes culture include real­
time PCR for adipokine and lipid metabolism related factor gene expression, 
density ultracentrifugation for VLDL, LDL and HDL fractionation, ELISA for the 
analysis of protein secretion and plasma concentration and immunohistochemistry 
for detection of CD-68 expression in adipose tissue. During this study, other 
techniques were also employed, ELISA and standard PCR.
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Interaction between adipose tissue and lipoproteins
Adipose tissue has a crucial role in storing nutrients predominantly dietary 
triglycerides following intake in the postprandial state. This involves sequentially 
hydrolysis of chylomicron (and indirectly VLDL) by lipoprotein lipase, release of 
fatty acids and uptake of fatty acids into adipocytes prior to re-esterification and 
storage. Lipoprotein lipase is therefore a key gatekeeper for the storage of dietary 
triglycerides. The present thesis showed that the nutrient storage function could be 
compromised in ESRD in several ways. Although direct measurement of LPL was 
not performed, gene expression for LPL showed significant decrease when normal 
adipocytes were exposed to uraemic pooled sera; this would be consistent with a 
decrease in LPL protein and activity and supports similar reported results by other 
groups (Dautin et al., 2007). Circulating triglycerides in serum and VLDL 
lipoproteins were also significantly increased compared with healthy sera, both 
consistent with decreased clearance of triglyceride-rich lipoproteins in the uraemia 
of ESRD. Similar findings of hypertriglyceridaemia in ESRD have been reported 
by other groups (Tsimihodimos et ah, 2011, van de Woestijne et al., 2011). These 
findings are strongly suggestive of a defective adipose tissue storage function in 
ESRD.
On the other hand appropriate release of fatty acids from stores is required in the 
post-absorptive and prolonged fasting states. This fatty acid release is necessary to 
allow cells, tissues and organs that can utilise fatty acids for energy purposes to 
survive during periods of energy deprivation. The key enzyme that is classically 
involved in hydrolysing triglycerides droplets from adipose tissue stores is 
hormone-sensitive lipase. The data in this thesis suggest that normal adipocytes
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when exposed to the uraemic sera down-regulate expression of hormone sensitive 
lipase genes; this is also consistent with the idea that release of fatty acids could 
be impaired in uraemia although confirmation will require protein measurements 
of HSL. Unfortunately circulating free fatty acid measurements were not carried 
out in the sera to further support these observations.
It could therefore be argued that the adipose tissue in ESRD could be 
characterised by an inability to take up nutrients and also an inability to release 
these nutrients when required. This would suggest an abnormality in a 
fundamental property of white adipose tissue suggesting that it may be 
dysfunctional in ESRD.
Besides triglyceride storage, dietary (and circulating) cholesterol is also taken up 
by white adipose tissue. Therefore in addition to circulating lipid and lipoprotein 
measurements, LDL-receptor gene expression was examined in this thesis. 
Despite down regulation of gene expression of LDL-R in this thesis, no 
differences in total and LDL-cholesterol in HD and PD groups compared with 
normal, were seen. One possible explanation for this could be that LDL could be 
cleared by other mechanisms including through the scavenger receptor on 
macrophages, a potentially atherogenic process.
It could therefore be argued that the ‘dysfunctional’ adipocytes in uraemic states 
could contribute to defective energy metabolism through impairment of 
triglyceride metabolism and also contribute to atherogenesis through defective 
cholesterol uptake. Other investigators have also observed that uraemia by down 
regulating VLDL receptor in adipose tissues can limit the long-term storage of
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energy and can contribute, in part, to wasting and weight loss in ESRD (Vaziri, 
2006).
Effect of dialysis
The cardiovascular risk remains very high in ESRD despite haemodialysis and 
peritoneal dialysis. Hyperlipidaemia is a well established risk factor of 
cardiovascular disease and it is therefore of interest to determine if HD affects 
circulating lipids.
The result in this thesis showed that haemodialysis may have effects on plasma 
lipids. This effect of haemodialysis includes increase in plasma total cholesterol 
and HDL-cholesterol. However, small increases in TG and LDL-cholesterol levels 
were also seen but were not statistically significant. Similar findings has been 
observed and attributed to the consequence of acetate used instead of bicarbonate 
as a dialysate buffer (Ya^in et al., 1999). Although mild to moderate increases in 
apolipoproteins (not measured in this thesis) have been reported following the 
institution of haemodialysis (Mesquita et al., 2010) , lipoprotein fractions did not 
show differences in this study between HD and PD. This is contrast to other data 
which suggested that treatment with either HD or PD may modulate plasma 
lipoprotein values (Attman et al., 2003). Overall, the effect of haemodialysis on 
lipid/lipoprotein abnormalities in ESRD does not appear to be major.
Dialysis is an important component of managing ESRD. Traditionally this has 
employed peritoneal or haemodialysis. Haemodialysis is used more widely and is 
excellent at clearing molecules less than 500 daltons. It has long been recognised 
that molecules between 500 to 5000 daltons, called middle molecules, are 
pathophysiologically important in uraemic syndrome. Conventional haemodialysis
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is poor at clearing the ‘middle molecules’. A new innovation, haemodiafiltration, 
is more effective at clearing the middle molecules (Vanholder et ah, 2008a). Since 
the cardiovascular mortality is very high in patients on haemodialysis, there is 
interest in determining whether post-dialysis metabolic mileau is less or more 
atherogenic.
Although many studies have reported that peritoneal dialysis is associated more 
with dyshpidaemia rather than haemodialysis (Attman et al., 2003), data obtained 
in this study was unable to detect any significant difference in lipid profile 
compared to healthy control. PD caused mild increases in plasma total cholesterol, 
LDL-cholesterol and VLDL-cholesterol in this thesis. Plasma HDL-cholesterol 
levels were significantly higher in PD patients compared to Pre-HD patients and 
surprisingly PD patients had normal levels of plasma TG. It is unlikely that this 
difference between HD and PD can be attributed to the nutritional status as there 
was no difference in BMI. However, the non-change in lipid profile could be 
explained by the low number of recruited subjects in this group and also that all 
patients were unavoidably under lipid lowering medication, such as statin.
When we started these studies, we were not aware of any other data that could 
have guided us. Because the studies in this thesis required detailed metabolic 
characterization, we believed that the numbers recruited would be sufficient in this 
pilot project. In retroscpect, we agree that studying a greater number of patients 
would have yielded better results. However, this was beyond the scope of the 
studies and will clearly need to be done future follow-up studies. Despite this, 
athough the numbers were small in these studies, the dialysis subjects showed an 
effect on the adipose tissue function in this pilot study. The preliminary results
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indicate that ESRD had altered lipid metabolism by downregulate lipolytic 
enzymes as well as by altering the lipid phenotype into an atherogenic lipid 
profile. Moreover, it is evident that changes in adipokines and enzymes studied 
were reliable and significant in some cases. Results in this study have shed some 
light on ESRD and its relationship with adipose tissue, where previously such 
knowledge was limited. Clearly, it will be necessary to conduct further studies to 
confirm the results of this thesis and extend these further involving a greater 
number of subjects.
The results in this thesis found no changes in the measurements made in before 
and after HD, suggesting that HD did not modify the ‘risk’ factors measured in 
this thesis. One interpretation of this would be that this would support the high 
CVD mortality despite HD. This does not exclude the possibility that other solutes 
not measured in this thesis could be playing a significant part in the CVD risk of 
ESRD. ESRD has been prioritised for early detection to allow early intervention 
(Winkelmayer et ah, 2001). This is because ESRD is associated with marked 
increase in cardiovascular morbidity and mortality (Schoenhagen and Tuzcu, 
2002). Staging of CKD, done by an estimation of GFR employing validated 
equations using plasma creatinine, is now routinely performed. Five stages (1 to 5) 
of CKD have been described using this approach with CKD 5 being end-stage 
renal failure. It has also become clear than less than 10% of people with CKD 
enter the end stage (ESRD), the majority dying from CVD earlier in the natural 
history of CKD (Wizemann, 1998). Traditional risk factors for CVD do not 
explain this increase in morbidity and mortality in ESRD. There is an urgent need 
to understand the reasons for this increased risk.
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ESRD patients may be malnourished or obese and the issue of nutrition in 
prognosis of ESRD is still under debate (Kaysen, 2006b, Stenvinkel et ah, 2002a). 
Increased visceral obesity is also a feature of ESRD. Metabolic syndrome 
characterised by increased visceral adipose tissue is now known to be causally 
related to CVD. The studies in this thesis except for those in Chapter 6 were 
mainly on subcutaneous adipose tissue largely due to practical difficulties in 
carrying out such studies on visceral fat. Alternative approaches are necessary to 
understand the contribution of the visceral adipose tissue in ESRD to CVD.
Lipoproteins in ESRD
Lipoproteins are central to the pathogenesis of atherosclerosis and CVD and these 
include LDL, HDL, VLDL and chylomicrons. Lipoprotein metabolism is altered 
in ESRD and its full characterisation may be important to clarify CVD in ESRD. 
Adipose tissue alters plasma lipoproteins both in health, obesity and anorexia 
(Zhou et ah, 2006). There is evidence that lipoproteins interact with the adipose 
tissue not just in order to engage in the nutrient functions but also in terms of 
adipokine secretion (Huang et al., 2009, Zhou et ah, 2006). Adipocytes 
phagocytose lipoproteins and are involved in their clearance. Lipoproteins are 
exposed to a uraemic environment in ESRD and thus may be qualitatively and 
quantitatively altered. Little is known about the interaction between the 
lipoproteins and adipose tissue in ESRD.
The present study demonstrates that ESRD patients had altered the lipoprotein 
profile. Major lipoprotein fractions VLDL, LDL and HDL were separated 
successfully by apply iodixanol gradient ultracentrifugation. The aim from
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fractionation was first to explore and characterize any lipoprotein abnormalities in 
ESRD in terms of haemodialysis and peritoneal dialysis and second, to incubate 
these fractions with human adipocyte culture in order to examine their potential 
effect on lipid metabolism-related factor expression, achieved in chapter 4. 
lodixanol gradient ultracentrifugation is a convenient, rapid and reliable method 
for lipoprotein fraction separation (Graham et ah, 1996). Cholesterol distribution 
of lipoprotein fractions showed a clear abnormal profile with VLDL enrichment, 
shift in peak LDL towards IDL and presence of small dense LDL. Although 
plasma levels of HDL-cholesterol were low in ESRD patients, HDL-cholesterol 
distribution failed to confirm this possibly because of a contamination with 
plasma protein especially albumin and this one disadvantage of using the gradient 
ultracentrifugation technique (Yee et ah, 2008). Despite this a change in structure 
of HDL with smaller particles predominating and also showing increased 
proportion of cholesterol compared with normal controls was seen.
VLDL-cholesterol, LDL-cholesterol and IDL-cholesterol have been reported as 
independent risk factors for atherosclerosis in ESRD patients (Shoji et ah, 2001). 
Several mechanisms have been proposed to explain lipoprotein abnormalities in 
ESRD, mentioned in chapters 3 and 4. The main lipoprotein abnormality that was 
identified was a decrease in plasma clearance of triglyceride-rich lipoproteins and 
decrease in plasma levels of HDL. Although earlier studies had suggested that 
dyslipidaemia was involved in the renal disease progression, mechanisms 
responsible for this are still unclear (Crook et ah, 2003). In addition, LDL and 
apo-B have been demonstrated to be associated with significant renal dysfunction 
(Samuelsson et ah, 1997). The mechanism of remodeling of lipoproteins when
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circulating triglycerides are increased results in the atherogenic lipoprotein 
phenotype that has been well researched and understood (Kaysen, 2011). This 
remodelling results in smaller denser LDL and smaller HDL, findings also 
observed in this thesis. It is believed that cholesterol ester transfer protein (CETP) 
mediates this remodelling when it becomes activated by increasing circulating 
triglycerides concentrations; CETP promotes transfer of triglycerides from 
triglyceride-rich particles (VLDL, chylomicrons and their remnants) to LDL and 
HDL receiving cholesterol in turn (Barter et ah, 2003) . CETP was not however 
measured in this thesis but the changes in circulating lipid profiles in consistent 
with this mechanism.
Accumulation of VLDL and remnant lipoproteins, due to decreased lipolysis, is 
considered as one of the main causes of hypertriglyceridaemia in addition to 
increase production in ESRD (Tsimihodimos et ah, 2011). It is well-known that 
dyslipidaemia is a risk factor for CVD in the general population (Lewington et ah, 
2007). In the ESRD population, controversy exists as to whether dyslipidaemia is 
a risk factor or not. It has been shown that dyslipidaemia is associated with CVD 
(Koch et ah, 1997) while others failed to show this association (Shlipak et ah, 
2005).
Expression of lipid metabolism related proteins
The gene expression of lipid metabolism related proteins such as LPL, HSL, LDL- 
R, and C3 were investigated using human adipocytes culture. The current study 
indicates that their gene expression is altered when treated with uraemic 
lipoproteins (Table 7.1). This suggests a possible atherogenic role for uraemic 
lipoproteins. Lipoproteins structure, function, and metabolism seems to be altered
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in renal disease (Mesquita et al., 2010). Therefore, dyslipidaemia in ESRD can be 
explained as a combination of both overproduction and low catabolism of 
lipoproteins, especially triglyceride-rich lipoproteins.
Adipokines and ESRD
There is currently limited information regarding the effect of uraemia on adipose 
tissue biology. Change in the adipose tissue composition, adipocytes number and 
the hormonal signalling either at the cellular level or at the organ level can all 
influence the secretory function of adipose tissue. The present results with 4 h 
treatment (acute effect) with uraemic serum from both types of dialysis, HD and 
PD, showed an inhibitory effect in adiponectin, leptin and IL-6 mRNA levels. 
This indicates that uraemic serum may alter the adipose tissue secretory function. 
Table 7.2 summarizes the results in chapter 5.
Changes in adiponectin
Although serum levels of adiponectin were high, its gene expression both in viti'o 
in the present thesis, and in vivo by other groups, was found to be down-regulated 
in ESRD. A recent published study indicates that higher levels of adiponectin in 
ESRD may be explained in part by decreased clearance (Komura et al., 2010). The 
assumption is that the uraemic solutes in added sera altered in vitro adipocyte 
metabolism leading to a down-regulation of genes such as adiponectin. It is not 
clear which particular solute(s) may be responsible as such studies are beyond the 
scope of this thesis and should form the basis for further investigation. A feedback 
mechanism is a possible explanation whether adipokines themselves that are
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increased due to lack of renal elimination in ESRD influence adipose tissue 
secretion.
The significance of the increased circulating total and high-molecular weight 
adiponectin in ESRD is not clear. Low plasma levels of adiponectin have been 
proposed as a new non-traditional risk factor for CVD in ESRD patients. 
However, whether those ESRD patients with high levels of adiponectin are 
protected from CVD is still not known. Many studies have supported low plasma 
levels of adiponectin as a risk factor for CVD in ESRD (Ignacy et ah, 2005, 
Zoccali et ah, 2002) while the opposite has been shown by other studies (Menon 
et ah, 2006).
Changes in leptin
The present study showed that ESRD patients also have higher levels of 
circulating leptin with no change observed in the mRNA adipocyte levels. Leptin, 
in addition to its role in food intake and appetite regulation, has been proposed as 
proinflammatory adipokine (Iglesias and Diez, 2010) and found to be associated 
with inflammation (Nordfors et ah, 1998). Although leptin is involved in appetite 
regulation, most studies failed to show any association between leptin and 
anorexia in ESRD (Heimburger and Stenvinkel, 2005). The high leptin observed 
in the present thesis is consistent with a pro-inflammatory consequence. Leptin is 
also considered to be a marker for fat mass. The relationship between the BMI and 
leptin in the present thesis is similar to the expected relationship in non-renal 
failure subjects and is consistent with a previous report in ESRD (Nishikawa et 
ah, 1999). A recent study also demonstrated that higher plasma levels of leptin 
were associated with atherogenic lipid profile in ESRD patients (Kastarinen et ah,
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2009b) .These data suggest that leptin could play a role in explaining at least in 
part the risk of CVD in ESRD.
Changes in IL-6 and MCP-1
In recent years it has become clear that cardiovascular disease due to 
atherosclerosis is a disease characterised by chronic low grade inflammation and 
there is a wealth of data supporting this key feature of atherosclerosis (Packard 
and Libby, 2008). Proinflammatory markers have also been found to be increased 
in ESRD. In the current study, described in greater detail in Chapter 5, IL-6 and 
MCP-1 gene expression were investigated in vitro. Interestingly, uraemic serum 
resulted in downregulation for IL-6 and no change in MCP-1 in normal adipocytes 
in vitro.
Although ESRD is associated with higher levels of IL-6, the current data showed 
no significant increase but a tendency towards high levels. The reason for the lack 
of increase in circulating IL-6 is debatable. On the other hand, it has been reported 
that normal or low levels of IL-6 could be present in ESRD patients, similar to 
what was seen in this thesis, and attributed to the genetic variation (Stenvinkel et 
ah, 2002b). IL-6 plasma levels are considered as a mortality marker in ESRD, 
suggesting that the present cohort as a group were probably at lower risk (Kimmel 
et ah, 1998). Patients in this study showed a significant higher level of 
adiponectin. IL-6 plasma levels were found to be inversely associated with 
adiponectin (Engeli et ah, 2003) and this may be another explanation for low IL-6 
mRNA levels. IL-6 is not produced exclusively by adipose tissue, about thirty 
percent of its plasma levels are produced by other cells and most of IL-6 that is 
produced by adipose tissue comes from stromal vascular fraction (Mohamed-Ali
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et al., 1998). The studies in thesis only investigated adipocytes rather than the 
complete adipose organ.
Adipokine interaction in ESRD
Taken together these findings in this thesis supports the idea that adipose tissue in 
vitro respond differently when treated with uraemic serum. The higher levels of 
circulating adipokines can be both due a response to uraemia and the result of 
decrease renal clearance, the relative contributions being difficult to isolate. It is 
not known what the effect of the altered adipose tissue in terms of adipokines 
secretion means in terms of outcome in ESRD. The high leptin was not 
accompanied by high IL-6 suggesting that evidence for inflammation in terms of 
studied adipokines was less than expected; this was also balanced by markedly 
increased adiponectin expected to be anti-inflammatory. However, further work 
including investigation of an extended selection of adipokine expression is needed 
to fully characterise the ‘uraemic’ effect and should be considered for future 
studies.
Macrophage infiltration in adipose tissue
It is now widely accepted that adipocytes are not the main source of inflammatory 
markers secreted by adipose tissue. Other components including macrophages 
appear to be the cause of chronic inflammation in obesity (Weisberg et al., 2003). 
The present study, limited in numbers, demonstrates a tendency towards high 
macrophage infiltration in ESRD adipose tissue. Follow up work, enrolling more 
patients, would need to investigate the expression of macrophage markers at the 
gene and protein levels.
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Future work
Time and resource constraints prevented a fuller investigation of ESRD and 
adipose tissue in this thesis. If these were not issues I would have considered these 
additional studies to inform on the relationship between adipose tissue and renal 
failure.
1. As clear differences in gene expression of adipokine have been shown in this 
thesis, however, further work including investigation of an extended selection of 
adipokine expression is needed to fully characterise the ‘uraemic5 effect and 
should be considered for future studies.
2. More detailed study design detailing the changes over time rather than 4 and 24 
hours changes assessed in this thesis needs to be performed.
3. Protein expression both by western blots and free protein in the supernatant 
where appropriate should be carried out in future studies.
4. Further studies in ESRD, both by broadening the number of adipocyte genes 
(and proteins) and undertaking a mechanistic approach to clarifying the reasons 
for the changes observed would be necessary and informative.
5. The assumption is that the uraemic solutes in added sera altered in vitro 
adipocyte metabolism leading to a down-regulation of genes such as adiponectin. 
It is not clear which particular solute(s) may be responsible as such studies are 
beyond the scope of this thesis and should form the basis for further investigation.
6. The patients used for investigating adipocyte effects in vitro in this thesis were 
on multiple drug therapy. In order to exclude drug effects, an animal model of 
chronic renal failure could be developed and studied. Alternatively newly
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diagnosed acute or chronic renal failure samples obtained before treatment is 
begun could be collected but will be challenging and there may be problems with 
obtaining sufficient numbers.
7. Samples for ESRD patients on haemodiafiltration would provide additional 
information about the effects of this form of renal replacement therapy on adipose 
tissue.
8. Samples from a range of renal impairment (CKD stages 1 to 5) could also be 
studied to further clarify ESRD effects.
9. Although this in vitro study demonstrated that uraemia altered adipose tissue 
but more extensive in vivo research is needed to confirm and extend these results.
Conclusion
In conclusion, an in vitro system to study the effect of uraemic lipoproteins and 
serum on adipose tissue nutrient and endocrine function through adipocyte gene 
expression was conducted and compared where available with the corresponding 
circulating protein measurements. More limited investigation of adipose tissue 
biopsies was also carried out. The results from the modulation of this in vitro 
adipocyte assay system not only serves as a convenient and unique model to study 
mechanisms of disease such as ESRD and its treatments but has so far also 
provided an initial insight that strongly suggests several mechanisms that could 
contribute to the CVD risk associated with ESRD. Further studies in ESRD, both 
by broadening the number of adipocyte genes (and proteins) and undertaking a 
mechanistic approach to clarifying the reasons for the changes observed would be 
necessary and informative.
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Appendix 1
Part of the work in this thesis has been presented in the following posters:
1. Sultan Alouffi, Lakshminarayan Ranganath, Paul Trayhurn, Matthew 
Howse, Gordon Lowe, Ian Davis, I. Stuart Wood (2011). Lipoprotein 
subfraction profile of patients with End Stage Renal Disease. 4th Meeting 
Uremic Toxins and Cardiovascular Disease, Groningen, the Netherlands.
2. Sultan Alouffi, Lakshminarayan Ranganath, Matthew Howse, and I. Stuart 
Wood .(2011) Reduced gene expression of adiponectin in human primary 
adipocytes culture treated with uraemic serum. 4th Meeting Uremic Toxins 
and Cardiovascular Disease, Groningen, the Netherlands.
3. Sultan Alouffi, Lakshminarayan Ranganath, Paul Trayhurn, Matthew 
Howse, Gordon Lowe, Ian Davis, I. Stuart Wood' (2011). Lipoprotein 
subfraction profile of patients with End Stage Renal Disease. 5th Saudi 
International Conference, the University of Warwick, United Kingdom.
4. Sultan Alouffi, Lakshminarayan Ranganath, Matthew Howse, and I. Stuart 
Wood. (2011) Reduced gene expression of adiponectin in human primary 
adipocytes culture treated with uraemic serum. 5th Saudi International 
Conference, the University of Warwick, United Kingdom.
Abstract 1
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Lipoprotein subfraction profile of patients with End Stage Renal
Disease
Sultan Alouffi1,2, Lakshminarayan Ranganath1, Paul Trayhurn2, Matthew Howse3, 
Gordon Lowe4, Ian Davies5 ,1. Stuart Wood2
‘Department of Clinical Chemistry, and 2Obesity Biology Research Unit, Institute of Ageing and 
Chronic Disease, University of Liverpool, UK
3Nephrology Department, Royal Liverpool University Hospital, Liverpool, UK,
4 Department of Biochemistry, Liverpool John Moores University, Liverpool, UK
5 Centre for Tourism, Events and Food, Liverpool John Moores University, Liverpool, UK
OBJECTIVE: Patients with end-stage renal disease (ESRD) have an extremely 
high morbidity and mortality from cardiovascular disease (CVD). Dyslipidaemia 
is one of the best-known risk factors of CVD in ESRD although no reliable pattern 
of dyslipidaemia can be attributed to this disease. We have investigated 
differences in cholesterol distribution in lipoprotein fractions in ESRD patients, 
and with two types of dialysis treatment to describe changes in terms of their 
potential contribution to CVD risk.
METHODS: lodixanol density gradients were employed to separate lipoproteins 
into VLDL, LDL, and HDL; lipid distribution was measured. Patients (n = 18) 
with ESRD (undergoing haemodialysis (n=l 1) or peritoneal dialysis (n=7)), and 9 
healthy controls were recruited. Biochemical parameters and lipid plasma profile 
(cholesterol, LDL cholesterol and triglycerides) were assessed in all subjects.
RESULTS: Patients undergoing haemodialysis had significantly higher serum 
levels of triglycerides, and low HDL-cholesterol compared with the control group. 
Cholesterol distribution of lipoprotein fractions showed that haemodialysis 
patients had significant increased VLDL-cholesterol (p=0.0075) and presence of 
small, dense LDL-cholesterol than control participants. Peritoneal dialysis 
patients had significant increased VLDL-cholesterol (p=0.042), presence of small 
dense LDL-cholesterol and a shift in cholesterol to IDL.
CONCLUSIONS: ESRD is associated with dyslipidaemia, which is dependent on 
the type of renal replacement therapy. Peritoneal dialysis was associated with a 
more atherogenic lipoprotein cholesterol distribution. This lipoprotein cholesterol 
distribution may contribute to increased CVD in ESRD patients on renal 
replacement therapy.
References:
Graham, J.M., Higgins, J.A., Gillott, T., Taylor, T., Wilkinson, J., Ford, T. & 
Billington, D. (1996) 'A novel method for the rapid separation of plasma 
lipoproteins using self-generating gradients of iodixanol', Atherosclerosis, 
vol. 124, no. l,pp. 125-135.
Abstract 2
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Reduced gene expression of adiponectin in human primary 
adipocytes culture treated with uraemic serum
Sultan Alouffi1-3. Lakshminarayan Ranganath1, Matthew Howse2,
Paul Tray burn3,1. Stuart Wood3
’Department of Clinical Chemistry, Institute of Ageing and Chronic disease, University of 
Liverpool, Liverpool L69 3GA, UK
2Nephrology Department, Royal Liverpool University Hospital, Liverpool, UK
3Obesity Biology Research Unit, Institute of Ageing and Chronic disease, University of Liverpool, 
Liverpool L69 3GA, UK
OBJECTIVE: End stage renal disease (ESRD) is accompanied by increased 
cardiovascular disease (CVD) morbidity and mortality. Despite renal replacement 
therapy being employed ESRD is associated with increased complications 
including inflammation and dyslipidaemia. Adiponectin, a major adipokine, is 
known to demonstrate anti-inflammatory properties. We have investigated 
whether uraemic serum influences adiponectin expression in a human primary 
adipocyte culture system.
METHODS: A cohort of 18 patients with ESRD (haemodialysis and peritoneal 
dialysis) and 9 healthy (control) were analysed in a prospective cross-sectional 
study. Single blood samples were taken pre- and post-dialysis. Human adipocytes 
were incubated for 4 and 24 hours in culture medium containing serum from 
either healthy (control) or patients with ESRD (low and high dose). Serum 
concentrations of total adiponectin and high molecular weight adiponectin were 
measured by ELISA. Other biochemical parameters (cholesterol, LDL cholesterol, 
and triglycerides) were also assessed at the same time. Gene expression of 
adiponectin was quantified using the real-time polymerase chain reaction.
RESULTS: Serum concentrations of total adiponectin and high molecular weight 
adiponectin were significantly higher in the ESRD versus control group 
(p=0.017). Gene expression of adiponectin was lower in ESRD patients compared 
with healthy control at low dose but not with high dose serum treatment.
CONCLUSIONS: These results provide an initial insight in understanding the 
putative role of adipose tissue contributing to the associated of CVD risk in CKD 
patients. Our data suggests that normal adipocyte function is altered when exposed 
to an uraemic environment in vitro.
212
Ap
pe
nd
ix
 2 C
lin
ic
al
 C
ha
ra
ct
er
is
tic
s o
f s
tu
di
ed
 pa
tie
nt
s
E3
l-S , o I w
_o
o
I -a
'y.oa
s <
cQ-c
CQ
p, , >'X
aQ.O
<DO
CQ
hr
s
pa
oL>-o
oo u
rrt ft
CQ
CoJS
_o 
o
E3
oa
CQ
E_3
•55
00 03
c
N
Us
-5 1 
E
2 >
oo ^
5 o-
-a rvO «oo .E « -o
cCQ
< .E
a.M
4 « O
w 5 n.2 CQ o
5 .E .ss
DC U 03
CQ
V-a
1
C0
ha*
IDQ.O
^ -3E io E
2
- o
“ -5
S 1
.3 'T’ •- £ ^ C
ux.
2 i—3 C/5cd O-D •5 X— OJD CLc~
U 0> CLo o#cd u u-cd _o cd oE <4-5 O o E < u JZUO bX) < < < s < J 5
Cl>>
jo
U
E_3
■5ooo
<13 2— C- <D
« .2 oC3 r'
- u o
8 
o 
on
o. ^
Cl
O -E 
E 13
CQ
rt .=
CQ Eo
Cl p
CQ *-■L- CQ
C
C
2 -OOC
■a o
« s—
C8o _
to
<
E O O
2 .« <
.H E 
o 2 
Pu
33
Ewc/i
3
£
u c
.1
■< £
ro
CN
13 u° orr\ s-<> 00
12 »-«t
S uS B
S o3 rt*
< O <
21
4
< ° 
^ rr\
2 U
2 H PQ
t; e
21
5
Q o
< <ft! H a, oo
REFERENCES
217
2002. Part 4. Definition and classification of stages of chronic kidney disease. 
American journal of kidney diseases : the official journal of the National 
Kidney Foundation, 39, S46-S75.
ADAMCZAK, M., CHUDEK, J. & WIECEK, A. 2009. Adiponectin in patients 
with chronic kidney disease. Semin Dial, 22, 391-5.
AHIMA, R. S. 2006. Adipose tissue as an endocrine organ. Obesity (Silver 
Spring), 14 Suppl 5, 242S-249S.
AHIMA, R. S. & OSEI, S. Y. 2008. Adipokines in obesity. Front Horm Res, 36, 
182-97.
ALSAYED, N. & REBOURCET, R. 1991. Abnormal concentrations of CII, CIII, 
and E apolipoproteins among apolipoprotein B-containing, B-free, and A- 
I-containing lipoprotein particles in hemodialysis patients. Clin Chem, 37, 
387-393.
ANAVEKAR, N. S. & PFEFFER, M. A. 2004. Cardiovascular risk in chronic 
kidney disease. Kidney Int, 66, S11-S15.
ANSELL, B. J., WATSON, K. E., FOGELMAN, A. M., NAVAB, M. & 
FONAROW, G. C. 2005. High-density lipoprotein function recent 
advances. J Am Coll Cardiol, 46, 1792-8.
ARES, M. P. & STOLLENWERK, M. M. 2006. Inflammatory effects of very 
low-density lipoprotein and fatty acids. Future Cardiol, 2, 315-23.
ARNADOTTIR, M. 1997. Pathogenesis of dyslipoproteinemia in renal 
insufficiency: the role of lipoprotein lipase and hepatic lipase. ScandJ Clin 
Lab Invest, 57, 1-11.
ARNADOTTIR, M., DALLONGEVILLE, J., FRUCHART, J.-C. & NILSSON-
218
EHLE, P. 1996. Very-low-density lipoprotein of uremic patients is a poor 
substrate for bovine lipoprotein lipase in vitro. Metabolism, 45, 686-690.
ARNER, P. 2003. The adipocyte in insulin resistance: key molecules and the 
impact of the thiazolidinediones. Trends Endocrinol Metab, 14, 137-45.
ATTMAN, P.-O., SAMUELSSON, O., JOHANSSON, A.-C., MOBERLY, J. B. 
& ALAUPOVIC, P. 2003, Dialysis modalities and dyslipidemia. Kidney 
Int, 63, S110-S112.
ATTMAN, P.-O. A., SAMUELSSON, O. G., MOBERLY, J., JOHANSSON, A.- 
C., LJUNGMAN, S., WEISS, L. G., KNIGHT-GIB SON, C. & 
ALAUPOVIC, P. 1999. Apolipoprotein B-containing lipoproteins in renal 
failure: The relation to mode of dialysis. Kidney Int, 55, 1536-1542.
ATTMAN, P. O. & SAMUELSSON, O. 2009. Dyslipidemia of kidney disease. 
Cnrr Opin Lipidol, 20, 293-9.
AXELSSON, J. 2008. Obesity in chronic kidney disease: good or bad? Blood 
Purif 26, 23-9.
AXELSSON, J., HEIMBURGER, O. & STENVINKEL, P. 2006a. Adipose tissue 
and inflammation in chronic kidney disease. Confrib Nephrol, 151, 165- 
74.
AXELSSON, J., M0LLER, H. J., WITASP, A., QURESHI, A. R., CARRERO, J. 
J., HEIMBURGER, O., BARANY, P., ALVESTRAND, A., LINDHOLM, 
B., MOESTRUP, S. K. & STENVINKEL, P. 2006b. Changes in Fat Mass 
Correlate With Changes in Soluble sCD163, a Marker of Mature 
Macrophages, in Patients With CKD. American Journal of Kidney 
Diseases, 48, 916-925.
AXELSSON, J., RASHID QURESHI, A., SULIMAN, M. E., HONDA, H.,
219
PECOITS-FILHO, R., HEIMBURGER, O., LINDHOLM, B, 
CEDERHOLM, T. & STENVINKEL, P. 2004. Truncal fat mass as a 
contributor to inflammation in end-stage renal disease. The American 
Journal of Clinical Nutrition, 80, 1222-1229.
BADMAN, M. K. & FLIER, J. S. 2007. The adipocyte as an active participant in 
energy balance and metabolism. Gastroenterology, 132, 2103-15.
BAIGENT, C., LANDRAY, M. J., REITH, C„ EMBERSON, J., WHEELER, D. 
C., TOMSON, C., WANNER, C., KRANE, V., CASS, A., CRAIG, J., 
NEAL, B., JIANG, L., HOOI, L. S., LEVIN, A., AGODOA, L„ 
GAZIANO, M., KASISKE, B., WALKER, R, MASSY, Z. A., FELDT- 
RASMUSSEN, B, KRAIRITTICHAI, U., OPHASCHAROENSUK, V., 
FELLSTROM, B., HOLDAAS, H., TESAR, V., WIECEK, A., 
GROBBEE, D., DE ZEEUW, D., GRONHAGEN-RISKA, C., 
DASGUPTA, T., LEWIS, D., HERRINGTON, W., MAFHAM, M., 
MAJONI, W., WALLENDSZUS, K., GRIMM, R., PEDERSEN, T„ 
TOBERT, J., ARMITAGE, J., BAXTER, A., BRAY, C., CHEN, Y., 
CHEN, Z., HILL, M., KNOTT, C, PARISH, S., SIMPSON, D., 
SLEIGHT, P., YOUNG, A. & COLLINS, R. 2011. The effects of lowering 
LDL cholesterol with simvastatin plus ezetimibe in patients with chronic 
kidney disease (Study of Heart and Renal Protection): a randomised 
placebo-controlled trial. The Lancet, 377,2181-2192.
BAKKALOGLU, S. A., BUYAN, N., FUNAHASHI, T., PASAOGLU, H., 
ELHAN, A. H., HASANOGLU, E. & SOYLEMEZOGLU, O. 2005. 
Adiponectin levels and atherosclerotic risk factors in pediatric chronic 
peritoneal dialysis patients. Per it Dial Int, 25, 357-361.
BARAZZONI, R., BERNARDI, A., BIASIA, F., SEMOLIC, A„ BOSUTTI, A., 
MUCCI, M., DORE, F., ZANETTI, M. & GUARNIERI, G. 2007. Low fat 
adiponectin expression is associated with oxidative stress in nondiabetic 
humans with chronic kidney disease—impact on plasma adiponectin
220
concentration. Am J Physiol Regid Integr Comp Physiol, 293, R47-54.
BARAZZONI, R„ ZANETTI, M„ SEMOLIC, A., PIRULLI, A., CATTIN, M. R., 
BIOLO, G., BOSUTTI, A., PANZETTA, G„ BERNARDI, A. & 
GUARNIERI, G. 2011, High Plasma Rbp4 Is Associated with Systemic 
Inflammation Independently of Low Rbp4 Adipose Expression and Is 
Normalized by Transplantation in Non-Obese, Non-Diabetic Patients with 
Chronic Kidney Disease. Clin Endocrinol (Oxf), no-no.
BARTER, P. J, BREWER, H. B., CHAPMAN, M. J., HENNEKENS, C. H., 
RADER, D. J. & TALL, A. R. 2003. Cholesteryl Ester Transfer Protein. 
Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 160-167.
BASTARD, J. P., LAGATHU, C., CARON, M. & CAPEAU, J. 2007. Point- 
counterpoint: Interleukin-6 does/does not have a beneficial role in insulin 
sensitivity and glucose homeostasis. J Appl Physiol, 102, 821-2; author 
reply 825.
BAUCHE, I. B., AIT EL MKADEM, S., REZSOHAZY, R., FUNAHASHI, T., 
MAEDA, N., MIRANDA, L. M. & BRICHARD, S. M. 2006. Adiponectin 
downregulates its own production and the expression of its AdipoR2 
receptor in transgenic mice. Biochem Biophys Res Commun, 345, 1414-24.
BAYS, H. E., GONZALEZ-CAMPOY, J. M., BRAY, G. A., KITABCHI, A. E., 
BERGMAN, D. A„ SCHORR, A. B„ RODBARD, H. W. & HENRY, R. 
R. 2008. Pathogenic potential of adipose tissue and metabolic 
consequences of adipocyte hypertrophy and increased visceral adiposity. 
Expert Rev Cardiovasc Ther, 6, 343-68.
BEBERASHVILI, I, SINUANI, I., AZAR, A., YASUR, H., FELDMAN, L, 
AVERBUKH, Z. & WEISSGARTEN, J. 2011. Longitudinal study of 
leptin levels in chronic hemodialysis patients. Nutrition Journal, 10, 68.
221
BEDDHU, S., KIMMEL, P, L., RAMKUMAR, N. & CHEUNG, A. K. 2005. 
Associations of Metabolic Syndrome With Inflammation in CKD: Results 
From the Third National Health and Nutrition Examination Survey 
(NHANES III). American Journal of Kidney Diseases, 46, 577-586.
BEDDHU, S. & KWAN, B. C.-H. 2007. Adiposity and Kidney Disease. Adipose 
Tissue and Adipokines in Health and Disease.
BEIGE, J., HEIPMANN, K., STUMVOLL, M., KORNER, A. & KRATZSCH, J. 
2009. Paradoxical role for adiponectin in chronic renal diseases? An 
example of reverse epidemiology. Expert Opin Ther Targets, 13, 163-73.
BEIGNEUX, A. P., DAVIES, B. S., GIN, P., WEINSTEIN, M. M., FARBER, E., 
QIAO, X., PEALE, F., BUNTING, S., WALZEM, R. L, WONG, J. S., 
BLANER, W. S., DING, Z. M„ MELFORD, K., WONGSIRIROJ, N, 
SHU, X., DE SAUVAGE, F., RYAN, R. O., FONG, L. G„ 
BENSADOUN, A. & YOUNG, S. G. 2007. Glycosylphosphatidylinositol- 
anchored high-density lipoprotein-binding protein 1 plays a critical role in 
the lipolytic processing of chylomicrons. Cell Metab, 5, 279-91.
BERG, A. H. & SCHERER, P. E. 2005. Adipose Tissue, Inflammation, and 
Cardiovascular Disease. Circ Res, 96, 939-949.
BILLON, N. & DANI, C. 2011. Developmental Origins of the Adipocyte 
Lineage: New Insights from Genetics and Genomics Studies. Stem Cell 
Review’s and Reports) 1-12.
BOULOUMIE, A., CURAT, C. A., SENGENES, C., LOLMEDE, K., 
MIRANVILLE, A. & BUSSE, R, 2005. Role of macrophage tissue 
infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care, 8, 
347-54.
BOURLIER, V. & BOULOUMIE, A. 2009. Role of macrophage tissue
222
infiltration in obesity and insulin resistance. Diabetes Metab, 35, 251-60.
BRASAEMLE, D. L. 2007. Thematic review series: Adipocyte Biology. The 
perilipin family of structural lipid droplet proteins; stabilization of lipid 
droplets and control of lipolysis. Journal of Lipid Research, 48, 2547- 
2559.
BRICHARD, S. M., DELPORTE, M, L. & LAMBERT, M. 2003. Adipocytokines 
in anorexia nervosa: a review focusing on leptin and adiponectin. Harm 
Metab Res, 35, 337-42.
BURRELL, D. E., ANTIGNANI, A, GOLDWASSER, P., MITTMAN, N., FEIN, 
P. A, SLATER, P. A, GAN, A. & AVRAM, M. M. 1991. Lipid 
abnormalities in black renal patients. NY State JMed, 91, 192-6.
CARRERO, J. J„ CORDEIRO, A. C., LINDHOLM, B. & STENVINKEL, P. 
2010. The emerging pleiotrophic role of adipokines in the uremic 
phenotype. Curr Opin Nephrol Hypertens, 19, 37-42.
CHAN, D. T., IRISH, A. B, DOGRA, G. K. & WATTS, G. F. 2008. 
Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic 
opportunities and clinical tndXs. Atherosclerosis, 196, 823-834.
CHARRIERE, G„ COUSIN, B, ARNAUD, E., ANDRE, M., BACOU, F, 
PENICAUD, L. & CASTEILLA, L. 2003. Preadipocyte Conversion to 
Macrophage. Journal of Biological Chemistry, 278, 9850-9855.
CHO, K. H. 2009. Biomedicinal implications of high-density lipoprotein: its 
composition, structure, functions, and clinical applications. BMB Rep, 42, 
393-400.
CHUDEK, J., ADAMCZAK, M„ KARKOSZKA, H., BUDZlA„SKI, G„ 
IGNACY, W., FUNAHASHI, T, MATSUZAWA, Y, CIERPKA, L.,
223
KOKOT, F. & WIE©CEK, A. 2003. Plasma adiponectin concentration 
before and after successful kidney transplantation. Transplantation 
proceedings, 35, 2186-2189.
CHUDEK, J.s ADAMCZAK, M, NIESZPOREK, T. & WIECEK, A. 2006. The 
adipose tissue as an endocrine organ—a nephrologists' perspective. Contrib 
Nephrol, 151,70-90.
CHUDEK, J. & WIECEK, A. 2006. Adipose tissue, inflammation and endothelial 
dysfunction. Pharmacol Rep, 58 Suppl, 81-8.
CIANFLONE, K., XIA, Z. & CHEN, L. Y. 2003. Critical review of acylation- 
stimulating protein physiology in humans and rodents. Biochimica et 
Biophysica Acta (BBA) - Biomembranes, 1609, 127-143.
CINTI, S. 2005. The adipose organ. Prostaglandins, Leukotrienes and Essential 
Fatty Acids, 73,9-15.
CINTI, S. 2007. The Adipose Organ. Adipose Tissue and Adipokines in Health 
and Disease.
COLLINS, A. J„ LI, S., GILBERTSON, D. T., LIU, J., CHEN, S.-C. & 
HERZOG, C. A. 2003. Chronic kidney disease and cardiovascular disease 
in the Medicare population. Kidney Int, 64, S24-S31.
COSTACOU, T. & ORCHARD, T. J. 2008. Adiponectin: good, bad, or just plain 
ugly? Kidney Int, 74, 549-51.
CROOK, E. D., THALLAPUREDDY, A., MIGDAL, S., FLACK, J. M., 
GREENE, E. L., SALAHUDEEN, A., TUCKER, J. K. & TAYLOR, H. 
A., JR. 2003. Lipid abnormalities and renal disease: is dyslipidemia a 
predictor of progression of renal disease? Am JMedSci, 325, 340-8.
224
CUMIN, F., BAUM, H. P. & LEVENS, N. 1996. Leptin is cleared from the 
circulation primarily by the kidney, bit J Obes Relat Metab Disord, 20, 
1120-6.
DAUTIN, G., SOLTANI, Z., DUCLOUX, D, GAUTIER, T., PAIS DE 
BARROS, J. P., GAMBERT, P, LAGROST, L. & MASSON, D. 2007. 
Hemodialysis reduces plasma apolipoprotein C-I concentration making 
VLDL a better substrate for lipoprotein lipase. Kidney Int, 72, 871-878.
DE LUCA, C. & OLEFSKY, J. M. 2008. Inflammation and insulin resistance. 
FEES Lett, 582, 97-105.
DEGAWA-YAMAUCHI, M., MOSS, K. A., BOVENKERK, J. E, SHANKAR, 
S. S., MORRISON, C. L., LELLIOTT, C. J., VIDAL-PUIG, A., JONES, 
R. 8c CONSIDINE, R. V. 2005. Regulation of adiponectin expression in 
human adipocytes: effects of adiposity, glucocorticoids, and tumor 
necrosis factor alpha. Obes Res, 13, 662-9.
DHONDT, A., VANHOLDER, R., VAN BIESEN, W. & LAMEIRE, N. 2000. 
The removal of uremic toxins. Kidney Int Suppl, 76, S47-59.
DINEL, A. L., KOLDITZ, C. & LANGIN, D. 2010. Metabolism of Fatty Acids in 
Adipocytes. In: CHRISTEN, Y., CLEMENT, K. & SPIEGELMAN, B. M. 
(eds.) Novel Insights into Adipose Cell Functions, Springer Berlin 
Heidelberg.
DUCHARME, N. A. & BICKEL, P. E. 2008. Minireview: Lipid Droplets in 
Lipogenesis and Lipolysis. Endocrinology, 149, 942-949.
EATON, D. C., POOLER, J. & VANDER, A. J. R, P. 2009. Vander's renal 
physiology, New York, McGraw-Hill Medical.
EIRAS, S., TEUEIRA-FERNANDEZ, E., SALGADO-SOMOZA, A., COUSO,
225
E., GARCIA-CABALLERO, T., SIERRA, J. & JUANATEY, J. R. 2010. 
Relationship between epicardial adipose tissue adipocyte size and MCP-1 
expression. Cytokine, 51, 207-12.
EJERBLAD, E., PORED, C. M„ LINDBLAD, P., FRYZEK, J„ MCLAUGHLIN, 
J. K. & NYREN, O. 2006. Obesity and risk for chronic renal failure. J Am 
Soc Nephrol, 17, 1695-702.
EMERGING RISK FACTORS, C., ERQOU, S., KAPTOGE, S., PERRY, P. L., 
DI AN GEL ANTONIO, E, THOMPSON, A., WHITE, I. R., 
MARCOVINA, S. M., COLLINS, R., THOMPSON, S. G. & DANESH, J. 
2009. Lipoprotein(a) concentration and the risk of coronary heart disease, 
stroke, and nonvascular mortality. JAMA, 302, 412-23.
ENGELI, S., FELDPAUSCH, M., GORZELNIAK, K., HARTWIG, F., 
HEINTZE, U, JANKE, J., MOHLIG, M., PFEIFFER, A. F. H., LUFT, F. 
C. & SHARMA, A. M. 2003. Association Between Adiponectin and 
Mediators of Inflammation in Obese Women. Diabetes, 52, 942-947.
EXPERT PANEL ON DETECTION, E. & TREATMENT OF HIGH BLOOD 
CHOLESTEROL IN, A. 2001. Executive Summary of the Third Report of 
the National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III). JAMA: The Journal of the American Medical 
Association, 285,2486-2497.
FARMER, S. R. 2010. Transcriptional Control of Gene Expression in Different 
Adipose Tissue Depots. In: CHRISTEN, Y., CLEMENT, K. & 
SPIEGELMAN, B. M. (eds.) Novel Insights into Adipose Cell Functions, 
Springer Berlin Heidelberg.
FELLSTROM, B. C, JARDINE, A. G, SCHMIEDER, R. E, HOLDAAS, H., 
BANNISTER, K, BEUTLER, J., CHAE, D. W., CHEVAILE, A.,
226
COBBE, S. M., GRONHAGEN-RISKA, C., DE LIMA, J. J., LINS, R., 
MAYER, G., MCMAHON, A. W., PARVING, H. H., REMUZZI, G., 
SAMUELSSON, O., SONKODI, S„ SCI, D„ SULEYMANLAR, G., 
TSAKIRIS, D., TESAR, V., TODOROV, V., WIECEK, A, WUTHRICH, 
R. P., GOTTLOW, M., JOHNSSON, E. & ZANNAD, F. 2009. 
Rosuvastatin and cardiovascular events in patients undergoing 
hemodialysis. iV Engl J Med, 360, 1395-407.
FERNSTROM, A., HYLANDER, B., MORITZ, A., JACOBSSON, H. & 
ROSSNER, S. 1998. Increase of intra-abdominal fat in patients treated 
with continuous ambulatory peritoneal dialysis. Perit Dial Int, 18, 166-71.
FISCHER-POSOVSZKY, P., NEWELL, F. S., WABITSCH, M. & 
TORNQVIST, H. E. 2008. Human SGBS cells - a unique tool for studies 
of human fat cell biology. Obes Facts, 1, 184-9.
FONTAN, M. P., RODRIGUEZ-CARMONA, A., CORDIDO, F. & GARCIA- 
BUELA, J. 1999. Hyperleptinemia in uremic patients undergoing 
conservative management, peritoneal dialysis, and hemodialysis: A 
comparative analysis. American Journal of Kidney Diseases, 34, 824-831.
FORD, T., GRAHAM, J. & RICKWOOD, D. 1994. lodixanol: A Nonionic Iso- 
osmotic Centrifugation Medium for the Formation of Self-Generated 
Gradients. Analytical Biochemistry, 220, 360-366.
FRESHNEY, R. I. 1994. Culture of animal cells : a manual of basic technique, 
New York ; Chichester, Wiley-Liss.
FRIEDMAN, A. N. 2006. UNRESOLVED ISSUES IN DIALYSIS: Adiposity in 
Dialysis: Good or Bad? Seminars in Dialysis, 19, 136-140.
FRUHBECK, G., GOMEZ-AMBROSI, J., MURUZABAL, F. J. & BURRELL, 
M. A. 2001. The adipocyte: a model for integration of endocrine and
227
metabolic signaling in energy metabolism regulation. American Journal of 
Physiology - Endocrinology And Metabolism, 280, E827-E847.
FURUKAWA, S., FUJITA, T., SHIMABUKURO, M., IWAKI, M., YAMADA, 
Y., NAKAJIMA, Y., NAKAYAMA, O., MAKISHIMA, ML, MATSUDA, 
M. & SHIMOMURA, I. 2004. Increased oxidative stress in obesity and its 
impact on metabolic syndrome. J Clin Invest, 114, 1752-61.
FUSTER, V. 2008. Hurst's the heart. New York, McGraw-Hill Medical.
GALIC, S., OAKHILL, J. S. & STEINBERG, G. R. 2010. Adipose tissue as an 
endocrine organ. Molecular and Cellular Endocrinology, 316, 129-139.
GENT, J. & BRAAKMAN, I. 2004. Low-density lipoprotein receptor structure 
and folding. Cellular and Molecidar Life Sciences, 61,2461-2470.
GIROUSSE, A. & LANGIN, D. 2011. Adipocyte lipases and lipid droplet- 
associated proteins: insight from transgenic mouse models. Int JObes,
GIULIETTI, A., OVERBERGH, L., VALCKX, D., DECALLONNE, B., 
BOUILLON, R. & MATHIEU, C. 2001. An Overview of Real-Time 
Quantitative PCR: Applications to Quantify Cytokine Gene Expression. 
Methods, 25,386-401.
GOLDBERG, A., SHERRARD, D. J. & BRUNZELL, J. D. 1978. Adipose Tissue 
Lipoprotein Lipase in Chronic Hemodialysis: Role in Plasma Triglyceride 
Metabolism. 7 C/w Endocrinol Metab, 47, 1173-1182.
GRAHAM, J., FORD, T. & RICKWOOD, D. 1994. The preparation of 
subcellular organelles from mouse liver in self-generated gradients of 
iodixanol. Anal Biochem, 220, 367-73.
GRAHAM, J. M., HIGGINS, J. A., GILLOTT, T, TAYLOR, T., WILKINSON,
228
J., FORD, T. & BILLINGTON, D. 1996. A novel method for the rapid 
separation of plasma lipoproteins using self-generating gradients of 
iodixanol. Atherosclerosis, 124, 125 -13 5.
GREENBERG, A. 8c CHEUNG, A. K. 2009. Primer on kidney diseases, 
Philadelphia, Pa. ; London, Saunders.
GREGOIRE, F. M., SMAS, C. M. & SUL, H. S. 1998. Understanding Adipocyte 
Differentiation. Physiological Reviews, 78, 783-809.
HABENICHT, A. J. R., JANftEN-TIMMEN, U., ZIEGLER, R. & SCHETTLER, 
G. 1994. Lipoproteins and their functions. Journal of Molecular Medicine, 
72, 639-652.
HAEMMERLE, G., LASS, A., ZIMMERMANN, R., GORKIEWICZ, G., 
MEYER, C, ROZMAN, J., HELDMAIER, G, MAIER, R., THEUSSL, 
C., EDER, S., KRATKY, D., WAGNER, E. F., KLINGENSPOR, M., 
HOEFLER, G. & ZECHNER, R. 2006. Defective lipolysis and altered 
energy metabolism in mice lacking adipose triglyceride lipase. Science, 
312, 734-7.
HALL, J. E, HENEGAR, J. R., DWYER, T. M., LIU, J., DA SILVA, A. A., 
KUO, J. J. & TALLAM, L. 2004. Is obesity a major cause of chronic 
kidney disease? Adv Ren Replace Ther, 11, 41-54,
HARA, K., HORIKOSHI, M, YAMAUCHI, T., YAGO, H., MIYAZAKI, O., 
EBINUMA, H., IMAI, Y., NAGAI, R. & KADOWAKI, T. 2006. 
Measurement of the high-molecular weight form of adiponectin in plasma 
is useful for the prediction of insulin resistance and metabolic syndrome. 
Diabetes Care, 29, 1357-62.
HAVEL, R. K., J. 2001. Introduction : structure and metabolism of plasma 
lipoproteins, New York, MaGraw-Hill.
229
HEIMBURGER, O. & STENVINKEL, P. 2005. Adipokines in chronic kidney 
disease-fat tissue gives nephrologists a message. Perit Dial Int, 25, 340-2.
HILL, J. 2007. Dialysis: A Complex Modality for Life. Biomedical 
Instrumentation & Technology, 41,287-288.
HIMMELFARB, J. & IKIZLER, T. A. 2010. Hemodialysis. New England Journal 
of Medicine, 363, 1833-1845.
HOLM, C., OSTERLUND, T., LAURELL, H. & CONTRERAS, J. A. 2000. 
Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. 
Annual Review of Nutrition, 20, 365-93.
HONDA, H., QURESHI, A. R., AXELSSON, J., HEIMBURGER, O., 
SULIMAN, M. E., BARANY, P., STENVINKEL, P. & LINDHOLM, B. 
2007. Obese sarcopenia in patients with end-stage renal disease is 
associated with inflammation and increased mortality. The American 
Journal of Clinical Nutrition, 86, 633-638.
HU, E., LIANG, P. & SPIEGELMAN, B, M. 1996. AdipoQ is a novel adipose- 
specific gene dysregulated in obesity. JBiol Chem, 271, 10697-703.
HUANG, J.-W, YEN, C.-L, CHIANG, H.-W., HUNG, K.-Y., TSAI, T.-J. & WU, 
K.-D. 2004. Adiponectin in peritoneal dialysis patients: a comparison with 
hemodialysis patients and subjects with normal renal function. American 
Journal of Kidney Diseases, 43, 1047-1055.
HUANG, Z., WANG, B., PACE, R. D. & YOON, S. 2009. Trans fat intake lowers 
total cholesterol and high-density lipoprotein cholesterol levels without 
changing insulin sensitivity index in Wistar rats. Nutr Res, 29, 206-12.
IFUDU, O. 1998. Care of Patients Undergoing Hemodialysis. N Engl J Med, 339, 
1054-1062.
230
IGLESIAS, P. & DIEZ, J. J. 2010. Adipose tissue in renal disease: clinical 
significance and prognostic implications. Nephrol Dial Transplant, 25, 
2066-77.
IGNACY, W., CHUDEK, J., ADAMCZAK, M., FUNAHASHI, T., 
MATSUZAWA, Y., KOKOT, F. & WIECEK, A. 2005. Reciprocal 
association of plasma adiponectin and serum C-reactive protein 
concentration in haemodialysis patients with end-stage kidney disease—a 
follow-up study. Nephron Clin Tract, 101, cl 8-24.
ISTVAN, E. S. & DEISENHOFER, J. 2001. Structural mechanism for statin 
inhibition of HMG-CoA reductase. Science, 292, 1160-4.
ITABE, H., OBAMA, T. & KATO, R. 2011. The Dynamics of Oxidized LDL 
during Atherogenesis. Journal of Lipids, 2011.
JACOBS, P., GLORIEUX, G. & VANHOLDER, R. 2004. Interleukin/cytokine 
profiles in haemodialysis and in continuous peritoneal dialysis. 
Nephrology Dialysis Transplantation, 19, v41-v45.
JAIN, K. S., KATHIRAVAN, M. K., SOMANI, R. S. & SHISHOO, C. J. 2007. 
The biology and chemistry of hyperlipidemia. Bioorg Med Chem, 15, 
4674-99.
JONES, G. E. 1996. Human cell culture protocols, Totowa, N.J., Humana Press.
KALAITZIDIS, R. & SIAMOPOULOS, K, 2011. The role of obesity in kidney 
disease: recent findings and potential mechanisms. International Urology 
and Nephrology, 1-14.
KALANTAR-ZADEH, K, KUWAE, N., WU, D. Y., SHANTOUF, R. S., 
FOUQUE, D., ANKER, S. D„ BLOCK, G. & KOPPLE, J. D. 2006. 
Associations of body fat and its changes over time with quality of life and
231
prospective mortality in hemodialysis patients. The American Journal of 
Clinical Nutrition, 83, 202-210.
KALBACHER, E., KOPPE, L., ZARROUKI, B., PILLON, N. J.5 FOUQUE, D. & 
SOULAGE, C. O. 2011. Human uremic plasma and not urea induces 
exuberant secretion of leptin in 3T3-L1 adipocytes. JRen Nutr, 21, 72-5.
KAMBHAM, N., MARKOWITZ, G. S., VALERI, A. M., LIN, J. & D'AGATI, 
V. D. 2001. Obesity-related glomerulopathy; An emerging epidemic. 
Kidney Int, 59, 1498-1509.
KANDA, H., TATEYA, S., TAMORI, Y., KOTANI, K., HIASA, K., 
KITAZAWA, R., KITAZAWA, S., MIYACHI, H., MAEDA, S., 
EGASHIRA, K. & KASUGA, M. 2006. MCP-1 contributes to 
macrophage infiltration into adipose tissue, insulin resistance, and hepatic 
steatosis in obesity. J Clin Invest, 116, 1494-505.
KANNAIYAN, S., STRIPPOLI GIOVANNI, F. M., DALY, C., RODERICK 
PAUL, J., WALLACE SHEILA, A. & MACLEOD ALISON, M. 2006. 
Haemodiafiltration, haemofiltration and haemodialysis for end-stage 
kidney disease. Cochrane Database of Systematic Reviews [Online]. 
Available:
http://www.inrw.interscience.wilev.com/cochrane/clsvsrev/articles/CD006
258/frame.html.
KARASTERGIOU, K. & MOHAMED-ALI, V. 2010. The autocrine and 
paracrine roles of adipokines. Mol Cell Endocrinol, 318, 69-78.
KASISKE, B. L., WANNER, C. & O’NEILL, W. C. 2006. An Assessment of 
Statin Safety by Nephrologists. The American Journal of Cardiology, 97, 
S82-S85.
KASTARINEN, H., HORKKO, S., KAUMA, H., KARJALAINEN, A.,
232
SAVOLAINEN, M. J. & KESANIEMI, Y. A. 2009a. Low-density 
lipoprotein clearance in patients with chronic renal failure. Nephrol Dial 
Transplant., gfp026.
KASTARINEN, H., KESAnNIEMI, Y. A. & UKKOLA, O. 2009b. Leptin and 
lipid metabolism in chronic kidney failure. Scandinavian Journal of 
Clinical and Laboratory Investigation, 69,401 -408.
KATAOKA, H. & SHARMA, K. 2006. Renal handling of adipokines. Contrib 
Nephrol, 151,91-105.
KAYSEN, G. A. 2006a. Dyslipidemia in chronic kidney disease: Causes and 
consequences. Kidney Int, 70, S55-S58.
KAYSEN, G. A. 2006b. Metabolic syndrome and renal failure: similarities and 
differences. Panminerva Med, 48, 151-64.
KAYSEN, G. A. 2011. New insights into lipid metabolism in chronic kidney 
diSQ&SQ. J Ren Nutr, 21, 120-3.
KHAZEN, W., M'BIKA J, P., TOMKIEWICZ, C., BENELLI, C., CHANY, C., 
ACHOUR, A. & FOREST, C. 2005. Expression of macrophage-selective 
markers in human and rodent adipocytes. FEES Lett, 579, 5631-4.
KIM, C. & VAZIRI, N. D. 2005. Down-regulation of hepatic LDL receptor- 
related protein (LRP) in chronic renal failure. Kidney Int, 67, 1028-32.
KIMMEL, P. L., PHILLIPS, T, M., SIMMENS, S. J., PETERSON, R. A., 
WEIHS, K. L., ALLEYNE, S., CRUZ, I., YANOVSKI, J. A. & VEIS, J. 
H. 1998. Immunologic function and survival in hemodialysis patients. 
Kidney International, 54,236-244.
KINDEL, T., LEE, D. M. & TSO, P. 2010. The mechanism of the formation and
233
secretion of chylomicrons. Atheroscler Suppl, 11, 11-6.
KLIM, R. A. & WILLIAMSON, D. H. 1983. Effects of glucose-containing 
peritoneal-dialysis solutions on rates of lipogenesis in vivo in the liver, 
brown and white adipose tissue of chronic uraemic rats. Biochem J, 214, 
459-64.
KOBAYASHI, J., NOHARA, A., KAWASHIRI, M. A., INAZU, A., KOIZUMI, 
J., NAKAJIMA, K. & MABUCHI, H. 2007. Serum lipoprotein lipase 
mass: clinical significance of its measurement. Clin Chim Acta, 378, 7-12.
KOCH, M., KUTKUHN, B., TRENKWALDER, E., BACH, D., GRABENSEE, 
B, DIEPLINGER, H. & KRONENBERG, F. 1997. Apolipoprotein B, 
fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict 
coronary artery disease in hemodialysis patients. Journal of the American 
Society of Nephrology, 8, 1889-1898.
KOKOT, F„ ADAMCZAK, M. & WIECEK, A. 1998. Plasma leptin 
concentration in kidney transplant patients during the early post-transplant 
period. Nephrology Dialysis Transplantation, 13, 2276-2280.
KOLDITZ, C. I. & LANGIN, D. 2010. Adipose tissue lipolysis. Curr Opin Clin 
Nutr Metab Care, 13,377-81.
KOMURA, N., KIHARA, S, SONODA, M., MAEDA, N., TOCHINO, Y., 
FUNAHASHI, T. & SHIMOMURA, I. 2010. Increment and impairment 
of adiponectin in renal failure. Cardiovasc Res, 86, 471-7.
KORNER, A., WABITSCH, M., SEIDEL, B., FISCHER-POSOVSZKY, P., 
BERTHOLD, A, STUMYOLL, M., BLUHER, M., KRATZSCH, J. & 
KIESS, W. 2005. Adiponectin expression in humans is dependent on 
differentiation of adipocytes and down-regulated by humoral serum 
components of high molecular weight. Biochemical and Biophysical
234
Research Communications, 337, 540-550.
KOSTAPANOS, M. S., MILIONIS, H. J., FILIPPATOS, T. D., 
CHRISTOGIANNIS, L. G., BAIRAKTARI, E. T., TSELEPIS, A. D. & 
ELISAF, M. S. 2009. Dose-dependent Effect of Rosuvastatin Treatment 
on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia. 
Journal of Cardiovascular Pharmacology and Therapeutics, 14, 5-13.
KRAEMER, F. B. & SHEN, W.-J. 2002. Hormone-sensitive lipase. Journal of 
Lipid Research, 43, 1585-1594.
KRAMER-GUTH, A., QUASCHNING, T., GALLE, J., BAUMSTARK, M. W„ 
KONIGER, M., NAUCK, M, SCHOLLMEYER, P., MARZ, W. & 
WANNER, C. 1997. Structural and compositional modifications of 
diabetic low-density lipoproteins influence their receptor-mediated uptake 
by hepatocytes. Eur J Clin Invest, 27,460-8.
KWAN, B. C. H. & BEDDHU, S. 2007. A Story Half Untold: Adiposity, 
Adipokines and Outcomes in Dialysis Population. Seminars in Dialysis, 
20, 493-497.
LAFONTAN, M. 2008. Advances in adipose tissue metabolism. Int J Obes 
(Lond), 32 Suppl 7, S39-51.
LAFONTAN, M. & LANGIN, D. 2009. Lipolysis and lipid mobilization in 
human adipose tissue. Progress in Lipid Research, 48, 275-297.
LAI, K. N. & LEUNG, J. C. K. 2010. Peritoneal adipocytes and their role in 
inflammation during peritoneal dialysis. Mediators of Inflammation, 2010.
LANGSTED, A. & NORDESTGAARD, B. G. 2011. Nonfasting Lipids, 
Lipoproteins, and Apolipoproteins in Individuals with and without 
Diabetes: 58 434 Individuals from the Copenhagen General Population
235
Study. Clin Chem, 57,482-489.
LARGE, V„ PERONI, O., LETEXIER, D., RAY, H. & BEYLOT, M. 2004. 
Metabolism of lipids in human white adipocyte. Diabetes Metab, 30, 294 - 
309.
LASS, A., ZIMMERMANN, R., OBERER, M. & ZECHNER, R. 2011. Lipolysis 
- a highly regulated multi-enzyme complex mediates the catabolism of 
cellular fat stores. Prog Lipid Res, 50, 14-27,
LEE, D. M., KNIGHT-GIBSON, C, SAMUELSSON, 0., ATTMAN, P.-O., 
WANG, C.-S. & ALAUPOVIC, P. 2002. Lipoprotein particle
abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int, 
61,209-218.
LEFEBVRE, A. M., LAVILLE, M., VEGA, N., RIOU, J. P., VAN GAAL, L., 
AUWERX, J. & VIDAL, H. 1998. Depot-specific differences in adipose 
tissue gene expression in lean and obese subjects. Diabetes, 47, 98-103.
LEVEY, A. S., CORESH, J., BALK, E., KAUSZ, A. T., LEVIN, A., STEFFES, 
M. W., HOGG, R. J., PERRONE, R. D., LAU, J. & EKNOYAN, G. 2003. 
National Kidney Foundation practice guidelines for chronic kidney 
disease: evaluation, classification, and stratification. Ann Intern Med, 139, 
137-47.
LEVEY, A. S., ECKARDT, K. U, TSUKAMOTO, Y., LEVIN, A., CORESH, J., 
ROSSERT, J, DE ZEEUW, D., HOSTETTER, T. H, LAMEIRE, N. & 
EKNOYAN, G. 2005. Definition and classification of chronic kidney 
disease: a position statement from Kidney Disease: Improving Global 
Outcomes (KDIGO). Kidney Int, 67, 2089-100.
LEWINGTON, S., WHITLOCK, G, CLARKE, R., SHERLIKER, P., 
EMBERSON, J., HALSEY, J., QIZILBASH, N., PETO, R. & COLLINS,
236
R. 2007. Blood cholesterol and vascular mortality by age, sex, and blood 
pressure: a meta-analysis of individual data from 61 prospective studies 
with 55,000 vascular deaths. Lancet, 370, 1829-39.
LI, Z. & FENGXIAN, H. 2011. Glucose Concentration in the Dialysate does not 
Contribute to Lipid Profiles in Patients Undergoing CAPD. Renal Failure, 
33, 124-130.
LIANG, K. & VAZIRI, N. D. 1997a. Gene expression of LDL receptor, HMG- 
CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal 
failure. Nephrol Dial Transplant, 12, 1381-6.
LIANG, K. & VAZIRI, N. D. 1997b. Gene expression of LDL receptor, HMG- 
CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal 
failure. Nephrology Dialysis Transplantation, 12, 1381-1386.
LIHN, A. S., BRUUN, J. M., HE, G., PEDERSEN, S. B., JENSEN, P. F. & 
RICHELSEN, B. 2004. Lower expression of adiponectin mRNA in 
visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol, 
219, 9-15.
LUMENG, C. N., BODZIN, J. L. & SALTIEL, A. R. 2007. Obesity induces a 
phenotypic switch in adipose tissue macrophage polarization. J Clin 
Invest, 117, 175-84.
LUND, S. S., PETERSEN, M., FRANDSEN, M., SMIDT, U. M., PARVING, H.- 
H., VAAG, A. A. & JENSEN, T. 2011. Agreement Between Fasting and 
Postprandial LDL Cholesterol Measured with 3 Methods in Patients with 
Type 2 Diabetes Mellitus. Clin Chem, 57, 298-308.
MADORE, F. 2003. Uremia-related metabolic cardiac risk factors in chronic 
kidney disease. Semin Dial, 16, 148-56.
237
MAENO, Y„ KASHIWAGI, A., NISHIO, Y., TAKAHARA, N. & KIKKAWA, 
R. 2000. IDL can stimulate atherogenic gene expression in cultured human 
vascular endothelial cells. Diabetes Res Clin Pract, 48, 127-38.
MAIRAL, A., LANGIN, D., ARNER, P. & HOFFSTEDT, J. 2006. Human 
adipose triglyceride lipase (PNPLA2) is not regulated by obesity and 
exhibits low in vitro triglyceride hydrolase activity. Diabetologia, 49, 
1629-36.
MAJUMDAR, A. & WHEELER, D. 2000. Lipid abnormalities in renal disease. J 
R Soc Med, 93, 178-182.
MARCHLEWSKA, A., STENVINKEL, P., LINDHOLM, B., DANIELS SON, A., 
PECOITS-FILHO, R., LONNQVIST, F., SCHALLING, M„ 
HEIMBURGER, O. & NORDFORS, L. 2004. Reduced gene expression of 
adiponectin in fat tissue from patients with end-stage renal disease. Kidney 
Int, 66,46-50.
MARRS, J. C. & SASEEN, J. J. 2010. Effects of lipid-lowering therapy on 
reduction of cardiovascular events in patients with end-stage renal disease 
requiring hemodialysis. Pharmacotherapy, 30, 823-9.
MASELLA, R., VARI, R., D'ARCHIVIO, M„ SANTANGELO, C., 
SCAZZOCCHIO, B., MAGGIORELLA, M. T., SERNICOLA, L., TITTI, 
F., SANCHEZ, M., DI MARIO, U., LETO, G. & GIOVANNINI, C. 2006. 
Oxidised LDL modulate adipogenesis in 3T3-L1 preadipocytes by 
affecting the balance between cell proliferation and differentiation. FEES 
Lett, 580,2421-9.
MAURY, E. & BRICHARD, S. M. 2010. Adipokine dysregulation, adipose tissue 
inflammation and metabolic syndrome. Molecidar and Cellular 
Endocrinology, 314, 1-16.
238
MEAD, J., IRVINE, S. & RAMJI, D. 2002. Lipoprotein lipase: structure, 
function, regulation, and role in disease. Journal of Molecular Medicine, 
80, 753-769.
MENON, V., LI, L., WANG, X., GREENE, T., BALAKRISHNAN, V., 
MADERO, M., PEREIRA, A. A., BECK, G. J., KUSEK, J. W., 
COLLINS, A. J., LEVEY, A. S. & SARNAK, M. J. 2006. Adiponectin 
and mortality in patients with chronic kidney disease. J Am Soc Nephrol, 
17,2599-606.
MERABET, E., DAGOGO-JACK, S., COYNE, D. W., KLEIN, S., SANTIAGO, 
J. V., HMIEL, S. P. & LANDT, M. 1997. Increased Plasma Leptin 
Concentration in End-Stage Renal Disease. J Clin Endocrinol Metab, 82, 
847-850.
MESQUITA, J., VARELA, A. & MEDINA, J. L. 2010. Dyslipidemia in renal 
disease: causes, consequences and treatment. Endocrinol Nutr, 57,440-8.
MICHAEL, H. D. & PETER, P. T. 2007. High-Density Lipoprotein Metabolism: 
Potential Therapeutic Targets. The American Journal of Cardiology, 100, 
S32-S40.
MILLER, L., SOOD, M, SOOD, A., RESLEROVA, M., KOMENDA, P„ 
RIGATTO, C. & BUETI, J. 2010. Cardiovascular disease in end-stage 
renal disease: the challenge of assessing and managing cardiac disease in 
dialysis patients. International Urology and Nephrology, 42, 1007-1014.
MINER, J. L. 2004. The adipocyte as an endocrine cell, J. Anim Sci., 82, 935-941.
MITKA, M. 2008. Report Notes Increase in Kidney Disease. JAMA: The Journal 
of the American Medical Association, 300, 2473-2474.
MOHAMED-ALI, V., GOODRICK, S., RAWESH, A, KATZ, D. R., MILES, J.
239
M., YUDKIN, J. S., KLEIN, S. & COPPACK, S. W. 1997. Subcutaneous 
adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, 
in vivo. J C/m Endocrinol Metab, 82,4196-200.
MOHAMED-ALI, V., PINKNEY, J. & COPPACK, S. 1998. Adipose tissue as an 
endocrine and paracrine organ. International Journal of Obesity & Related 
Metabolic Disorders: Journal of the International Association for the 
Study of Obesity, 22, 1145 - 1158.
MOLITCH, M. E. 2006. Management of dyslipidemias in patients with diabetes 
and chronic kidney disease. Clin JAm Soc Nephrol, 1, 1090-9.
MONTAGUE, T. & MURPHY, B. 2009. Lipid management in chronic kidney 
disease, hemodialysis, and transplantation. Endocrinol Metab Clin North 
Am, 38, 223-34.
MORENA, M, CRISTOL, J. P, DANTOINE, T., CARBONNEAU, M. A., 
DESCOMPS, B. & CANAUD, B. 2000. Protective effects of high-density 
lipoprotein against oxidative stress are impaired in haemodialysis patients. 
Nephrol Dial Transplant, 15, 389-95.
MULLEROVA, D. & KOPECKY, J. 2007. White adipose tissue: storage and 
effector site for environmental pollutants. Physiol Res, 56, 375-81.
MURUGAN, S. & KEN, F. 2007. Haemodialysis. 35, 461-465.
NAIR, P. K., MULUKUTLA, S. R. & MARROQUIN, O. C. 2010. Stents and 
statins: history, clinical outcomes and mechanisms. Expert Rev Cardiovasc 
Ther, 8, 1283-95.
NIELSEN, H. 2011. Working with RNA. Methods Mol Biol, 703, 15-28.
NISHIKAWA, M., TAKAGI, T, YOSHIKAWA, N., SHOUZU, A.,
240
MURAKAMI, T., KONO, M, OWAE, H., TANAKA, K., IWASAKA, T. 
& INADA, M. 1999. Measurement of serum leptin in patients with chronic 
renal failure on hemodialysis. Clin Nephrol, 51, 296-303.
NISHIZAWA, Y., SHOJI, T„ KAKIYA, R., TSUJIMOTO, Y., TABATA, T„ 
ISHIMURA, E., NAKATANI, T„ MIKI, T. & INABA, M. 2003. Non- 
high-density lipoprotein cholesterol (non-HDL-C) as a predictor of 
cardiovascular mortality in patients with end-stage renal disease. Kidney 
Int, 63, S117-S120.
NORATA, G. D., BARAGETTI, L, RASELLI, S., STUCCHI, A., 
GARLASCHELLI, K., VETTORETTI, S., PILONI, G., BUCCIANTI, G. 
& CATAPANO, A. L. 2009. Plasma adiponectin levels in chronic kidney 
disease patients: Relation with molecular inflammatory profile and 
metabolic status. Nutrition, Metabolism and Cardiovascular Diseases, In 
Press, Corrected Proof.
NORDFORS, L., LONNQVIST, F., HEIMBURGER, O., DANIELSSON, A., 
SCHALLING, M. & STENVINKEL, P. 1998. Low leptin gene expression 
and hyperleptinemia in chronic renal failure. Kidney Int, 54, 1267-1275.
OLIVECRONA, T„ HULTIN, M, BERGO, M. & OLIVECRONA, G. 1997. 
Lipoprotein lipase: regulation and role in lipoprotein metabolism. 
Proceedings of the Nutrition Society, 56, 723 - 729.
OREOPOULOS, D, THODIS, E., PASSADAKIS, P. & VARGEMEZIS, V. 
2009. Home dialysis as a first option: a new paradigm. International 
Urology and Nephrology, 41, 595-605.
OTTO, T. & LANE, M. 2005. Adipose Development: From Stem Cell to 
Adipocyte. Critical Reviews in Biochemistry and Molecular Biology, 40, 
229-242.
241
OUCHI, N„ KIHARA, S., ARITA, Y., OKAMOTO, Y., MAEDA, K., 
KURIYAMA, H., HOTTA, K., NISHIDA, M., TAKAHASHI, M., 
MURAGUCHI, M., OHMOTO, Y., NAKAMURA, T., YAMASHITA, S., 
FUNAHASHI, T. & MATSUZAWA, Y. 2000. Adiponectin, an adipocyte- 
derived plasma protein, inhibits endothelial NF-kappaB signaling through 
a cAMP-dependent pathway. Circulation, 102, 1296-301.
PACKARD, R. R. S. & LIBBY, P. 2008. Inflammation in Atherosclerosis: From 
Vascular Biology to Biomarker Discovery and Risk Prediction. Clin 
Chem, 54, 24-38.
PANDAK, W. M., VLAHCEVIC, Z. R., HEUMAN, D. M., KRIEG, R. J., 
HANNA, J. D. & CHAN, J. C. M. 1994. POSTTRANSCRIPTIONAL 
REGULATION OF 3 -HYDROXY - 3 -METH YLGLUTAR YL
COENZYME-A REDUCTASE AND CHOLESTEROL 7-ALPHA- 
HYDROXYLASE IN RATS WITH SUBTOTAL NEPHRECTOMY. 
Kidney International, 46, 358-364.
PECOITS-FILHO, R., LINDHOLM, B, AXELSSON, J. & STENVINKEL, P. 
2003. Update on interleukin-6 and its role in chronic renal failure. Nephrol 
Dial Transplant, 18, 1042-5.
PEKKANEN, J., LINN, S., HEISS, G., SUCHINDRAN, C. M., LEON, A., 
RIFKIND, B. M. & TYROLER, H. A. 1990. 10-YEAR MORTALITY 
FROM CARDIOVASCULAR-DISEASE IN RELATION TO 
CHOLESTEROL LEVEL AMONG MEN WITH AND WITHOUT 
PREEXISTING CARDIOVASCULAR-DISEASE. New England Journal 
of Medicine, 322, 1700-1707.
POULOS, S. P., DODSON, M. V. & HAUSMAN, G. J. 2010. Cell line models 
for differentiation: preadipocytes and adipocytes. Exp. Biol Med., 235, 
1185-1193.
242
PRICHARD, S. S. 2003. Impact of dyslipidemia in end-stage renal disease. JAm 
Soc Nephrol, 14, S315-20.
PRINSEN, B. H. C. M. T., DE SAIN-VAN DER VELDEN, M. G. M., DE 
KONING, E. J. P., KOOMANS, H. A., BERGER, R. & RABELINK, T. J. 
2003. Hypertriglyceridemia in patients with chronic renal failure: Possible 
mechanisms. Kidney Int, 63, S121-SI24.
QUASCHNING, T., KRANE, V., METZGER, T, & WANNER, C. 2001. 
Abnormalities in uremic lipoprotein metabolism and its impact on 
cardiovascular disease. Am J Kidney Dis, 38, S14-9.
QUINTAO, E. C. & CAZITA, P. M. 2010. Lipid transfer proteins: past, present 
and perspectives, 209, 1-9.
RAFF, A. C., MEYER, T. W. & HOSTETTER, T. H. 2008. New insights into 
uremic toxicity. Current Opinion in Nephrology and Hypertension, 17, 
560-565.
REDGRAVE, T. G. 2004. Chylomicron metabolism. Biochem Soc Trans, 32, 79- 
82.
RITZ, E. 2008. Metabolic syndrome and kidney disease. Blood Purif, 26, 59-62.
ROSEN, E. D. & MACDOUGALD, O. A. 2006. Adipocyte differentiation from 
the inside out. Nat Rev Mol Cell Biol, 7, 885-896.
ROSS, M. H., G.I. KAYE, ET AL 2003. Adipose Tissue, In: Histology: a text and 
atlas., London,Lippincott Williams & Wilkins.
ROUBICEK, T., BARTLOVA, M., KRAJICKOVA, J, HALUZIKOVA, D, 
MRAZ, M., LACINOVA, Z., KUDLA, M., TEPLAN, V. & HALUZIK, 
M. 2009. Increased production of proinflammatory cytokines in adipose
243
tissue of patients with end-stage renal disease. Nutrition, 25, 762-768.
ROUSSET, X., VAISMAN, B., AMAR, M., SETHI, A. A. & REMALEY, A. T. 
2009. Lecithin: cholesterol acyltransferase—from biochemistry to role in 
cardiovascular disease. Curr Opin Endocrinol Diabetes Obes, 16, 163-71.
RUCKER, D. & TONELLI, M. 2009. Cardiovascular risk and management in 
chronic kidney disease. Nat Rev Nephrol, 5,287-96.
RUTKOWSKI, P., KLASSEN, A, SEBEKOVA, K., BAHNER, U. & 
HEIDLAND, A. 2006. Renal disease in obesity: the need for greater 
attention. J Ren Nutr, 16,216-23.
SAHADEVAN, M. & KASISKE, B. L. 2002. Hyperlipidemia in kidney disease: 
causes and consequences. Curr Opin Nephrol Hypertens, 11, 323-9.
SALAND, J. & GINSBERG, H. 2007. Lipoprotein metabolism in chronic renal 
insufficiency. Pediatric Nephrology, 22, 1095-1112.
SAMUELSSON, O., MULEC, H., KNIGHT-GIBSON, C., ATTMAN, P. O., 
KRON, B., LARS SON, R., WEISS, L., WEDEL, H. & ALAUPOVIC, P. 
1997. Lipoprotein abnormalities are associated with increased rate of 
progression of human chronic renal insufficiency. Nephrol Dial 
Transplant, 12, 1908-15,
SARNAK, M. J, 2003. Cardiovascular complications in chronic kidney disease. 
Am J Kidney Dis, 41, 11-7.
SARNAK, M. J. & LEVEY, A. S. 2000. Cardiovascular disease and chronic renal 
disease: a new paradigm. Am J Kidney Dis, 35, SI 17-31.
SARNAK, M. J., LEVEY, A. S., SCHOOLWERTH, A. C., CORESH, J., 
CULLETON, B., HAMM, L. L, MCCULLOUGH, P. A., KASISKE, B.
244
l.3 kelepouris, e, klag, m. j., parfrey, p., pfeffer, m., raij,
L., SPINOSA, D. J. & WILSON, P. W. 2003. Kidney Disease as a Risk 
Factor for Development of Cardiovascular Disease: A Statement From the 
American Heart Association Councils on Kidney in Cardiovascular 
Disease, High Blood Pressure Research, Clinical Cardiology, and 
Epidemiology and Prevention. Hypertension, 42, 1050-1065.
SARTIPY, P. & LOSKUTOFF, D. J. 2003. Monocyte chemoattractant protein 1 
in obesity and insulin resistance. Proc Natl AcadSci USA, 100, 7265-70.
SCHAFFLER, A., MULLER-LADNER, U., SCHOLMERICH, J. & BUCKLER, 
C. 2006. Role of Adipose Tissue as an Inflammatory Organ in Human 
Diseases. Endocrine Reviews, 27, 449-467.
SCHOENHAGEN, P. & TUZCU, E. M. 2002. Coronary artery calcification and 
end-stage renal disease: vascular biology and clinical implications. Cleve 
Clin J Med, 69 Suppl 3, SI 2-20.
SCHRAW, T., WANG, Z. V., HALBERG, N., HAWKINS, M. & SCHERER, P. 
E. 2008. Plasma adiponectin complexes have distinct biochemical 
characteristics. Endocrinology, 149,2270-82.
SCHWARTZ, G. & FURTH, S. 2007. Glomerular filtration rate measurement and 
estimation in chronic kidney disease. Pediatiic Nephrology, 22, 1839- 
1848.
SHAPIRO, L. & SCHERER, P. E. 1998. The crystal structure of a complement-lq 
family protein suggests an evolutionary link to tumor necrosis factor. Curr 
Biol, 8, 335-8.
SHARMA, K, CONSIDINE, R. V., MICHAEL, B., DUNN, S. R., WEISBERG, 
L. S., KURNIK, B. R., KURNIK, P. B„ O'CONNOR, J., SINHA, M. & 
CARO, J. F. 1997. Plasma leptin is partly cleared by the kidney and is
245
elevated in hemodialysis patients. Kidney Int, 51, 1980-5.
SHELNESS, G. S. & SELLERS, J. A. 2001. Very-low-density lipoprotein 
assembly and secretion. Cnrr Opin Lipidol, 12, 151-7.
SHEN, W., PUNYANITYA, M., CHEN, J., GALLAGHER, D., ALBU, J., PI- 
SUNYER, X., LEWIS, C. E., GRUNFELD, C., HESHKA, S. & 
HEYMSFIELD, S. B. 2006. Waist circumference correlates with 
metabolic syndrome indicators better than percentage fat. Obesity (Silver 
Spring), 14, 727-36.
SHEN, Y. Y., PEAKE, P. W. & CHARLESWORTH, J. A. 2008. Review article: 
Adiponectin: its role in kidney disease. Nephrology (Carlton), 13, 528-34.
SHLIPAK, M. G., FRIED, L. F., CUSHMAN, M„ MANOLIO, T. A., 
PETERSON, D., STEHMAN-BREEN, C., BLEYER, A., NEWMAN, A., 
SISCOVICK, D. & PSATY, B. 2005. Cardiovascular mortality risk in 
chronic kidney disease: comparison of traditional and novel risk factors. 
JAMA, 293, 1737-45.
SHOJI, T., ISHIMURA, E., INABA, M., TABATA, T. & NISHIZAWA, Y. 2001. 
Atherogenic lipoproteins in end-stage renal disease. American Journal of 
Kidney Diseases, 38, S30-S33.
SHOJI, T., NISHIZAWA, Y., KAWAGISHI, T., KAWASAKI, K., TANIWAKI, 
H., TABATA, T., INOUE, T. & MORII, H. 1998. Intermediate-density 
lipoprotein as an independent risk factor for aortic atherosclerosis in 
hemodialysis patients. Journal of the American Society of Nephrology, 9, 
1277-1284.
SHOJI, T., NISHIZAWA, Y, NISHITANI, H., YAMAKAWA, M. & MORII, H. 
1991. Roles of hypoalbuminemia and lipoprotein lipase on 
hyperlipoproteinemia in continuous ambulatory peritoneal dialysis.
246
Metabolism, 40, 1002-1008.
STLVERSTEIN, D. 2009. Inflammation in chronic kidney disease: role in the 
progression of renal and cardiovascular disease. Pediatric Nephrology, 24, 
1445-1452.
SKAGGS, B. J, HAHN, B. H., SAHAKIAN, L., GROSSMAN, J. & 
MCMAHON, M. 2010. Dysfunctional, pro-inflammatory HDL directly 
upregulates monocyte PDGFRbeta, chemotaxis and TNFalpha production. 
Clin Immunol, 137, 147-56.
SKURK, T., ALBERTI-HUBER, C., HERDER, C. & HAUNER, H. 2007. 
Relationship between adipocyte size and adipokine expression and 
sewotian. J Clin Endocrinol Metab, 92, 1023-33.
SOWERS, J. R. 2008. Endocrine functions of adipose tissue: focus on 
adiponectin. Clin Cornerstone, 9, 32-8; discussion 39-40.
STATNICK, M. A, BEAVERS, L. S., CONNER, L. J., COROMINOLA, H., 
JOHNSON, D., HAMMOND, C. D., RAFAELOFF-PHAIL, R., SENG, 
T., SUTER, T. M., SLUKA, J. P, RAVUSSIN, E., GADSKI, R. A. & 
CARO, J. F. 2000. Decreased expression of apMl in omental and 
subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp 
Diabetes Res, 1,81-8.
STENVINKEL, P. 2006. Inflammation in end-stage renal disease: the hidden 
enemy. Nephrology (Carlton), 11, 36-41.
STENVINKEL, P. 2010. Chronic kidney disease: a public health priority and 
harbinger of premature cardiovascular disease. J Intern Med, 268, 456-67.
STENVINKEL, P., BARANY, P., CHUNG, S. H, LINDHOLM, B. & 
HEIMBURGER, O. 2002a. A comparative analysis of nutritional
247
parameters as predictors of outcome in male and female ESRD patients. 
Nephrol Dial Transplant, 17, 1266-74.
STENVINKEL, P., BARANY, P.} HEIMBURGER, O., PECOITS-FILHO, R. & 
LINDHOLM, B. 2002b. Mortality, malnutrition, and atherosclerosis in 
ESRD: what is the role of interleukin-6? Kidney Int Suppl, 103-8.
STENVINKEL, P., CARRERO, J. J., AXELSSON, J., LINDHOLM, B., 
HEIMBURGER, O. & MASSY, Z. 2008. Emerging Biomarkers for 
Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: 
How Do New Pieces Fit into the Uremic Puzzle? Clinical Journal of the 
American Society of Nephrology, 3, 505-521.
STENVINKEL, P., KETTELER, M., JOHNSON, R. J., LINDHOLM, B., 
PECOITS-FILHO, R., RIELLA, M., HEIMBURGER, O., CEDERHOLM, 
T. & GIRNDT, M. 2005. IL-10, IL-6, and TNF-[alpha]: Central factors in 
the altered cytokine network of uremia[mdash]The good, the bad, and the 
ugly. Kidney Int, 67, 1216-1233.
STENVINKEL, P., LINDHOLM, B. & HEIMBURGER, O. 2004. Novel 
approaches in an integrated therapy of inflammatory-associated wasting in 
end-stage renal disease. Semin Dial, 17, 505-15.
STEVENS, L. A., CORESH, J., GREENE, T. & LEVEY, A. S. 2006a. Assessing 
kidney function—measured and estimated glomerular filtration rate. N Engl 
J Med, 354, 2473-83.
STEVENS, L. A., CORESH, J., GREENE, T. & LEVEY, A. S. 2006b. Assessing 
Kidney Function — Measured and Estimated Glomerular Filtration Rate. 
New England Journal of Medicine, 354, 2473-2483.
STINGHEN, A. E. M., GONSALVES, S. M., MARTINES, E. G., NAKAO, L. 
S., RIELLA, M. C., AITA, C. A. & PECOITS-FILHO, R. 2009. Increased
248
Plasma and Endothelial Cell Expression of Chemokines and Adhesion 
Molecules in Chronic Kidney Disease. Nephron Clinical Practice, 111, 
cl 17-0126.
STOLLENWERK, M. M., LINDHOLM, M. W., PORN-ARES, M. I., 
LARS SON, A., NILSSON, J. & ARES, M. P. 2005. Very low-density 
lipoprotein induces interleukin-1 beta expression in macrophages. Biochem 
Biophys Res Commun, 335, 603-8.
SUMNER, A. E, VEGA, G. L., GENOVESE, D. J., FINLEY, K. B, 
BERGMAN, R. N. & BOSTON, R. C. 2005. Normal triglyceride levels 
despite insulin resistance in African Americans: role of lipoprotein lipase. 
Metabolism, 54, 902-909.
SURMI, B. K. & HASTY, A. H. 2008. Macrophage infiltration into adipose 
tissue: initiation, propagation and remodeling. Future Lipidol, 3, 545-556.
TAKAHASHI, S., SAKAI, J., FUJINO, T., HATTORI, H., ZENIMARU, Y., 
SUZUKI, J., MIYAMORI, I. & YAMAMOTO, T. T. 2004. The very low- 
density lipoprotein (VLDL) receptor: characterization and functions as a 
peripheral lipoprotein receptor. JAtheroscler Thromb, 11,200-8.
TANITA, T., MIYAKOSHI, H. & NAKANO, Y. 2008. Performance of ELISA 
for specific measurement of high-molecular-weight (HMW) adiponectin. J 
Immunol Methods, 333, 139-46.
TARTAGLIA, L. A. 1997. The leptin receptor. J Biol Chem, 272, 6093-6.
TASKAPAN, M. C., TASKAPAN, H., SAHIN, L, KESKIN, L., ATMACA, H. & 
OZYALA±N, F. 2007. Serum Leptin, Resistin, and Lipid Levels in 
Patients with End Stage Renal Failure with Regard to Dialysis Modality. 
Renal Failure, 29, 147 - 154.
249
TCHKONIA, T, LENBURG, M., THOMOU, T., GIORGADZE, N., 
FRAMPTON, G., PIRTSKHALAVA, T., CARTWRIGHT, A., 
CARTWRIGHT, M., FLANAGAN, J., KARAGIANNIDES, L, GERRY, 
N.} FORSE, R. A„ TCHOUKALOVA, Y., JENSEN, M. D., 
POTHOULAKIS, C. & KIRKLAND, J. L. 2007. Identification of depot- 
specific human fat cell progenitors through distinct expression profiles and 
developmental gene patterns. American Journal of Physiology - 
Endocrinology And Metabolism, 292, E298-E307.
TCHOUKALOVA, Y„ KOUTSARI, C. & JENSEN, M. 2007. Committed 
subcutaneous preadipocytes are reduced in human obesity. Diabetologia, 
50, 151-7.
TIM, E. & MARTIN, W. 2007. Peritoneal dialysis. 35, 466-469.
TORRES-LEAL, F. L., FONSECA-ALANIZ, M. H., ROGERO, M. M. & 
TIRAPEGUI, J. 2010. The role of inflamed adipose tissue in the insulin 
resistance. Cell Biochemistry and Function, 28, 623-631.
TRAYHURN, P. 2005. Adipose tissue in obesity—an inflammatory issue. 
Endocrinology, 146, 1003-5.
TRAYHURN, P. 2007. Adipocyte biology. Obes Rev, 8 Suppl 1,41-4.
TRAYHURN, P. & BEATTIE, J. H. 2001. Physiological role of adipose tissue: 
white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc, 
60, 329-39.
TRAYHURN, P. & WOOD, I. S. 2004. Adipokines: inflammation and the 
pleiotropic role of white adipose tissue. British Journal of Nutn'tion, 92, 
347-355.
TSIMIHODIMOS, V., DOUNOUSI, E. & SIAMOPOULOS, K. C. 2008.
250
Dyslipidemia in chronic kidney disease: an approach to pathogenesis and 
XxsdAmQnt. Am JNephrol, 28, 958-73.
TSIMIHODIMOS, V., MITROGIANNI, Z. & ELISAF, M. 2011. Dyslipidemia 
associated with chronic kidney disease. Open Cardiovasc MedJ, 5, 41-8.
TZANATOS, H. A., TSEKE, P. P., PIPILI, C., RETSA, K., SKOUTELIS, G. & 
GRAPSA, E. 2009. Cardiovascular risk factors in non-diabetic 
hemodialysis patients: a comparative study. Ren Fail, 31,91-7.
VAN DE WOESTIJNE, A. P., MONAJEMI, H., KALKHOVEN, E. & 
VISSEREN, F. L. 2011. Adipose tissue dysfunction and 
hypertriglyceridemia: mechanisms and management. Obes Rev, 12, 829- 
40.
VAN LENTEN, B. J., HAMA, S. Y., DE BEER, F. C., STAFFORINI, D. M., 
MCINTYRE, T. M, PRESCOTT, S. M., LA DU, B. N., FOGELMAN, A. 
M. & NAVAB, M. 1995. Anti-inflammatory HDL becomes pro- 
inflammatory during the acute phase response. Loss of protective effect of 
HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest, 
96,2758-67.
VANHOLDER, R., DE SMET, R., GLORIEUX, G., ARGILES, A., 
BAURMEISTER, U., BRUNET, P., CLARK, W., COHEN, G., DE 
DEYN, P, P., DEPPISCH, R., DESCAMPS-LATSCHA, B., HENLE, T., 
JORRES, A., LEMKE, H. D., MASSY, Z. A., PASSLTCK-DEETJEN, J., 
RODRIGUEZ, M., STEGMAYR, B., STENVINKEL, P., TETTA, C., 
WANNER, C. & ZIDEK, W. 2003. Review on uremic toxins: 
Classification, concentration, and interindividual variability. Kidney Int, 
63, 1934-1943.
VANHOLDER, R., VAN LAECKE, S. & GLORIEUX, G. 2008a. What is new in 
uremic toxicity? Pediatric Nephrology, 23,1211-1221.
251
VANHOLDER, R., VAN LAECKE, S. & GLORIEUX, G. 2008b. What is new in 
uremic toxicity? Pediafr Nephrol, 23, 1211-21.
VAZIRI, N. D. 2006. Dyslipidemia of chronic renal failure: the nature, 
mechanisms, and potential consequences. Am J Physiol Renal Physiol, 
290, F262-272.
VAZIRI, N. D. 2009. Causes of dysregulation of lipid metabolism in chronic renal 
failure. Semin Dial, 22, 644-51.
VAZIRI, N. D. & LIANG, K. 1996. Down-regulation of tissue lipoprotein lipase 
expression in experimental chronic renal failure. Kidney Int, 50, 1928- 
1935.
VAZIRI, N. D. & MORADI, H. 2006. Mechanisms of dyslipidemia of chronic 
renal failure. Hemodial Int, 10, 1-7.
VEGA, G. L., CLARK, L. T., TANG, A., MARCOVINA, S., GRUNDY, S. M. & 
COHEN, J. C. 1998. Hepatic lipase activity is lower in African American 
men than in white American men: effects of 5' flanking polymorphism in 
the hepatic lipase gene (L\YC). J Lipid Res, 39, 228-32.
VIEDT, C. & ORTH, S. R. 2002. Monocyte chemoattractant protein-1 (MCP-1) 
in the kidney: does it more than simply attract monocytes? Nephrol Dial 
Transplant, 17,2043-7.
WABITSCH, M., BRENNER, R. E., MELZNER, I., BRAUN, M„ MOLLER, P., 
HEINZE, E., DEBATIN, K. M. & HAUNER, H. 2001. Characterization of 
a human preadipocyte cell strain with high capacity for adipose 
differentiation. Int J Obes Relat Metab Disord, 25, 8-15.
WANG, H. & ECKEL, R. H. 2009. Lipoprotein lipase: from gene to obesity. Am J 
Physiol Endocrinol Metab, 297, E271-288.
252
WANG, S., SONI, K. G., SEMACHE, ML, CASAVANT, S., FORTIER, M., 
PAN, L. & MITCHELL, G. A. 2008a. Lipolysis and the integrated 
physiology of lipid energy metabolism. Mol Genet Metab, 95, 117-26.
WANG, Y., CHEN, X., SONG, Y„ CABALLERO, B. & CHESKIN, L, J. 2008b. 
Association between obesity and kidney disease: a systematic review and 
meta-analysis. 73, 19-33.
WANNER, C. & KRANE, V. 2002. Uremia-specific alterations in lipid 
metabolism. Blood Purif, 20,451-3.
WANNER, C„ KRANE, V., MARZ, W, OLSCHEWSKI, M., ASMUS, H. G., 
KRAMER, W., KUHN, K. W., KUTEMEYER, H, MANN, J. F, RUF, G. 
& RITZ, E. 2004. Randomized controlled trial on the efficacy and safety 
of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): 
demographic and baseline characteristics. Kidney Blood Press Res, 27, 
259-66.
WANNER, C. & RITZ, E. 2008. Reducing lipids for CV protection in CKD 
patients[mdash]current evidence. Kidney Int, 74, S24-S28.
WASAN, K. M., CASSIDY, S. M., KENNEDY, A. L. & PETEHERYCH, K. D. 
2000. Lipoprotein Isolation and Analysis from Serum by Preparative 
Ultracentrifugation.
WEBER, O., BISCHOFF, H„ SCHMECK, C. & BOTTCHER, M. F. 2010. 
Cholesteryl ester transfer protein and its inhibition. Cell Mol Life Sci, 61, 
3139-49.
WEISBERG, S. P., MCCANN, D., DESAI, M., ROSENBAUM, M„ LEIBEL, R. 
L. & FERRANTE, A. W., JR. 2003. Obesity is associated with 
macrophage accumulation in adipose tissue. JC/w Invest, 112, 1796-808.
253
WELLEN, K. E. & HOTAMISLIGIL, G. S. 2005. Inflammation, stress, and 
diabetes. J Clin Invest, 115, 1111-9.
WHEELER, D. C. 2007. Cardiovascular complications of chronic kidney disease. 
Medicine, 35, 453-456.
WIECEK, A., KOKOT, F., CHUDEK, J. & ADAMCZAK, M. 2002. The adipose 
tissue—a novel endocrine organ of interest to the nephrologist. Nephrol. 
Dial. Transplant., 17, 191-195.
WINKELMAYER, W. C, GLYNN, R. J., LEVIN, R., OWEN, W. F., JR. & 
AVORN, J. 2001. Determinants of delayed nephrologist referral in patients 
with chronic kidney disease. Am J Kidney Dis, 38, 1178-84.
WITASP, A., CARRERO, J. J., HEIMBURGER, O., LINDHOLM, B., 
HAMMARQVIST, F., STENVINKEL, P. & NORDFORS, L. 2010. 
Increased expression of pro-inflammatory genes in abdominal 
subcutaneous fat in advanced chronic kidney disease patients. J Intern 
Med.
WIZEMANN, V. 1998. Coronary artery disease in dialysis patients. Contrih 
Nephrol, 124, 1-9; discussion 9-17.
WOLF, G., CHEN, S., HAN, D. C. & ZIYADEH, F. N. 2002. Leptin and renal 
disease. Am J Kidney Dis, 39, 1-11.
WOLF, G., HAMANN, A., HAN, D. C., HELMCHEN, U., THAISS, F., 
ZIYADEH, F. N. & STAHL, R. A. 1999. Leptin stimulates proliferation 
and TGF-beta expression in renal glomerular endothelial cells: potential 
role in glomerulosclerosis [seecomments]. Kidney Int, 56, 860-72.
WOZNIAK, S., GEE, L., WACHTEL, M. & FREZZA, E. 2009. Adipose Tissue: 
The New Endocrine Organ? A Review Article. Digestive Diseases and
254
Sciences,
XU, H., BARNES, G. T., YANG, Q., TAN, G, YANG, D„ CHOU, C. J., SOLE, 
L, NICHOLS, A., ROSS, J. S., TARTAGLIA, L. A. & CHEN, H. 2003. 
Chronic inflammation in fat plays a crucial role in the development of 
obesity-related insulin resistance. J C/m Invest, 112, 1821-30.
YADAV, A., SAINI, V. & ARORA, S. 2010. MCP-1: chemoattractant with a role 
beyond immunity: a review. Clin Chim Acta, 411, 1570-9.
YALQIN, A., KOCAOGIU, §., AKgigEK, F. & OZYER, A. 1999. Effects of 
Acetate or Bicarbonate Dialysis Solutions on Serum HDL and HDL 
Subfractions of Patients Undergoing Haemodialysis. Current Medical 
Research and Opinion, 15,310-315.
YAMAMOTO, S. & KON, V. 2009. Mechanisms for increased cardiovascular 
disease in chronic kidney dysfunction. Current Opinion in Nephrology and 
Hypertension, 18, 181-188 10.1097/MNH.0b013e328327b360.
YAMAUCHI, T., KAMON, J., MINOKOSHI, Y„ ITO, Y., WAKI, H., UCHIDA, 
S„ YAMASHITA, S., NODA, M„ KITA, S., UEKI, K., ETO, K., 
AKANUMA, Y., FROGUEL, P, FOUFELLE, F., FERRE, P., CARLING, 
D„ KIMURA, S., NAGAI, R., KAHN, B. B. & KADOWAKI, T. 2002. 
Adiponectin stimulates glucose utilization and fatty-acid oxidation by 
activating AMP-activated protein kinase. Nat Med, 8, 1288-95.
YEE, M. S., PAVITT, D. V., TAN, T., VENKATESAN, S., GODSLAND, I. F„ 
RICHMOND, W. & JOHNSTON, D. G. 2008. Lipoprotein separation in a 
novel iodixanol density gradient, for composition, density, and phenotype 
analysis. Journal of Lipid Research, 49, 1364-1371.
YOKOYAMA, S. 2006. Assembly of high-density lipoprotein. Arterioscler 
Thromb Vase Biol, 26, 20-7.
255
YOON, M. J., LEE, G. Y„ CHUNG, J. J., AHN, Y. H, HONG, S. H. & KIM, J. 
B. 2006. Adiponectin increases fatty acid oxidation in skeletal muscle cells 
by sequential activation of AMP-activated protein kinase, p38 mitogen- 
activated protein kinase, and peroxisome proliferator-activated receptor 
alpha. Diabetes, 55, 2562-70.
YOUNG, G. A., WOODROW, G., KENDALL, S., OLDROYD, B„ TURNEY, J. 
H., BROWNJOHN, A. M. & SMITH, M. A. 1997. Increased plasma 
leptin/fat ratio in patients with chronic renal failure: a cause of 
malnutrition? Nephrol Dial Transplant, 12, 2318-23.
YU, H. T. 2003. Progression of Chronic Renal Failure. Arch Intern Med, 163, 
1417-1429.
ZANETTI, M., BARAZZONI, R. & GUARNIERI, G. 2008. Inflammation and 
Insulin Resistance in Uremia. Journal of Renal Nutrition, 18, 70-75.
ZHANG, Y., PROENCA, R., MAFFEI, M., BARONE, M., LEOPOLD, L. & 
FRIEDMAN, J. M. 1994. Positional cloning of the mouse obese gene and 
its human homologue. Nature, 372, 425-32.
ZHOU, H., LI, Z., HOJJATI, M. R., JANG, D., BEYER, T. P., CAO, G., TALL, 
A. R. & JIANG, X. C. 2006. Adipose tissue-specific CETP expression in 
mice: impact on plasma lipoprotein metabolism. JZzp/n? Res, 47, 2011-9.
ZIMMERMANN, R., STRAUSS, J. G., HAEMMERLE, G., SCHOISWOHL, G., 
BIRNER-GRUENBERGER, R., RIEDERER, M., LASS, A., 
NEUBERGER, G., EISENHABER, F., HERMETTER, A. & ZECHNER, 
R. 2004. Fat mobilization in adipose tissue is promoted by adipose 
triglyceride lipase. Science (New York, NY), 306, 1383-6.
ZOCCALI, C. & MALLAMACI, F. 2008. Obesity, diabetes, adiponectin and the 
kidney: a podocyte affair*. Nephrology Dialysis Transplantation, 23,
256
3767-3770.
ZOCCALI, C. & MALLAMACI, F. 2011. Does adipose tissue have a key role in 
inflammation in CKD? Journal of Internal Medicine, 269, 407-409.
ZOCCALI, C., MALLAMACI, F. & TRIPEPI, G. 2003. Adipose tissue as a 
source of inflammatory cytokines in health and disease: Focus on end- 
stage renal disease. Kidney Int, 63, S65-S68,
ZOCCALI, C., MALLAMACI, F. & TRIPEPI, G. 2004. Inflammatory proteins as 
predictors of cardiovascular disease in patients with end-stage renal 
disease. Nephrol Dial Transplant., 19, v67-72.
ZOCCALI, C., MALLAMACI, F., TRIPEPI, G., BENEDETTO, F. A., 
CUTRUPI, S., PARLONGO, S., MALATINO, L. S., BONANNO, G., 
SEMINARA, G., RAPISARDA, F., FATUZZO, P., BUEMI, M., 
NICOCIA, G., TANAKA, S., OUCHI, N., KIHARA, S., FUNAHASHI, 
T. & MATSUZAWA, Y, 2002. Adiponectin, metabolic risk factors, and 
cardiovascular events among patients with end-stage renal disease. J Am 
Soc Nephrol, 13, 134-41.
257
